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Abstract
“Chronic disease will never reach its clinical horizon to compromise health if it is
attacked at its origin” [1]. Knowledge that one’s risk for cardiovascular events is related to the
severity of endothelial dysfunction, and evidence that exercise training can improve endothelial
function, has prompted speculation that measures of vascular function may serve as a
“barometer” for cardiovascular health. This dissertation consists of three experiments intended to
study vascular function and the manner in which it may influence or may be influenced by
physical function.
Project one examined the influence of high and low volume circuit weight training on
forearm vascular function. Thirty-five individuals participated in a program consisting of 3
sessions/week for 5 weeks. Results indicated significant but similar strength gains in both groups
(Hand Grip: Δ15.55%, Knee Extension: Δ21.00%, Bench Press: Δ35.31%; p<0.05). Reactive
hyperemic responses, a measure of vascular function, only changed in those individuals with the
lowest pre-training vascular measures, independent of group assignment.
Project two examined the link between vascular and physical function in peripheral
neuropathy patients. Reactive hyperemic responses were significantly related to the time up and
go test (r=-0.31, p=0.02) and the 6-minute walk distance (r=0.37, p=0.007). These data suggest a
link between measures of vascular and physical function in these patients, indicating that those
with better vascular function have greater physical function.
Project three examined the effects of an acute bout of exercise on nitric oxide, oxidative
stress and anti-oxidants, and brachial vasoreactivity, before, at peak exercise, and in recovery, in
trained individuals. The results indicated a significant increase in reactive oxygen species and
peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at peak exercise. Brachial
iv

vasoreactivity was significantly lower immediately after exercise, but returned to pre-exercise
levels at 20 minutes into recovery. These findings suggest an acute bout of exercise contributes
to a significant rise in oxidative stress, which can in part be buffered by anti-oxidants systems,
but may cause temporary blunting of arterial reactivity. Collectively, these findings indicate the
importance of examining vascular function, and its controllers, and may extend the current
understanding of preserving and/or maintaining vascular health.
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Chapter 1
Introduction
The purpose of this introductory chapter is to provide a foundation upon which the
subsequent doctoral work is based. Chapter 2 is an extensive review of the scientific literature
pertinent to this dissertation. Chapters 3 to 5 are original investigations conducted by this
investigator. Finally, chapter 6 is a conclusion chapter designed to give the reader a summary
and connect the findings of the projects outlined.
The endothelium regulates vascular homeostasis by elaborating a variety of paracrine
factors that act locally in the blood vessel wall and lumen [2]. Under normal conditions, the sum
total effect of these endothelial factors is to maintain normal vascular tone, blood fluidity, and
limit vascular inflammation and smooth muscle cell proliferation [2]. Endothelial function may
be measured invasively or non-invasively. For example, invasive measures involve the intraarterial administration of substances (e.g. acetycholine and bradykinin) that enhance the release
of endothelial nitric oxide and lead to measurable vasodilatation in normal subjects but
vasoconstriction in states of endothelial dysfunction [3]. However, the obvious disadvantage
with such a method is that its invasive nature precludes its widespread use in the population.
Therefore, the development of non-invasive techniques could easily be used to evaluate
endothelial function in conditions where the invasive techniques could not be implemented
properly.
Vascular function assessments in this laboratory are done using non-invasive techniques
in order to assess vascular reactivity and structure in a variety of populations. The non-invasive
techniques commonly used in this laboratory are: (a) mercury strain gauge plethysmography, it is
used to determine upper and/or lower regional blood flow, and (b) the brachial artery flow
1

mediated dilation model using ultrasonography, is a tool used to evaluate functional and/or
structural changes and alterations of one single conduit artery. Generally it has been observed
that individuals who are less fit, are older, or have chronic diseases, have lower vascular
reactivity than fitter, younger and healthier individuals [4].
The main focus of this dissertation was to determine how the vasculature may be
influenced or may influence physical function. The first step in the research process started with
a follow-up study of previous work from this laboratory. Previous data from this laboratory, has
reported regional vascular adaptations when a localized forearm training stimulus was used [5,6].
These studies were used as a foundation to keep exploring the effects of training on the
vasculature, specifically the effects of resistance training on blood flow responses. Consequently
the goal of the first study was to examine the influence of two volumes (high and low) of wholebody circuit weight training on reactive hyperemia blood flow, venous capacitance and outflow
in younger healthy college individuals. The findings revealed significant and similar increases in
strength for the high and low volume groups. Although vascular function did not change
following circuit weight training, those individuals with the lowest pre-training vascular
measures did have significant increases in forearm reactive hyperemia blood flow and venous
outflow, independent of group assignment.
The second project in this dissertation focused on individuals who may have lower
vascular function due to some sort of pathologic condition. The prevalence of peripheral
neuropathy increases significantly in the older adult population and nearly one-third of all
diabetics suffer from this condition [7]. In addition, irrespective of etiology, pathological
changes associated with peripheral neuropathy are in many cases consistent with ischemia,
secondary to vascular insufficiencies [8]. Thus the second study was intended to examine the
2

relationship between measures of vascular (both arterial and venous) and physical function
(mobility and lower extremity strength) in individuals with peripheral neuropathy. These data
indicated a relationship between measures of vascular and physical function in peripheral
neuropathy. Indeed, individuals with greater physical function scores exhibited more favorable
measures of arterial inflow and venous outflow.
Although the previous studies were able to provide important information on how the
vasculature may be influenced or may influence physical function, these findings also
demonstrated how complex the study of vascular function could be. Finally, last step in this
process was to begin the exploration in some putative factors thought to control vascular
function. Clearly, vascular homeostasis is important to maintain vascular function. In that regard,
Deanfield et al., [9] have speculated the vascular function is very much influenced by the balance
of pro- and anti-oxidants. Thus the last study investigated the effects of an acute bout of exercise
on nitric oxide bioavailability, oxidative stress markers, and antioxidants markers at three time
points, before, at peak exercise, and at 20 minutes into the recovery phase in aerobically trained
individuals. These data suggest that an acute bout of exercise contributes to a significant rise in
reactive oxygen stress on the brachial artery, which can in part be buffered by anti-oxidants
systems, but may cause temporary blunting of the reactivity of the brachial artery. In summary
the findings of this dissertation further add to the current understanding of the role of the
vasculature in physical function.
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Chapter 2
Review of Literature
2.1 Introduction
Cardiovascular diseases remain the leading cause of death in the United States and most
western countries. Mortality data show that cardiovascular disease total mentioned in 2002
constituted about 58% of all deaths that year [10]. Furthermore, cardiovascular disease is the
underlying cause of death accounted for 36.3% of all deaths in 2004, or 1 of every 2.8 deaths in
the United States. In fact, an estimated 79 million American adults (1 in 3) have 1 or more types
of cardiovascular disease. Of these, 37 million are estimated to be age 65 or older [11]. Finally,
the economic burden of cardiovascular disease is enormous [12]. In fact, in 2004 the costs of
cardiovascular disease totaled an estimated $352 billion dollars in the United States [12].
Proper treatment of cardiovascular disease includes risk factor modification, pharmacotherapy, and surgery. Among the modifiable behaviors that increase risk of cardiovascular
disease are cigarette smoking, high blood pressure, obesity, and physical inactivity. In regard to
this last factor, there is no doubt that physical activity is beneficial for improving health.
Therefore, the role of physical activity will be addressed in this review, in part because of the
interest by the author, and second because evidence suggests that regular physical activity, as a
therapeutic intervention, not only beneficially effects symptoms and enhances myocardial
perfusion but also reduces mortality in patients with coronary artery disease/myocardial
infarction [13,14].
Over the last decade, exercise training has emerged as a very important intervention for
primary and secondary prevention of coronary artery disease [15]. Position statements developed
by the Surgeon General [16], the National Institutes of Health Consensus Development Panel on
4

Physical Activity and Cardiovascular Health [17], and the Centers for Disease Control and
Prevention and the American College of Sports Medicine [18] call for every adult to accumulate
at least 30 minutes of moderate-intensity physical activity on most, preferably all, days of the
week to prevent cardiovascular heart disease and other chronic diseases. Furthermore, exercise
should promote all aspects of physical conditioning, including aerobic capacity and muscular
endurance, range of motion and flexibility, and muscular strength.
Importantly, despite the evidence of the benefits of regular physical activity in the
management of individuals with cardiovascular disease, the manner in which exercise is
prescribed is often “generic” rather than tailored to an individual’s state, severity and type of
cardiovascular disease. This is particularly important given the evidence that individuals’
responses, adaptations, and compensations to a disease are often highly variable. In fact, the
problems with cardiovascular disease are not just limited to the cardiovascular system. In most
cases cardiovascular disease is the “tip” of the iceberg, as many other physiologic systems
attempt to compensate for the problems incurred by the cardiovascular system. These
“compensatory changes” are critical to understand as they to a large degree contribute to the
clinical course of patients afflicted by cardiovascular diseases.
This is particularly relevant in terms of choosing an appropriate treatment path. More
specifically, a “generic” recommendation to accumulate 30 minutes of exercise over the course
of a day may be insufficient to truly alter the disease progression or could in fact be harmful. For
example, clinicians may need to recognize that in many cases compensatory changes to a
particular form of cardiovascular disease is dramatically different from other manifestations of
the same disease. This is critical as we need to move from generic exercise programs to
individualized targeted treatment plans that may be more effective in its delivery. It is with this
5

concern in mind that has led me to examine the literature more closely. In doing so, two
interesting distinctive outcomes of cardiovascular disease are discussed: (a) Heart Failure, and
(b) Peripheral Arterial Disease.
The first one, heart failure is a condition that results from myocardial dysfunction that
impairs the heart's ability to pump blood at a rate sufficient to maintain the metabolic needs of
peripheral tissues and various organs. As a result of the cardiac problems, skeletal muscle blood
flow decreases contributing to the cardinal symptoms of heart failure including breathlessness
and fatigue on exertion. Although the primary defective organ in heart failure is the heart, the
periphery, including skeletal muscle becomes a secondary defective organ of major clinical
significance in the manifestation of the disease. Of major concern is preferential skeletal muscle
atrophy, in that more oxidative muscle fibers (Type I) are lost, and non-oxidative muscle fibers
(Type IIa and IIb) are preferentially maintained.
The second condition included is peripheral arterial disease, a manifestation of systemic
atherosclerosis in the lower limb distal to the aortic bifurcation. As with heart failure, peripheral
arterial disease is associated with significant morbidity and mortality. Anatomically peripheral
arterial disease is defined as atherosclerotic arterial disease, while functionally it is defined as
arterial narrowing, causing a decrease in muscle blood flow, and consequently a mismatch
between the oxygen supply and metabolic demand resulting in symptoms of intermittent
claudication, exercise limitations, or tissue loss. Patients with peripheral arterial disease also
undergo significant compensatory changes in skeletal muscle. However, in contrast to heart
failure, peripheral arterial disease patients show significant atrophy in non-oxidative (Type IIa
and IIb) skeletal muscle fibers, and preferentially retain the oxidative fibers (Type I). Thus, two
conditions, which essentially have a common underlying problem of reduced muscle blood flow
6

and subsequent exercise intolerance, have vastly different physiological and morphological
compensatory changes. It is this differential compensatory adaptation that serves as the major
stimulus for this review. The reason being that if patients with such a different compensation to
essentially the same problem, that is reduced blood flow, a generic recommendation for exercise
cannot be effective. Thus ultimately the quest is to determine the most effective exercise
strategies for individuals with cardiovascular disease. Those strategies can only evolve from a
detailed understanding of the underlying pathophysiological changes. Therefore, it is with that in
mind that this review is written. Consequently, the main focus of this review is to discuss the
central and peripheral mechanisms of exercise intolerance in patients with heart failure and
peripheral arterial disease.
2.2 Heart Failure
A major physiologic problem for patients with heart failure is a reduction in muscle blood
flow. As a consequence the cardinal symptoms of this disease are exercise intolerance, shortness
of breath, and chronic fatigue. In this section the following issues will be addressed: (a) the
definition, (b) the incidence and prevalence, (c) the etiology and pathophysiology, (d) the
cardinal symptoms and clinical outcomes, (e) the diagnostic tests and the prognostic value of
exercise testing, and finally (f) the classification of heart failure related to the degree of symptom
severity. Next, this section will present information regarding the principal circulatory and
muscular compensatory adaptations in heart failure patients. Finally, this section will discuss the
acute exercise responses, and the response to exercise training in heart failure patients. The
purpose of this section is to increase the understanding of the manner in which patients with
heart failure compensate to their reduction in blood flow, and the potential ramifications for
treatment strategies.
7

2.2.1 Definition
Heart failure is defined as "the pathophysiological state in which an abnormality of
cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with
the requirements of the metabolizing tissues and/or to be able to do so only from an elevated
filling pressure" [19]. This definition implies that there is an alteration in the normal
physiological pumping capacity of the heart.
Heart failure is a complex clinical syndrome that can result from any structural or
functional cardiac disorder (e.g. myocardial dysfunction) that impairs the heart's ability to
circulate blood at a rate sufficient to maintain the metabolic needs of peripheral tissues and
various organs [20]. The cardinal manifestations of heart failure are fatigue or dyspnea on
exertion progressing to dyspnea at rest [20].
Patients with heart failure suffer from decreased exercise capacity, impaired quality of
life, and poor prognosis [21]. Furthermore, the inability to perform exercise without discomfort
may be one of the first symptoms experienced by patients with heart failure and is often the
principal reason for seeking medical care. Therefore, exercise intolerance is inextricably linked
to the diagnosis of heart failure [22].
2.2.2 Incidence and Prevalence
Heart failure is a major and growing public health problem in the United States.
Approximately 5 million patients in this country have heart failure, and over 550 000 patients are
diagnosed with heart failure for the first time each year [23]. The disorder is the primary reason
for 12 to 15 million office visits and 6.5 million hospital days each year [24]. Indeed, heart
failure is the most common Medicare diagnosis-related group (i.e. hospital discharge diagnosis),
and more Medicare dollars are spent for the diagnosis and treatment of heart failure than for any
8

other diagnosis [25]. In addition, the estimated direct and indirect cost of heart failure in the
United States for 2007 is $33.2 billion [11].
The incidence of heart failure approaches 10 per 1000 population after age 65 [23]. Heart
failure is primarily a condition of the elderly [26], and thus the widely recognized “aging of the
population” also contributes to the increasing incidence of heart failure. Furthermore, a
community-based cohort study using the resources of the Rochester Epidemiology Project
conducted in Olmsted County, Minnesota [27], showed that the incidence of heart failure has not
declined during 2 decades, but survival after onset has increased overall, with less improvement
among women and elderly persons. Finally, the Framingham Heart Study [28] have revealed that
at age 40, the lifetime risk of developing heart failure for both men and women is 1 in 5, and the
lifetime risk of heart failure occurring without antecedent of myocardial infarction is 1 in 9 for
men and 1 in 6 for women.
The Framingham Heart Study and the Framingham Offspring Study [29] indicated that
hypertension is a very common risk factor for heart failure. Truly, seventy-five percent of heart
failure cases have antecedent of hypertension [28], and the lifetime risk doubles for people with
blood pressure greater than 160/90 mm Hg versus those with blood pressure less than 140/90
mm Hg [28]. In addition, the Heart and Estrogen/progestin Replacement Study (HERS) of the
predictors of heart failure among women with coronary heart disease found that diabetes was the
strongest risk factor [30]. Furthermore, it is relevant to mention that heart failure is a common
manifestation of the later stages of various cardiovascular diseases, including coronary artery
disease, hypertension, valvular disease, and primary myocardial disease [11].
Heart failure total-mentioned mortality in 2002 was 286 700 [11]. On the basis of the 44year follow-up among Framingham Heart Study participants, 80% of men and 70% of women
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under age 65 who have heart failure will die within 8 years [28]. After heart failure is diagnosed,
survival is poorer in men than in women, but fewer than 15% of women survive more than 8 to
12 years. In people diagnosed with heart failure, sudden cardiac death occurs at 6 to 9 times the
rate of the general population [28]. The 2004 overall death rate for heart failure was 19.1 %.
Death rates were 20.3% for white males, 22.9% for black males, 18.3% for white females, and
19.0% for black females [31].
2.2.3 Etiology and Pathophysiology
The etiology of heart failure is displayed in table 2.1. The clinical syndrome of heart
failure may result from disorders of the pericardium, myocardium, endocardium, or great vessels,
but the majority of patients with heart failure has symptoms due to an impairment of left
ventricular myocardial function [32]. Heart failure may be associated with a wide spectrum of
left ventricular functional abnormalities, which may range from patients with normal left
ventricular size and preserved ejection fraction to those with severe dilatation and/or markedly
reduced ejection fraction [32].
In most patients, abnormalities of systolic and diastolic dysfunction coexist, regardless of
ejection fraction. Patients with normal ejection fraction may have a different natural history and
may require different treatment strategies than patients with reduced ejection fraction, although
such differences remain controversial [32]. The most common causes of heart failure in the
United States are coronary artery disease, systemic hypertension, non-ischemic dilated
cardiomyopathy, and valvular heart disease [23].
Other frequent causes are myocarditis and diabetes mellitus, but there are a great many
less common causes [20]. As a result, when an excessive workload is imposed on the heart by
increased systolic blood pressure (pressure overload), increased diastolic volume (volume
10

overload), or loss of myocardium, normal myocardial cells hypertrophy in an effort to enhance
contractile force of the normal areas [33]. The subsequent alterations in biochemistry,
electrophysiology, and contractile function lead to mechanical alterations of myocardial function.
Table 2.1 Etiology of heart failure
Etiology
Coronary artery disease
Hypertension
Valvular heart disease
Familial/genetic cardiomyopathy
Metabolic disorders
Myocarditis
Collagen vascular disease
Endocrine disorders
Electrolyte disorders
Acidosis
Sepsis
Hypoxia
Alcohol
Toxins (chemotherapy, cocaine)
Peripartum

The rate of contraction slows, the time to develop peak tension increases, and myocardial
relaxation is delayed. Peak force development may be well preserved with enough viable
myocardium and adequate time for the development of force. Thickening of the ventricular wall
limits the rate of ventricular filling (diastolic dysfunction), which is worsened by increased heart
rate because it shortens the duration of ventricular filling [34].
The force of myocardial contraction is eventually reduced as cell loss and hypertrophy
continues, leading to significant geometric ventricular alterations and increased volumes [20].
After the initial compensatory phase, the increase in intracavitary volume is usually associated
with further reductions in ventricular ejection fraction (progressive systolic dysfunction) and
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eventually abnormalities in the peripheral circulation from activation of various neurohumoral
compensatory mechanisms [33].
Finally, the abnormal neurohumoral responses lead to increased systemic sympathetic
tone and activation of the renin-angiotensin system [35]. Production of angiotensin increases,
causing peripheral vasoconstriction. The increase in peripheral arterial resistance limits cardiac
output during exercise. The increased levels of angiotensin II also stimulate release of
aldosterone by the adrenal glands, enhancing sodium retention and thus leading to fluid retention
and peripheral edema [33].
2.2.4 Symptoms
The symptoms of heart failure can be caused by either an abnormality in systolic function
that leads to a defect in the ejection of blood from the heart (systolic heart failure) or an
abnormality in myocardial diastolic function that leads to a defect in ventricular filling (diastolic
heart failure) [32]. Reduced left ventricular filling caused by diastolic dysfunction leads to
decreased stroke volume and associated symptoms of low cardiac output, whereas increased
filling pressures lead to symptoms of pulmonary congestion [20]. Thus, some characteristics of
heart failure (e.g. the inability of the left ventricle to provide adequate forward output to meet the
demands of the skeletal muscles during exercise while maintaining normal filling pressures) may
result primarily from diastolic dysfunction, which, in some patients, can occur with normal left
ventricular systolic function [32]. There are no exact data on the prevalence of diastolic
dysfunction leading to heart failure in the presence of normal systolic function.
Several studies have shown, however, that as many as 40% of all patients with a clinical
diagnosis of heart failure may have preserved LV systolic function, and many of these patients
have evidence of diastolic dysfunction [32]. The following section will present a brief overview
12

of the clinical findings in heart failure patients. First, the major symptoms that affect heart failure
patients will be outlined.
2.2.4.1 Shortness of Breath
Dyspnea or breathlessness (a subjective feeling of air hunger), is the earliest and most
frequent symptom in heart failure. Initially, dyspnea on exertion will be noted by a change in the
extent of physical activity that causes shortness of breath. As heart failure worsens, the intensity
of exertion required will decrease. The patient with heart failure will progressively develop
paroxysmal nocturnal dyspnea, orthopnea, and eventually dyspnea at rest [36].
2.2.4.1.1 Paroxysmal Nocturnal Dyspnea
Paroxysmal nocturnal dyspnea normally occurs after the patient has been asleep and in
the supine position for some time. Suddenly, the patient wakes up with a sensation of choking
and air hunger; assuming an upright posture usually relieves the symptoms. Frequently the
patient will feel better after opening a window or going outside to catch a breath of fresh air.
Paroxysmal nocturnal dyspnea usually precedes orthopnea; it may be associated with
bronchospasm and wheezing (cardiac asthma) and can be confused with an attack of bronchial
asthma, especially in patients with prior known chronic obstructive pulmonary disease [33].
Many patients with heart failure also have chronic obstructive pulmonary disease; it may be
difficult to distinguish between the dyspneic symptoms secondary to heart failure and those that
are due to chronic obstructive pulmonary disease.
Most severe episodes of paroxysmal nocturnal dyspnea can cause a feeling of intense
suffocation and may leave the patient gasping for breath. The uncomfortable sensation may
persist for 30 minutes or more after the patient has assumed an upright posture [37]. Paroxysmal
nocturnal dyspnea is primarily caused by mobilization of interstitial fluid (especially in patients
13

with edema). The result is increased circulating blood volume and increased pulmonary venous
pressure, especially in patients with left ventricular diastolic dysfunction [38].
2.2.4.1.2 Orthopnea
Orthopnea is defined as dyspnea that occurs often within a few minutes when the patient
assumes a supine position; sitting up or standing usually improves the symptoms. The most
severely affected patients usually sleep sitting upright in a chair. Orthopnea has the same cause
as paroxysmal nocturnal dyspnea, but it represents more severe cardiac impairment [33].
2.2.4.1.3 Nocturnal Dyspnea or Exertional Dyspnea
Nocturnal dyspnea is a dry or nonproductive cough. This is due to pulmonary congestion
and in patients with heart failure is usually relieved by successful treatment of the heart failure
[36].
2.2.4.2 Fatigue and Weakness
Fatigue and generalized weakness are present in heart failure patients particularly in the
limbs. These symptoms are secondary to low cardiac output with decreased perfusion of skeletal
muscles and can occur with exertion or at rest; they may be worsened after eating because of the
increased splanchnic demand for blood flow, which may stress the limited reserve. Low-output
syndromes can be present, without evidence of pulmonary congestion, and limit performance
during exercise testing [37]. It is important to emphasize that breathlessness and fatigue on
exertion are the dominant symptoms of heart failure [39]. Indeed, these symptoms are the
primary determinants of their health- related quality of life [22].
A traditional view of the pathophysiology of the symptoms runs as follows: first, the
failing heart has an impaired response to exercise. In turn, this leads to failure to perfuse the
exercising muscle adequately; the unhappy skeletal muscle signals the brain, and this sensation is
14

interpreted as fatigue. Second, the failing heart requires an ever higher left ventricular filling
pressure to maintain output, particularly during exertion; the filling pressure can rise high enough
to cause either stiff lungs or even transudation of fluid into the alveoli, which causes
breathlessness [39].
2.2.4.3 Nocturia and Oliguria
Nocturia is a common and early symptom in heart failure. Renal filtration of sodium and
water is decreased in patients with compromised left ventricular function, in part, because of the
redistribution of blood flow away from the kidneys in the upright position and during physical
activity. Urine formation is enhanced in the recumbent position when renal stimulus for
vasoconstriction decreases and venous return to the heart increases. Oliguria is associated with a
markedly reduced cardiac output and is usually a sign of terminal heart failure; it indicates a poor
prognosis [36].
2.2.4.4 Cerebral Symptoms
Elderly patients with advanced heart failure may develop confusion, memory impairment,
anxiety, headaches, insomnia, nightmares, and, occasionally, disorientation, delirium, and
hallucinations. These cerebral symptoms are predominantly related to reduce cardiac output and
poor perfusion of brain and other neurologic tissues [33].
2.2.4.5 Abdominal Symptoms
Patients with heart failure may also develop gastrointestinal complaints because of
hepatic congestion and edema of the abdominal wall and intraabdominal organs [36]. Congestion
of abdominal organs may be present with ascites, abdominal fullness and enlargement, easy
satiety, bloating, anorexia, nausea, vomiting, constipation, and upper abdominal discomfort. The
abdominal discomfort is usually described as a dull ache or heaviness that can be enhanced or
15

reproduced by upper abdominal or hepatic palpation. This is consistent with the likely cause, the
stretching of the hepatic capsule [40]. Patients can frequently detect early re-accumulation of
fluid by the recurrence of abdominal fullness before the signs become obvious. This symptom
can be easily overlooked, however. Asking the patient about a recent change in waist size or
atightening of the clothing at the waist is often helpful [40].
After describing the major symptoms among heart failure patients, it is necessary to
review the clinical outcomes obtained in a medical examination. Normally, during a physical
examination, patients with heart failure of recent onset appear acutely ill but well nourished. On
the other hand, patients with advanced stages of heart failure frequently appear malnourished,
and occasionally cachectic. Thus, some of the clinical outcomes or signs revealed throughout a
physical examination will be outlined in the next section.
2.2.5 Clinical Outcomes
2.2.5.1 Cardiomegaly
Cardiomegaly with a laterally displaced, enlarged, and sustained ventricular impulse may
be found on physical examination, but this is a nonspecific finding and can be absent,
particularly in patients with acute heart failure. The decrease in ventricular compliance may
initially become apparent by the presence of a late diastolic atrial sound (S4 gallop). A
protodiastolic sound (S3 gallop) occurs in patients with more advanced heart failure and is
caused by acute deceleration of ventricular inflow after the early filling phase [41]. An S3 gallop,
however, can also be detected in other conditions such as mitral and tricuspid regurgitation and a
left-to-right shunt.
Gallop sounds are more readily audible in the presence of a rapid heart rate. The presence
of a third heart sounds appears to be associated with an increased risk of death, death from pump
16

failure, and hospitalization for heart failure [41]. Systolic murmurs are common in heart failure
and are largely secondary to mitral or tricuspid regurgitation that can result from ventricular
dilatation. These murmurs frequently diminish or disappear after adequate treatment and
reduction of ventricular size [40].
2.2.5.2 Systemic Venous Hypertension
Can be detected by abnormal distension of the jugular veins (the upper limit of the
jugular venous pressure is about 4 cm above the sternal angle with the patient recumbent at a 45°
angle) [41]. Although the jugular venous pressure normally declines on inspiration, it can rise in
patients with right heart failure (Kussmaul's sign). Persistent elevation of the jugular venous
pressure is one of the earliest and most reliable signs of right-heart failure [41]. The inability of
the right ventricle to accept transient increases in venous return (hepatojugular reflux) is
observed during transient compression (≥30 s) of the upper abdomen [40].
Systolic pulsations of the liver may be felt in patients with tricuspid regurgitation. Liver
enlargement and tenderness on palpation are marked by epigastric fullness and dullness to
percussion in the right upper quadrant. These findings may persist after other signs of heart
failure have disappeared because it takes longer for hepatic congestion to disappear. In some
cases, the liver enlargement does not disappear because of structural changes in patients with
long-standing heart failure. The presence of an elevated jugular venous pressure appears to be
associated with an increased risk of death, death from pump failure, and hospitalization for heart
failure [36,41].
2.2.5.3 Pulsus Alternans
Pulsus alternans is common in patients with heart failure; when severe, it can be detected
by sphygmomanometry or by palpation of peripheral pulses, particularly the femoral pulse. This
17

sign is characterized by a regular rhythm of alternating strong and weak pulsations [42].
Sometimes the weak beat may be so small that the aortic valve does not open and no aortic or
arterial pulse is produced, resulting in total alternans and a pulse that is only half as fast as the
apical beats [40]. With total alternans, a first heart sound will occur, but no second heart sound if
both the aortic and pulmonic valves fail to open.
Pulsus alternans appears to be due to an alternation in the stroke volume of the left
ventricle, possibly because of an incomplete recovery of myocardial cells and thus a decrease in
the responsiveness of contracting cells on alternate beats [43]. It can be persistent or paroxysmal,
or it may occur only after a premature beat or with the Valsalva maneuver. The hemodynamic
response to the Valsalva maneuver has been found useful in the clinical evaluation of patients
with heart failure [43].
In this maneuver the blood pressure cuff is inflated to just about 15 mm Hg above the
systolic blood pressure before the maneuver. In a normal response, the Korotkoff sounds
disappear during sustained maneuver and reappear after completion of the maneuver. An
abnormal response, in which blood pressure sounds either do not disappear or are maintained
throughout the maneuver, has been found in patients with heart failure [42]. In normal patients,
the decrease in blood pressure during the maneuver is associated with tachycardia and the
increase in blood pressure after release with bradycardia. No changes in heart rate are observed
in heart failure patients.
Although heart failure is a clinical diagnosis based on a careful history and physical
examination, there are diagnostic tests that have shown being reliable in the evaluation of
patients with heart failure [40]. Thus, the following section will present information regarding
these diagnostic tests.
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2.2.6 Diagnostic Tests
2.2.6.1 Chest Radiograph
Cardiomegaly (cardiothoracic ratio > 50%) can be found on chest film in 87% of patients
when first diagnosed with primary dilated cardiomyopathy [40]. The lower lobes of the lung are
normally better perfused than are the upper lobes; with heart failure, there is progressive
vasoconstriction of vessels in the lower lobes and redistribution of the pulmonary flow to the
upper lobes. Interstitial and perivascular edema develop with acute increases in pulmonary
capillary wedge pressure above 20-25 mm Hg; bronchovascular markings at the bases are
prominent.
Interstitial edema can present as perivascular or peribronchial edema (initially in perihilar
and then in peripheral zones) [36]. Kerley's lines, spindle-shaped linear opacities at the periphery
of the lung bases, occur in the later stages of heart failure; pleural fluid can produce discrete
interlobular-type linear opacities and subpleural fluid accumulation between the lung and
adjoining pleura [40].
The accumulation of fluid in major and minor lung fissures can be of considerable size
and may be incorrectly diagnosed as a tumor mass in the lung [37]. These "phantom tumor"
shadows, however, have smooth margins and disappear with resolution of heart failure. With
acute increases in pulmonary capillary wedge pressures above 25 mm Hg, alveolar edema,
pleural effusions, or both may occur. Heart failure patients may show elevated pulmonary
capillary pressures in the range of 25-35 mm Hg or more without interstitial or alveolar edema,
reflecting associated increased lymphatic flow [44]. After therapy that lowers pulmonary
capillary pressure, there may be a delay of 24-48 h before improvement and clearing of
pulmonary infiltrates can be seen on chest radiograph [40].
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2.2.6.2 Electrocardiography
Changes in the 12-lead electrocardiography are generally nonspecific. Sinus tachycardia
is usually present in uncompensated heart failure or in end-stage disease with a low stroke
volume that requires tachycardia to maintain the cardiac output. Isolated premature ventricular
beats are common, and complex ventricular arrhythmias can be detected in most patients during
prolonged (24-48 h) Holter monitoring. Electrocardiographic findings suggestive of atrial and
ventricular chamber enlargement may be evident. Intraventricular conduction delays are also
common and include left bundle branch block as well as other, nonspecific repolarization
changes [40].
2.2.6.3 Exercise Stress Testing
There are three major types of exercise tests used to obtain an objective measurement of
exercise performance in heart failure patients [45]; (a) the symptom-limited progressive exercise
test carried to the point of exhaustion (cardiopulmonary exercise stress testing); (b) the test of
endurance at a predetermined level of exercise (which is submaximal); and (c) tests of
submaximal exercise performance, such as the time taken to complete a typical walking task or
the distance covered at a comfortable walking speed along a corridor (the corridor walking test)
or a self-propelled treadmill [46]. The first two tests are done using a bicycle ergometer or
treadmill [47]. For the last one, submaximal exercise performance, the 6-min walk test has been
promoted as a safe, well-tolerated, and a simple measure of functional capacity in heart failure
patients [48].
In addition, the most common measure of fatigue in practice is the Borg scale [49], which
can be graded separately for fatigue and dyspnea. Although fatigue remains a major complaint of
patients, it is rare in practice to monitor this symptom or its progression [50]. It is important to
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emphasize the prognostic value of some of the above exercise tests used to evaluate patients with
heart failure. Therefore, two specific modalities will be addressed in the next section. The first
one, an incremental test with metabolic gas exchange measurement, which is the most useful
[39]; the second, the 6-minute walk test, which is commonly used and simple to administer [51].
The prognostic value of exercise testing in heart failure is as follow:
2.2.6.3.1 Cardiopulmonary Exercise Stress Testing
A cardiopulmonary exercise stress testing properly performed provides an objective
measurement of peak functional capacity, and has become an important clinical tool with which
to define disease severity and to predict outcome in patients with heart failure due to left
ventricular systolic dysfunction [52]. Indeed, cardiopulmonary exercise stress testing plays a
pertinent role in decision-making about the workup of the heart failure patient [47].
During a cardiopulmonary exercise stress testing, the subject exercises to exhaustion,
breathing through a tight fitting mask or mouthpiece, and the expired air is collected and
analysed [53]. Contrary to what is observed in athletes or fit subjects, what is measured at the
end of exercise in a heart failure patient is not a plateau of maximum oxygen consumption
(VO2max) [54]. Heart failure patients generally stop exercising early because of fatigue or
dyspnea. Other reasons for stopping a test include chest pain, ischemia, decrease in blood
pressure, arrthymias [53].
The cardiopulmonary exercise stress testing provides information concerning three
important variables [39]; (a) peak oxygen consumption (VO2), (b) the slope of the relation
between ventilation and carbon dioxide production (VE/VCO2), and (c) the respiratory exchange
ratio (RER). Peak oxygen consumption is defined as the maximum rate of oxygen consumption
achieved and is used as an index of exercise performance. The slope of the relation between
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ventilation and carbon dioxide production is used as an index of the ventilatory response to
exercise. Finally, the respiratory exchange ratio is defined as the ratio of carbon dioxide
production to peak oxygen consumption.
There is overwhelming evidence of the role played by peak oxygen consumption in
stratifying risk in heart failure [39,55,56]. In fact, a study by Mancini et al., [57] is considered to
be the cornerstone of the documentation of the prognostic power of peak oxygen consumption.
In that regard, the study by Mancini et al., [57] divided heart failure patients into the following
three groups (see table 2.2).
Table 2.2 Peak oxygen consumption (VO2) in stratifying risk in heart failure patients
Group

Peak VO2

1-Year
Survival
Rates
48%

1

Patients with peak VO2 of < 14 mL/kg/min who
had been accepted for heart transplantation

2

Patients with peak VO2 of ≥ 14 mL/kg/min who
had transplant deferred

94%

3

Patients with peak VO2 of < 14 mL/kg/min but
with significant comorbidity that precluded heart
transplantation

47%

Furthermore, a peak VO2 of < 10 mL/kg/min was associated with significantly poorer
predicted survival [45]. Lastly, the results of the study by Mancini et al., [57] were adopted by
the American Heart Association/American College of Cardiology consensus statement on the
selection and treatment of candidates for heart transplantation [58].
In addition, the anaerobic threshold has been proposed as a submaximal index of exercise
capacity, independent of the patient’s motivation, and has been classically defined as the point
where lactate increases in plasma during exercise, as a consequence of the transition from total
aerobic to aerobic plus anaerobic metabolism [45]. A failure to reach the ventilatory anaerobic
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threshold strongly suggests poor motivation or non-cardiovascular limitation of exercise
tolerance. Indeed, Opasich et al., [59] evaluated the predictive role of peak VO2 in 505 heart
failure patients when the ventilatory anaerobic threshold (VAT) was or was not detected (see
table 2.3).
These findings were also reported by Corra et al., [45]. Indeed, the study by Corra et al.,
[45] concluded that when ventilatory anaerobic threshold is detected, patients with a peak VO2
of < 10 mL/kg/min have a high event rate, whereas those with a peak VO2 of > 18 mL/kg/min
havea good prognosis. However, it is important to recognize that a multiplicity of factors
influence any given peak VO2 value [45]. In fact, it is well-known that peak VO2 is affected by
age, gender, body weight, muscle mass, and conditioning status [60,61].
Table 2.3 Predictive role of peak VO2 and VAT in heart failure patients
Peak VO2

VAT was identified
cardiac event rates

VAT was not detected
cardiac event rates

≤ 10 mL/kg/min
> 10 to ≤ 14 mL/kg/min
> 14 to ≤ 18 mL/kg/min
> 18 mL/kg/min

59%
32%
32%
15%

46%
29%
23%
22%

In addition, many studies have revealed that ventilatory expired gas parameters obtained
from symptom-limited cardiopulmonary exercise stress testing represent prognostic value in
heart failure patients [62,63]. In that regard, figure 2.1 displays the relationship between
ventilation and carbon dioxide production (VE/ VCO2). The VE/ VCO2 slope is highly linear, and
the slope is increased with increasing severity of heart failure that is, for any given level of
carbon dioxide production, the ventilator response is increased with worsening heart failure
symptoms [39].
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Finally, Corra et al., [45] after reviewing some of those findings have suggested that the
risk stratification procedure with symptom-limited cardiopulmonary exercise stress testing in
heart failure patients, traditionally based on peak oxygen consumption and ventilator anaerobic
threshold, should be replaced by a new prognosticating algorithm that is structured on a
multiparametric decoding scrutiny employing the stepwise introduction of peak VO2, VE/VCO2
slope, and peak respiratory exchange ratio [45].

Figure 2.1. Ventilation/carbon dioxide production (VE/ VCO2) slope in heart failure.
Note that the relation between VE and VCO2 remains linear but that the slope
increases with worsening heart failure. Thus, for a VCO2 of 1 L/min, a normal subject
has to ventilate at 22 L/min and the patient with moderate heart failure ventilates at
42 L/min [39].
2.2.6.3.2 The 6- Minute Walk Test
The 6-minute walk test is considered to be realistically related to daily physical activity
[64]. Furthermore, the 6-minute walk test is used to estimate functional capacity in patients with
a variety of medical conditions, and can be performed by those who are unable or unwilling to
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undertake formal treadmill or bicycle exercise tests [65]. Thus, among heart failure patients, it
has been incorporated into studies of assessment of exercise capacity [66], of quality of life [67],
of efficacy of new therapeutic agents [68] including beta-blockers [69], of physical training
programs [70], and of prognostic stratification [71,72].
According to the American Thoracic Society (ATS) Statement for Guidelines for the SixMinute Walk Test [73], the 6-minute walk test should be performed indoors, along a long, flat,
straight, enclosed corridor with a hard surface that is seldom traveled. If the weather is
comfortable, the test may be performed outdoors. The walking course must be 30 m in length. A
100-ft hallway is, therefore, required. The length of the corridor should be marked every 3 m.
The turnaround points should be marked with a cone (such as an orange traffic cone). A starting
line, which marks the beginning and end of each 60-m lap, should be marked on the floor using
brightly colored tape.
In order to study the potential usefulness of the 6-minute walk test, the Studies of Left
Ventricular Dysfunction (SOLVD) Registry Substudy followed 833 heart failure patients for an
average of 242 days [71]. This cohort reported that the 6-minute walk test is a safe and simple
clinical tool that strongly and independently predicts morbidity and mortality in patients with left
ventricular dysfunction. Indeed, table 2.4 displays the significance of the 6-minute walk test in
estimating a patient’s prognosis in heart failure [71]. Furthermore, previous studies have
identified that walking <300 m during the 6-minute walk test is a simple prognostic marker of
subsequent cardiac death in patients with mild-to-moderate heart failure [74].
However, studies that have evaluated the relationship between the 6-minute walk test to
peak oxygen consumption (VO2) in heart failure patients have reported that the 6-minute walk
test cannot be used in the individual heart failure patient as an alternative to, or as a surrogate of,
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peak VO2 [48,64,75]. In that regard, Opascih et al., [64] found no significant correlation between
the distance walked during the 6-minute walk test and hemodynamic indices (left ventricular
ejection, cardiac index, right and left filling pressures) and found only a moderate correlation
with functional capacity indicators (peak VO2).
Therefore, these investigators concluded that the walking performance does not provide
prognostic information which can either complement or substitute that provided by peak VO2 or
the New York Heart Association (NYHA) classification for heart failure [64].
Table 2.4 Relationship between 6-minute walk test distance and heart failure
readmission rates and mortality
6-minute walk test
distance

Heart failure
readmissions

Mortality

<300 m
300–374.9 m
375–449.9 m
≥450 m

22.16%
11.20%
3.72%
1.99%

10.23%
7.88%
4.19%
2.99%

Furthermore, the prediction of peak VO2 based on regression equations derived from the
relationship between peak VO2 and 6-minute walk test results in too much variability to be
clinically useful [48]. While 6-minute walk test may be appealing based on its ease of application
and potential prognostic value in a subset of heart failure patients, this variable does not correlate
well with peak and submaximal exercise parameters that have proven validity and reliability in
heart failure patients [48]. This investigator concluded that when an accurate determination of
functional capacity is required, direct measurements of peak VO2 and ventilatory anaerobic
threshold are still the preferred outcome measures in heart failure patients.
In summary, peak VO2 is a convincing, strong, and independent predictor of outcome,
supporting the value of cardiopulmonary exercise stress testing as a clinical tool in heart failure.
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However, in the last few years recent research have discovered that a single arbitrary cut point
value for peak VO2 is unlikely to describe the true risk of events, and that a multiparametric
stepwise approach may be more successful. Finally, the 6-minute walk test, a submaximal
exercise test, may serve as a more straightforward clinical tool to assess functional capacity
when the cardiopulmonary exercise stress testing could not be evaluated in heart failure patients.
The above section have outlined the significant prognostic value of two exercise tests
modalities, the cardiopulmonary exercise stress testing and the 6-minute walk test. The next
section will continue addressing the additional diagnostic tools used in patients with heart failure.
2.2.6.4 Echocardiography
The single most useful diagnostic test in the evaluation of patients with heart failure is the
comprehensive 2-dimensional echocardiogram coupled with Doppler flow studies to determine
whether abnormalities of myocardium, particularly cardiomyopathy (dilated, restrictive,
hypertrophic), heart valves, or pericardium are present and which chambers are involved [40].
2.2.6.5 Laboratory Blood Tests
In severe heart failure, neurohumoral compensatory mechanisms frequently lead to hyponatremia
and other significant electrolyte abnormalities, even without the use of diuretics, which
(especially the thiazide type) may contribute to hyponatremia [76]. This effect is less prominent
with furosemide, the only diuretic that increases free water clearance through a mechanism that
is resistant to the action of vasopressin [43]. In fact, furosemide may be necessary to correct
hyponatremia in patients with heart failure [43]. Hypokalemia is also very common with use of
diuretics, especially the long-acting thiazides. Hyperkalemia may occur in patients with very low
cardiac output or renal insufficiency. It can also occur in patients who are ingesting additional
potassium through salt substitutes, especially when given in addition to a potassium-sparing
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diuretic or angiotensin-converting-enzyme inhibitor, such as captopril, which also blocks the
release of aldosterone. Reduced renal blood flow can lead to moderate increases in the blood
urea nitrogen and mild increases in sodium creatinine [40].
2.2.6.6 Cardiac Catheterization
Left-heart catheterization and angiography are necessary when the presence and extent of
coronary artery disease need to be determined, particularly if cardiac surgery (valve replacement,
aneurysmectomy, coronary artery bypass surgery) can possibly improve ventricular dysfunction.
Right-heart catheterization may be useful in evaluating and selecting patients with refractory
heart failure who require customized treatment [40].
2.2.6.7 Radionuclide Ventriculography
This method is helpful in documenting the severity of left ventricular systolic dysfunction
and indicating whether the wall motion abnormalities are global or regional. This test is
especially helpful in patients who present technical difficulties for echocardiography; it can, for
example, be obtained easily even in obese patients. Comparison of right and left ventricular
stroke volumes is also helpful in establishing the severity of regurgitant lesions [76].
So far, this review has presented the major symptoms, signs and diagnostic tools in heart
failure patients that help physicians to determine the current clinical status of these patients. In
addition, the information presented until now is needed to properly quantify the degree of
functional limitation in heart failure patients.
2.2.7 Classification According to the Symptom Severity
The approach that is most commonly used to quantify the degree of functional limitation
imposed by heart failure is one first developed by the New York Heart Association (NYHA)
[77]. The NYHA classification has 4 classes. This system assigns patients to 1 of 4 functional
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classes, depending on the degree of effort needed to elicit symptoms (see table 2.5).
In addition, The American College of Cardiology (ACC) and the American Heart
Association (AHA) have jointly engaged in the production of guidelines in the area of
cardiovascular disease since 1980. This effort is directed by the ACC/AHA Task Force on
Practice Guidelines. The 2001 report by the ACC/AHA Guidelines for the Evaluation and
Management of Chronic Heart Failure in the Adult [78] have identified 4 stages involved in the
development of the heart failure syndrome (see table 2.6). Stages A and B patients are best
defined as those with risk factors that clearly predispose toward the development of heart failure.
Table 2.5 The NYHA classification for heart failure
Class
Class I

The New York Heart Association Classification
Patients with cardiac disease but without resulting limitations of
physical activity. Ordinary physical activity does not cause
undue fatigue, palpitation, or dyspnea
Class II Patients with cardiac disease resulting in slight limitation of
physical activity. They are comfortable at rest. Ordinary physical
activity results in fatigue, palpitation, or dyspnea
Class III Patients with cardiac disease resulting in marked limitation of
physical activity. They are comfortable at rest. Less than
ordinary activity causes fatigue, palpitation, or dyspnea
Class IV Patients with cardiac disease resulting in inability to carry on
any physical activity without discomfort. Symptoms are present
even at rest or minimal exertion

This classification recognizes that there are established risk factors and structural
prerequisites for the development of heart failure and that therapeutic interventions introduced
even before the appearance of left ventricular dysfunction or symptoms can reduce the
population morbidity and mortality of heart failure. Furthermore, this classification system is
intended to complement but in no way to replace the New York Heart Association functional
classification [77], which primarily gauges the severity of symptoms in patients who are in Stage
C or Stage D.
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Table 2.6 The ACC/AHA classification for heart failure
Stage
Stage A
Stage B
Stage C
Stage D

The American College of Cardiology and the American Heart
Association Classification
Patients with coronary artery disease, hypertension, or diabetes
mellitus who do not yet demonstrate impaired left ventricular
(LV) function, hypertrophy, or geometric chamber distortion
Patients who are asymptomatic but demonstrate LV
hypertrophy (LVH) and/or impaired LV function
Patients with current or past symptoms of heart failure
associated with underlying structural heart disease (the bulk of
patients with heart failure)
Patients with truly refractory heart failure who might be
eligible for specialized, advanced treatment strategies, such as
mechanical circulatory support, procedures to facilitate fluid
removal, continuous inotropic infusions, or cardiac
transplantation or other innovative or experimental surgical
procedures, or for end-of-life care, such as hospice

In summary, heart failure is a major and growing public health problem in the United
States. Heart failure is a clinical syndrome that impairs the heart's ability to circulate blood at a
rate sufficient to maintain the metabolic needs of peripheral tissues and various organs. The
cardinal manifestations of heart failure are fatigue or dyspnea on exertion. In addition, exercise
intolerance is inextricably linked to the diagnosis of heart failure. Finally, the New York Heart
Association classification is used to quantify the degree of functional limitation imposed by heart
failure. The next section will present information regarding the principal circulatory and
muscular compensatory adaptations in heart failure patients.
2.2.8 Compensatory Adaptations to Heart Failure
Heart failure develops in response to an insult to the cardiovascular system [79]. This
alteration is principally due to three distinct etiologies [80]; (a) intrinsic myocardial disease
secondary to coronary heart disease, cardiomyopathy, and infiltrative disease; (b) excess work
load due to increased resistance to ejection (pressure load) secondary to hypertension and
hypertrophic cardiomyopathy or increased stroke volume (volume load) secondary to aortic
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insufficiency and valvular insufficiency; and (c) iatrogenic myocardial damage from drugs
(doxorubicin and disopyramide) or radiation therapy for mediastinal tumors or Hodgkin's
disease.
The insult to the cardiovascular system is frequently met with a variety of compensatory
adaptations with short-to long-time constants aimed to maintain cardiac output and arterial
pressure to adequately perfuse the brain and the heart. These compensatory adaptations include:
(a) an increase in ventricular end-diastolic volume and pressure (ventricular dilatation); (b)
sympathetic nervous system activation; (c) neurohumoral vasoconstriction; (d) renal sodium and
water retention; (e) myocardial hypertrophy; (f) impaired vasodilatory capacity; and (g) intrinsic
changes in skeletal muscle. Although, these compensatory adaptations may be remarkably
effective under resting conditions, the capacity to sustain cardiac performance in the face of
hemodynamic overload relative to myocardial contractility is finite and exacts a price [81].
Indeed, it is those compensatory mechanisms that ultimately contribute significantly to the
clinical severity of the disease.
Therefore, the focus of this section of this review is on the morphological, biochemical,
cellular, and neurohumoral changes characteristic of heart failure and how these relate to the
exercise tolerance, a marker of the clinical severity of the disease. A particular focus of the
review is the manner in which these changes alter skeletal muscle blood flow, thereby
significantly affecting the patient’s functional abilities.
2.2.8.1 Cardiovascular Compensatory Adaptations
It is important to reinforce that regardless of the etiology, heart failure results from
myocardial dysfunction that impairs the heart's ability to circulate blood at a rate sufficient to
maintain the metabolic needs of peripheral tissues and various organs [82]. This applies to both
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the resting and active states and results in significant vasoconstriction and the shunting of blood
toward vital organs and away from peripheral structures [83].
In addition, the manifestations of heart failure depend on the rate at which the syndrome
develops [82]. Generally, if the underlying cardiac abnormality develops slowly, compensatory
mechanisms have time to become activated, and the patient will be able to adjust to the altered
cardiac output [40]. In contrast, if the underlying condition develops rapidly or an acute
precipitating factor is present, the result may be inadequate organ perfusion or acute congestion
of the venous bed draining into the affected ventricle, causing sudden cardiac decompensation,
with a concomitant reduction in cardiac output and an acute onset of symptoms [40,82].
Thus, the development and progression of heart failure depend on the etiology and
severity of the underlying disease. Furthermore, there are basically four mechanisms that initiate
the sequence leading to heart failure: (a) pressure overload, (b) volume overload, (c) primary
myocardial disease (myocarditis, cardiomyopathy), and (d) myocardial infarction [40,84]. In
each case, through different mechanisms, the myocardium mechanically compensates for the
primary defect before the stage of overt myocardial failure develops. In addition, complex
neuroendocrine changes [84,85] attempt to maintain the circulation and normal organ perfusion
in the face of decreasing myocardial function. These changes engage activation of the reninangiotensin and other systems that cause peripheral vasoconstriction, thereby maintaining the
blood pressure while punishing the heart by increasing the afterload [83,84]. Although the
central hemodynamic abnormalities are the primary pathophysiological features of heart failure,
the neurohumoral responses play an important role in its progression and prognosis. Therefore,
this section will review first the major hemodynamic adaptations, and then the neurohumoral
reactions.
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2.2.8.1.1 Hemodynamic Adaptations
2.2.8.1.1.1 The Heart
In healthy circumstances, the anatomy and physiology of the heart are carefully construed
and maintained so as to perform compressive mechanical work at near-maximal efficiency to
deliver an adequate cardiac output over the normal range of rest and exertional pressure-volume
conditions, commensurate with the demands of the body’s metabolizing tissues [83]. On the
other hand, chronic heart failure is the pathophysiological state in which either the delivery of
cardiac output is inadequate to meet the metabolic demands of tissues or an adequate cardiac
output is delivered only under conditions of abnormally elevated intracardiac pressures, which
prematurely precipitate systemic or pulmonary venous congestion [86].
Although still debated, the primary ‘‘locus’’ of dysfunction in most instances of heart
failure appears to reside largely within the myocyte compartment of the heart [83]. Indeed,
studies support a marked reduction in ‘‘contractility reserve’’ in response to increasing heart rate
of sympathetic stimulation [87]. The normal integrated function of the heart depends upon a host
of factors that include: (a) normal ultrastructural and gross architecture of the heart, (b) an
adequate number of myocytes, (c) normal myocyte contractile and relaxant function, (d) normal
structure and function of cardiac valves, (e) normal structure, composition, and metabolism of
the myocardial extracellular matrix, (f) adequate myocardial perfusion, and (g) normal
myocardial metabolism [40,83].
However, heart failure patients exhibit abnormalities in any of these major anatomic and
functional components. Indeed, heart failure patients can present: (a) loss of myocytes (ischemic,
inflammatory or toxic necrosis, apoptosis), (b) acute or chronic contractile dysfunction of
myocytes (inflammation, alcohol, chemotherapeutic agents, sepsis, hypoxia), (c) excessive
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myofiber architectural disorganization or disarray (hypertrophic cardiomyopathy), (d) infiltrative
cardiomyopathy, (e) extracellular matrix structural or functional abnormalities (excessive fibrosis
leading to abnormal force transduction, myocyte linkage, and inadequate compressive force
efficiency), (f) distortion of the three-dimensional shape of the heart itself (aneurysm, infarction,
chronic valvular disease), and (g) intractable pressure or volume overload (hypertension,
valvular heart disease) [83,87]. As a result, an initial injury causes dysfunction of the left
ventricle that leads to decrease in cardiac output and blood pressure [83].
2.2.8.1.1.2 Cardiac Hypertrophy
Left ventricular dysfunction is generally a progressive process, even in the absence of a
new identifiable insult to the heart [40]. The principal manifestation of such progression is a
change in the geometry and structure of the left ventricle, so the chamber dilates and/or
hypertrophies and becomes more spherical, a process referred to as cardiac remodeling [88]. Left
ventricular remodeling is defined as the alterations in ventricular mass, chamber size, and shape
that result from myocardial injury, or pressure or volume overload [88]. This change in chamber
size and structure not only increases the hemodynamic stresses on the walls of the failing heart
and depresses its mechanical performance but may also increase regurgitant flow through the
mitral valve. These effects, sequentially, serve to sustain and exacerbate the remodeling process.
Cardiac remodeling generally precedes the development of symptoms (occasionally by
months or even years), continues after the appearance of symptoms, and contributes substantially
to worsening of symptoms despite treatment [88]. The increase in pressure as a result of aortic
stenosis or sustained severe hypertension requires that the left ventricular pressure must increases
in order to overcome the resistance to the ejection of blood [40,88]. The initial mechanism for
the increase at a cellular level is probably a stretch-induced increase in the inotropic state,
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involving mechanoreceptors and increased cytosolic calcium. The result is that the left
ventricular systolic pressure rises, the obstruction to the outflow of blood from the left ventricle
is overcome, and the cardiac output is maintained [40,84]. However, the disadvantage of this
form of adaptations is that the left ventricle wall stress is greatly increased.
As a result cardiac concentric hypertrophy develops, it means that the left ventricle
becomes thicker without increasing in radius, and the wall stress normalizes. However, the
compensatory hypertrophy in chronic heart failure patients has a greater susceptibility to
ischaemia and abnormal diastolic function [84]. In addition, left ventricular hypertrophy is
characterised by an increased left ventricular wall thickness and mass, with abnormal diastolic
properties [37]. There is a triad of loss of (a) distensibility (so that the ventricle is stiffer), (b)
impaired relaxation and (c) decreased early diastolic filling. This pattern is responsible for the
exertional shortness of breath that chronic heart failure experience. [84,89].
In contrast, the increase in volume due to valvular regurgitation (incompetence) of either
the mitral valve or the aortic valve requires that the heart respond in a different way. First, the
preload increases, so that the heart functions at the length limit of the Frank-Starling curve [38].
Second, the sustained volume load causes longitudinal hypertrophy, thereby increasing the size
of the left ventricle cavity, which, in turn, could increase the chamber size without increasing the
wall thickness [90]. The end-result of the volume overload is enhanced early diastolic filling and
decreased left ventricular stiffness [91]. As a result, the diastolic function improves rather than
deteriorates, as in a pressure overload. Nonetheless, as the chamber size increases, wall tension
must rise. The consequence will be modest and proportional hypertrophy, to allow the left
ventricle cavity to regain a normal wall stress [40,84]. At the cellular level, myocardial
pathologic changes accompany left ventricular remodeling and involve myocyte hypertrophy and
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fibroblast hyperplasia accompanied by an increase in collagen deposition within the interstitium.
These processes, which occur in the noninfarcted myocardium, contribute to progressive left
ventricular remodeling and left ventricular dysfunction [50].
Progression of coronary artery disease, diabetes mellitus, hypertension, or the onset of
atrial fibrillation may also contribute to the progression of heart failure. The development of
structural abnormalities can have 1 of 3 outcomes: (a) patients die before developing symptoms
(in Stage A or B of the New York Heart Association Classification for Heart Failure), (b)
patients develop symptoms controlled by treatment, or (c) patients die of progressive heart
failure. Sudden death can interrupt this course at any time. Although several factors can
accelerate the process of left ventricular remodeling, there is substantial evidence that the
activation of endogenous neurohormonal systems plays an important role in cardiac remodeling
and thereby in the progression of heart failure. Indeed, substantial amounts of experimental and
clinical data now exist that support the pivotal role of the Renin-Angiotensin-AldosteroneSystem in contributing to these cellular processes [32,84,89].
Patients with heart failure have elevated circulating or tissue levels of norepinephrine,
angiotensin II, aldosterone, endothelin, vasopressin, and cytokines, which can act (alone or in
concert) to adversely affect the structure and function of the heart. These neurohormonal factors
not only increase the hemodynamic stresses on the ventricle by causing sodium retention and
peripheral vasoconstriction but may also exert direct toxic effects on cardiac cells and stimulate
myocardial fibrosis, which can further alter the architecture and impair the performance of the
failing heart. Neurohormonal activation also has direct deleterious effects on the myocytes and
interstitium, altering the performance and phenotype of these cells [78]. Finally, it is important to
mention that in response to a sustained pressure or volume load, the myocardium passes from a
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compensated phase to a dilated failing phase. It is speculated that the hypertrophied myocardium
is susceptible to an imbalance in the ratio of oxygen supply and demand [84,92].
2.2.8.1.1.3 Cardiac Output
Cardiac output is defined as the amount of blood ejected from the ventricles per minute,
and it represents a measure of the pumping ability of the heart. It is determined by the heart rate
and the stroke volume [83]. Among healthy individuals the average resting cardiac output is
around 5.00 L/min [93]. Early in the process of heart failure, cardiac output may be normal at
rest [20]. During stressful conditions, such as physical exercise and other periods of increased
metabolic demand, however, cardiac output fails to increase normally.
As a result the glomerular filtration rate declines and the renal mechanism for salt and
water retention becomes activated [20,83]. Furthermore, ventricular filling pressure as well as
pressures in the atrium and venous system behind the affected ventricle may rise abnormally
during periods of stress. This may cause transudation of fluid and symptoms of tissue congestion
during exercise [20,40]. In such early stages, physical rest may induce diuresis and relieve
symptoms in many patients with mild heart failure; however, excessive and repeated strenuous
physical activities will worsen the compromised hemodynamic state and cause progression of
heart failure [37,38]. The impaired left ventricular function causes inadequate blood flow to
active skeletal muscle secondary to reduced cardiac output and consequently low maximal
oxygen uptake in these patients [83].
2.2.8.1.2 Neuroendocrine (neurohumoral) Reaction
The impaired contraction and/or relaxation of the heart, which is the major component in
the pathophysiology of heart failure patients, result in the inability to fulfill its pumping function
normally. In addition, left ventricular dysfunction leads to reduction in cardiac output and blood
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pressure. As a result, a complex series of events leading to a neuroendocrine reaction, also called
the neurohumoral response [84], which creates the self-perpetuating vicious circle of heart
failure (see figure 2.2).

Figure 2.2. The neuroendocrine vicious circle in chronic heart failure [84].
The initial activation of the neuroendocrine system would restore the hemodynamic
balance through vasoconstriction and retention of salt and water. However, at the same time this
also contributes to progression of heart failure due to the hemodynamic effects and the direct
harmful hormonal effects on the cardiomyocytes [89]. Several neurohumoral systems are
activated in heart failure. Furthermore, extensive reviews discussing the impact the
neuroendocrine system and heart failure can be found elsewhere [85,94-96].
Although several neurohormonal systems are activated in heart failure patients, the next
section will outline the more important of those systems with emphasis on prognostic and
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diagnostic of heart failure. The topics presented will include; (a) alterations in cardiovascular
reflexes, (b) catecholamines and the sympathetic nervous system, (c) humoral activation, (d)
renin-angotensin-aldosterone system, (e) vasopressin, (f) atrial natriuretic peptide, (g)
endothelin-1, (h) cytokines, and (i) the ergoreflex.
2.2.8.1.2.1 Alterations in Cardiovascular Reflexes
The arterial baroreflexes include an afferent limb, a central neural component, and an
autonomic neuroeffector component. A rise in pressure stretches the baroreceptors located in the
heart, lungs, and great vessels and causes them to transmit signals to the central nervous system
[97]. These signals normally inhibit sympathetic outflow as well as suppress renin and
vasopressin release while increasing parasympathetic outflow.
Conversely, a sudden reduction in arterial pressure results in a strong sympathetic
discharge throughout the body. The short-term effect of the sympathetic discharge is to enhance
stroke volume, cardiac output and increase vasoconstriction in an effort to compensate for a loss
in arterial pressure [98]. However, the long-term consequences are thought to be deleterious [99].
In the acute phase of low-output heart failure, arterial and cardiopulmonary baroreflexes are
activated to help maintain systolic blood pressure. However, both arterial and cardiopulmonary
baroreceptors become desensitized in heart failure [100]. The absence of baroreflex inhibitory
input to medullary centers results in excessive sympathetic excitation [39,84]. It is thought that
the marked desensitization of this reflex contributes to the neurohumoral abnormalities [89].
2.2.8.1.2.2 Catecholamines and the Sympathetic Nervous System
A rise in systemic vascular resistance is accomplished initially, by activation of the
sympathetic nervous system. Activation of the sympathetic nervous system is very effective over
the short term to maintain blood pressure [101]. Plasma norepinephrine concentration [102,103],
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an index of the activity of this system, is generally two or three times higher in patients with
heart failure in comparison to healthy controls, and it is usually correlated to the degree of left
ventricular dysfunction and hemodynamic abnormalities [104], and it carries an ominous
prognosis [102,103]. In addition, it has been shown that plasma norepinephrine reflects
sympathetic activity in heart failure patients fairly well [105].
The increase in sympathetic activation is to maintain cardiac output and arterial pressure
through stimulation of myocardial contractility and α-1 adrenoreceptors in the vascular wall.
Stimulation of the α-1 adrenoreceptors causes an increase in vasomotor tone and systemic
vascular resistance. However, any supportive effect of the increased sympathetic nervous system
activity on arterial blood pressure is, in time, superseded by a number of organ-specific
consequences. The potential adverse effects of sympathetic activation on cardiac muscle, the
kidneys, and the vasculature are numerous and contribute to the clinical manifestations of heart
failure [106].
2.2.8.1.2.3 Humoral Activation
Humoral activation is one of the biochemical hallmarks in patients with heart failure
[107,108]. The main function of the humoral activation is to maintain arterial pressure despite a
loss in myocardial function. However, as a result of chronic humoral activation two vicious
cycles develop: (a) vasoconstriction and (b) sodium and water retention. Arterial
vasoconstriction causes an increase in systemic vascular resistance and inevitably an increase in
afterload and systolic wall stress.
The sodium and water retention causes an increase in circulating volume, which may be
beneficial at first, but ultimately results in an increased ventricular filling pressure and diastolic
wall stress. Together, these vicious cycles may eventually lead to progressive myocardial and
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vascular dysfunction, peripheral tissue abnormalities, fluid accumulation, and finally the clinical
picture of heart failure [109].
2.2.8.1.2.4 Renin-Angiotensin-Aldosterone System
Renin is a proteolytic enzyme synthesized and secreted into the blood by the
juxtaglomerular cells located in the macula densa in the afferent arterioles of the glomeruli [110].
Renin, itself, is not a vasoactive substance. Instead it acts on another plasma protein called
angiotensinogen, produced by the liver, to release a 10-amino acid peptide, angiotensin I [110].
Although angiotensin I has mild vasoconstrictor properties, within a few seconds following its
formation two additional amino acids are split to form an 8-amino acid peptide, angiotensin II.
The formation of angiotensin II is catalyzed by angiotensin converting enzyme which is located
in the endothelium of the vascular tree [110].
The effects of angiotensin II are multiple and include: (a) raising peripheral resistance
through vasoconstriction, (b) enhancing renal sodium reabsorption, (c) facilitating catecholamine
release from sympathetic nerve endings, and (d) stimulating mineralcorticoid production in the
adrenal gland [89,111]. More recently angiotensin II has also been implicated as a growth factor
or growth modulator in the cardiovascular system [112-114]. In fact, Dzau et al., [112] have
reported that the renin-angiotensin-aldosterone system is markedly activated in patients with
decompensated heart failure. In addition, data from the Study of Left Ventricular Dysfunction
(SOLVD) Registry report resting values for plasma renin activity in healthy adults ranging from
0.3 to 0.8 (mean 0.6) ng•ml-1•h-1 [115]. In the same study, plasma renin activity in patients with
heart failure ranged from 0.5 to 8.7 (mean 2.5) ng•ml-1•h-1 [115]. The mechanism of the
increased plasma renin activity in heart failure is not entirely known but is thought to be
secondary to (a) a reduction in renal perfusion, (b) elevated efferent renal sympathetic nerve
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activity, (c) increased circulating catecholamines, (d) alterations of sodium load presented to the
macula densa, or (e) a combination of all the above [108,116].
As a result of the increased renin-angiotensin-aldosterone system activation systemic
vascular resistance increases [89]. In addition, the formation of angiotensin II causes sodium and
fluid retention secondary to production of the mineralcorticoid, aldosterone. Aldosterone causes
a marked increase in sodium reabsorption from the renal tubules, thereby raising extracellular
sodium, followed by fluid expansion [110]. The function of the increased fluid is to increase
preload in patients with heart failure secondary to myocardial dysfunction. It is thought that the
increase in preload subsequently stretches the sarcomeres in the myocardium to a more optimal
length during the intermediate period until myocardial hypertrophy develops.
Angiotensin II is potentially a stimulus to fibrosis, as is aldosterone. Indeed, in animal
experiments it has been shown that angiotensin II has a direct effect on the myocardium which
eventually leads to hypertrophy, remodeling and fibrosis [117,118] and thereby to loss of
function. In physiological amounts, collagen may help to limit ventricular dilation when it is
increased in proportion to the degree of myocardial hypertrophy. On the contrary, when there is
an excessive collagen response to ischaemia or endocrine signals such as angiotensin II, then
compliance decreases with an increase in chamber stiffness, or a decrease in distensibility [119].
These modifications promote poor diastolic relaxation and, hence, diastolic failure. The
wall tension therefore rises more than expected, with a corresponding increase in the oxygen
demand. Therefore, it contributes to relative ischaemia of the hypertrophied myocardium and
further promotes interstitial fibrosis. With the discovery that the renin-angiotensin-aldosterone
system is markedly activated in heart failure, it is not surprising that a significant number of
investigators have focused on the role of angiotensin-converting-enzyme (ACE) inhibitors
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as a strategy to treat patients with heart failure. Results from clinical trials, The SOLVD
Investigators [120] and The CONSENSUS Trial Study Group [121], have shown that
cardiovascular morbidity and mortality can be reduced in patients with left ventricular
dysfunction (ejection fraction < 40%) secondary to ischemic heart disease following long-term
use of ACE-inhibitors.
Interestingly, the precise mechanism(s) of action of ACE-inhibitors are still not fully
understood. It is thought that the mechanism of action of ACE-inhibition is in part
cardioprotective and vasculoprotective. A reduction in systemic vascular resistance secondary to
inhibition of angiotensin II generation may reduce afterload and myocardial work. Mechanisms
for the vasculoprotective properties include in addition to a reduction in angiotensin II
production, decreased bradykinin degradation, antagonism of macrophage function and
migration as well as inhibition of sympathetic nervous system and thrombotic activity [122]. All
of these could result in plaque stabilization, protection against plaque rupture, and prevention of
acute coronary occlusion [122].
2.2.8.1.2.5 Vasopressin
Vasopressin is synthesized as a larger pre-hormone in nerve cells located in the
hypothalamus. Then, it is transported through the axons of the nerve cells to their end located in
the neurohypophysis [110]. The physiological actions of vasopressin are vasoconstriction
mediated via V1-receptors and decrease in free-water clearance mediated via renal V2-receptors.
In heart failure patients the vasopressinergic system is activated, contributing to vasoconstriction
and water retention. It has been shown that the sensitivity of the vasopressin system for changes
in osmolality and volume is decreased in heart failure [123,124]. In addition, some studies have
reported that vasopressin is increased in heart failure [125,126] and that the increase could not be
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explained by changes in osmolality. Vasopressin is especially elevated in heart failure with
hyponatraemia. Hyponatremia is a common manifestation of severe heart failure and occurs
when water is retained in excess of sodium. It has been shown to be a powerful independent
predictor of cardiovascular mortality [127].
2.2.8.1.2.6 Atrial Natriuretic Peptide
Atrial natriuretic peptide is primarily produced in the atria and released by atrial
distention. Atrial natriuretic peptide dilates arterioles and increases sodium excretion from the
kidneys and is an antagonist to both the sympathetic and the renin-angiotensin-aldosterone
system. Three known natriuretic receptors exist, A, B and C. Atrial natriuretic peptide has
highest affinity for the A receptor [110]. Thus, the action of atrial natriuretic peptide is to
decrease plasma volume. It have been reported that atrial natriuretic peptide caused a net transfer
of fluid from the vascular to the interstitial space. This raises the possibility that atrial natriuretic
peptide may have a vascular effect which may contribute to edema formation in heart failure
[128].
The plasma concentration of atrial natriuretic peptide is elevated in heart failure and in
general correlates with the degree of heart failure [103,126,129,130]. In addition, the activation
of the atrial natriuretic peptide in heart failure patients initially counteracts the effect of the
vasoconstrictor systems, but the effect is not lasting. Hence, it has been reported that the
natriuretic response to atrial natriuretic peptide is blunted in heart failure [131].
2.2.8.1.2.7 Endothelin-1
Endothelin-1 is synthesized from a larger pre-propeptide which after enzymatic cleavage
becomes the propeptide “big endothelin-1”. Endothelin-1 levels are increased in heart failure
patients [132,133], and it has been reported that correlates strongly with the pulmonary pressure
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[132,134]. Endothelin-1 acting via selective receptors has strong vasoconstrictor effects and
possibly also a trophic effect on cardiac myocytes, found in in vitro studies [135]. In addition,
endothelin-1 was found to contain prognostic information, in a multivariate analysis including
other hormones (atrial natriuretic peptide and noradrenaline) and hemodynamic measures [136].
2.2.8.1.2.8 Cytokines
Cytokines act locally in one of several manners: (a) autocrine; active on the cells of
origin, (b) paracrine; acting on neighboring cells, or (c) justacrine; acting on adjacent cells [84].
Among the cytokines that appear to be involved in heart failure, tumor necrosis factor-alpha has
drawn special attention. Indeed, Bozkurt et al., [137] have reported that tumor necrosis factoralpha causes dilatation and remodeling of the left ventricle in rats. In addition, tumor necrosis
factor-alpha is increased in heart failure and seems to reflect the severity of the disease
[138,139].
2.2.8.1.2.9 The Ergoreflex
Ergoreceptors are intramuscular receptors sensitive to work performed. They are
stimulated by metabolites formed during skeletal muscular activity. Their stimulation increase
ventilation and sympathetic activation (the ergoreflex). The stimulus is in part sensitive to work
performed by each unit of muscle mass. This effect can be seen in normal subjects, where the
ventilation and carbon dioxide production slope is considerably greater when arms are used than
when legs are used to perform the same external workload [140].
In addition Piepoli et al., [141] showed how these receptors were more active in patients
with heart failure and that the increased ventilatory response to exercise was proportional to the
ergoreflex activity. The signal is due to metabolic stimulation of receptors rather than being
merely a response to movement. Possible stimuli for initiating the ergoreflex are local release of
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prostaglandins, potassium, and hydrogen ion. Furthermore, in heart failure there is enhanced
activity of these receptors (“Coats hypothesis”) [142], which contributes to the excessive
neuroendocrine response.
2.2.8.2 Skeletal Muscle Compensatory Adaptations
The result of impaired cardiac pumping capacity and limited vasodilatory capacity is an
inadequate blood supply to metabolizing tissues [143]. Therefore, a reduction in skeletal muscle
perfusion may be an important contributor to the decreased exercise capacity and tolerance in
heart failure patients. However, even when oxygen availability to skeletal muscle is improved
oxygen uptake remains unchanged [144,145]. This observation suggests the presence of intrinsic
alterations of skeletal muscle. Recently, considerable attention has been given to identify those
intrinsic alterations in skeletal muscle which may contribute to the clinical severity of patients
with heart failure [146-152].
These studies strongly suggest the presence of skeletal muscle abnormalities including (a)
ultrastructural abnormalities, such as significant atrophy of muscle fibers classified as Type I
[144,148,150,151]; (b) a marked decline in mitochondrial enzyme concentration and activity
(Succinate dehydrogenase, Citrate synthase and cytochrome oxidase); and (c) a reduction in
mitochondrial volume and density [144,146].
2.2.8.2.1 Skeletal Muscle Atrophy
Muscle atrophy is common in patients with heart failure [144,148,150,153,154]. Indeed,
Minotti et al., [154] found that maximal cross-sectional area of the thigh, measured by magnetic
resonance imaging, was markedly reduced in patients with end-stage heart failure compared to
age-matched controls. These data have been confirmed by Magnusson et al., [155] who reported
a 13% smaller muscle cross-sectional area of the quadriceps in heart failure patients. In addition,
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Mancini et al., [156] noted a 15% reduction in muscle volume in the lower legs of patients with
mild-to-moderate heart failure.
The mechanism for the muscle atrophy in heart failure is presently not clear but has been
linked to malnutrition, deconditioning, an increased catabolic state due to sympathetic nervous
system hyperactivation, an increase in serum cortisol, corticotropin, and/or tumor necrosis factor
[126]]. Consequently, it appears that skeletal muscle atrophy could be an important and
potentially reversible contributor to exercise intolerance in patients with heart failure. However,
it should be noted that parameters of muscle mass only show a weak correlation with peak
oxygen consumption (VO2peak), suggesting that muscle atrophy contributes only modestly to
exercise intolerance in heart failure [156].
2.2.8.2.2 Skeletal Muscle Blood Flow
Many studies have reported reduced resting blood flow to the arm and leg in heart failure
[143,144,157,158]. On the other hand, Wiener et al., [159] found no evidence of reduced blood
flow at rest in ambulatory, optimally diuresed heart failure patients. Although the reason for
these different findings at rest are speculative it may be related to (a) the level of circulatory
dysfunction, (b) the position in which the measurements were obtained (supine or standing), (c)
the amount of muscle atrophy present, and/or (d) the pharmacotherapy of the patient.
2.2.8.2.3 Histologic and Biochemical Alterations in Skeletal Muscle
It appears that skeletal muscle atrophy in heart failure is selective and more pronounced
in the type I (oxidative) muscle fibers. Indeed, Lipkin et al., [160] have reported atrophy of type I
and type II fibers, increased interstitial cellularity, and excess lipid accumulation, in patients with
heart failure. Mancini et al., [146] and Sullivan et al., [148] also reported a relative greater
decrease of highly oxidative, fatigue resistant, type I fibers in the calf muscle of patients with
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heart failure secondary to coronary artery disease. In addition, Drexler et al., [149] found a shift
in fiber type distribution to type II fibers. In this comprehensive study, the authors indicate that
because type IIb fibers possess less oxidative capacity than type IIa or even I, a reduction in
oxidative capacity could be attributed to a shift in fiber type distribution.
Furthermore, to these morphologic changes, Sullivan et al., [148] reported a decrease in
the number of capillaries per fibers for type I and type IIa fibers. The apparent loss in oxidative
capacity in heart failure is further evident from studies which have performed biochemical
analysis of skeletal muscle. In fact, Lipkin et al., [160] was the first to demonstrate an
accumulation of intracellular lipids in heart failure suggesting a possible abnormality in lipid
metabolism. Sullivan et al., [148] examined patients with long-standing heart failure and found
significant reductions in mitochondrial enzyme concentration for succinate dehydrogenase and
citrate synthetase. Furthermore, they found a decrease in 3-hydroxacyl-coenzyme Adehydrogenase and glycogen content.
Drexler et al., [144] reported that the ultrastructural morphometry of muscle biopsies of
the vastus lateralis indicated significant abnormalities of skeletal muscle as compared to normals.
The volume density of mitochondria and surface density of mitochondrial cristae, markers of
structural correlates of oxidative capacity, were significantly reduced by 20% in patients with
severe heart failure.
In addition, capillary length density was reduced and fiber type distribution of skeletal
muscle was shifted to type II fibers. Cytochemical analysis of cytochrome oxidase activity also
revealed significant decreases in heart failure. Both the volume density of mitochondria and
surface density of mitochondrial cristae were significantly related to oxygen consumption
(VO2peak), but inversely related to the duration of heart failure.
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These studies support the notion that a major component of heart failure is a reduction in
oxidative capacity due to intrinsic alterations in skeletal muscle. This reduction in oxidative
capacity may play an important role in the clinical syndrome of heart failure by adversely
affecting exercise capacity. Although, the mechanisms for the alterations in skeletal muscle
metabolism in heart failure patients are unknown, several factors (neurohumoral, chronic
reductions in muscle perfusion, and deconditioning) may be involved [144].
Chronic deconditioning may be a key factor in the alterations in skeletal muscle
metabolism, since recent studies have shown that physical training can improve exercise capacity
in patients with heart failure by delaying the onset of anaerobic metabolism [161-163]. However,
chronic muscle underperfusion (at rest or during exercise) and/or increased sympathetic
stimulation could also cause many of the above mentioned abnormalities in skeletal muscle
metabolism.
2.2.8.3 Summary of Compensatory Adaptations in Heart Failure
In summary the "Heart Failure Syndrome" is characterized by a series of compensatory
mechanisms designed to maintain cardiac output and arterial pressure at a level compatible with
life. There are compensatory mechanisms designed to cope quickly with a reduction in stroke
volume, and there are mechanisms which operate over a longer period of time.
The cardiac compensatory changes include (a) ventricular dilation to stretch the
sarcomeres (fast adaptation); (b) ventricular hypertrophy (slow adaptation) and aim to preserve
cardiac output. The circulatory changes include (a) autonomic nervous system activation (fast
adaptation); (b) humoral activation (intermediate to slow adaptation); (c) impaired vascular
responsiveness (slow adaptation), and aim to maintain blood pressure. Alterations in skeletal
muscle include (a) skeletal muscle atrophy (slow adaptation) and (b) impaired oxidative
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metabolism (slow adaptation). Although speculative, it is thought that those mechanisms with an
intermediate to long-time constant eventually contribute to the severe clinical manifestations.
2.2.9 The Role of Exercise in Heart Failure
2.2.9.1 The Acute Exercise Response in Heart Failure
Under normal resting conditions, patients with heart failure generally do not exhibit signs
or symptoms of their disease. It is not until a physiologic stress, such as exercise, is introduced
that the morbidity associated with heart failure becomes apparent. Therefore, the purpose of this
section is to review the effects of a single bout of exercise on patients with heart failure. In
particular, this review will focus on: (a) the cardiovascular responses and (b) the skeletal muscle
responses.
2.2.9.1.1 Cardiovascular Responses to an Acute Bout of Exercise
2.2.9.1.1.1 Cardiac Output
Normally, the capacity for performing aerobic exercise depends on the ability of the heart
to increase cardiac output to the exercising muscles and the ability of these muscles to utilize
oxygen from the delivered blood. The increase in cardiac output during acute exercise can be
accomplished through an increase in heart rate and/or stroke volume. In general, patients with
heart failure demonstrate characteristic responses to dynamic exercise. However, as functional
class declines there is a progressive decrease in peak cardiac output, stroke volume, and heart
rate [164]. Cardiac output is the product of heart rate and stroke volume. It has been shown that
the increase in heart rate contributes to cardiac output throughout exercise [165], whereas stroke
volume is thought to be most important during the early stages of exercise [166]. Normally,
during maximal upright exercise, cardiac output increases 4 to 6 fold in healthy subjects. This is
accomplished by a 2- to 4-fold increase in heart rate and a 20% to 50% augmentation of stroke
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volume. The stroke volume increase is accomplished both by use of the Frank-Starling
mechanism to maintain left ventricular end-diastolic volume and by more complete left
ventricular emptying to reduce end-systolic volume. Both enhanced left ventricular contractility
and peripheral vasodilation contribute to the more complete left ventricular emptying observed
during exercise. Studies have reported that cardiac output is reduced at any given peak oxygen
consumption (VO2max) in patients with heart failure [163,167]. The reduction in aerobic capacity
in heart failure patients seems to be largely mediated by inadequate blood flow to active skeletal
muscle secondary to impaired cardiac output [157,168]. Indeed, patients with heart failure may
achieve < 50% of the maximal cardiac output attained by healthy individuals at peak exercise.
Stroke volume, which is already decreased at rest, rises only modestly up to a peak of 50 to 65
mL, compared with ≥ 100 mL in healthy subjects.
Stroke volume is determined by four factors; [97] (a) the volume of blood returned to the
heart, (b) ventricular distensibility, or the capacity to enlarge the ventricle, (c) ventricular
contractility, and (d) aortic and/or pulmonary artery pressure, or the pressure against which the
ventricles must contract. Although there are conflicting reports about stroke volume changes
during exercise, the traditional thought in healthy individuals suggests that stroke volume
increases with increasing rates of work, and seems to level off at approximately 50-60% of
maximal capacity [166]. The explanation for the increased stroke volume in healthy individuals
is that the Frank-Starling mechanism, defined by an increase in left ventricular end-diastolic
volume, operates at lower work rates, whereas an increased degree of contractility, defined by a
decrease in left ventricular end-systolic volume, has its greatest effect at higher work rates.
In patients with heart failure stroke volume is consistently lower at any given work load
compared to normals [169]. In fact, Weber et al., [169] have reported that the stroke volume
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response to exercise was related to severity of disease as defined by functional class. Using this
classification they showed that as functional class declined so did stroke volume at rest. In
addition, they indicated that those patients with the most severe impairments lost the reserve
capacity to raise stroke volume during exercise. Studies have shown that the mechanism to
increase stroke volume during exercise in heart failure patients with diastolic dysfunction is
further impaired [36]. In these patients changes in ventricular relaxation and filling may increase
diastolic pressure in the absence of an increase in left ventricular end-diastolic volumes. This
indicates that the exercise intolerance in patients with diastolic dysfunction may be secondary to
an inability to rely on the Frank-Starling mechanism to increase left ventricular end-diastolic
volumes and stroke volume. This has been confirmed in several studies indicating a close
association between indices of ventricular filling and exercise tolerance. In that regard, Sullivan
et al., [163] have reported increases in left ventricular filling pressures in patients with heart
failure without an increase in left ventricular end-diastolic volume suggesting the presence of
diastolic dysfunction. These data suggest that in patients with diastolic dysfunction ventricular
filling may be attenuated and contribute to a reduction in stroke volume and exercise tolerance.
The increase in heart rate observed during exercise is linearly related to the work
intensity. In patients with heart failure heart rates at rest and during submaximal exercise are
increased, possibly indicating an increased demand on the heart. There is an inverse relationship
between resting heart rate and mortality in patients with heart failure [170]. In contrast, peak
heart rate (HRpeak) responses to an incremental exercise test are generally lower when compared
to age-matched healthy normals. This indicates that the heart rate reserve for patients with heart
failure is also reduced. The inability to raise the heart rate during exercise is termed chronotropic
incompetence [171]. The mechanism responsible for chronotropic incompetence in patients with
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heart failure has been linked to abnormal reflex control and down-regulation or decreased
responsiveness of beta-receptors.
2.2.9.1.1.2 Autonomic Responses
The sympathetic nervous system has an important role in mediating the response to
exercise in healthy individuals [172]. Normally, during exercise plasma norepinephrine levels
increase in normal subjects, which is thought to be indicative of increased participation of the
sympathetic nervous system [172]. In contrast, patients with heart failure have much greater rise
in plasma norepinephrine levels at submaximal exercise work-loads, although at peak exercise,
healthy subjects exhibit higher levels of norepinephrine [126]. It is generally believed that the
rise in sympathetic nervous system with exercise causes blood to be shunted away from nonexercising tissue to working skeletal muscle [173]. Although the release of epinephrine and
norepinephrine is affected by a variety of factors, plasma levels increase gradually with
increasing intensities until approximately 50-70% of peak oxygen consumption (VO2peak). At this
point plasma levels increase markedly reaching an apex at peak exercise. During exercise,
patients with heart failure exhibit greater-than-normal increases in plasma norepinephrine levels
at submaximal workloads than healthy controls [126].
It has been speculated that this may result in significant sympathetic vasoconstrictor
activity and contributing to muscle underperfusion [173]. In addition, studies have reported that
patients with heart failure had significant higher resting muscle sympathetic nervous system
activity than age-matched controls [174]. Wilson et al., [175] have reported that exercise did not
produce a major increase in plasma norepinephrine and sympathetic vasoconstriction in
ambulatory patients with marked reduced exercise capacity. In fact, blood flow to non-exercising
tissue remained unchanged during exercise.
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Based on this research, Wilson et al., [175] have suggested that patients with heart
failure do not develop major redistribution of blood flow from non-exercising beds to working
muscle. Thus, the current contention does not necessarily support that the reduced exercise
tolerance in heart failure is governed by an activated sympathetic nervous system. Nevertheless,
it does appear reasonable to postulate that vasoconstriction mediated in part by the sympathetic
nervous system could play a role in limiting skeletal muscle blood flow during exercise in heart
failure patients [101].
2.2.9.1.1.3 Vascular Responsiveness
During acute exercise the ability of the peripheral vasculature to dilate plays an important
role in determining blood flow to exercising muscle. The ability to dilate the vasculature is
largely dependent on the integrity of the vascular wall, including the endothelial lining. The
vasodilatory response to increased shear stress is markedly abnormal in patients with heart
failure [153,176,177]. Jondeau et al., [153] have linked the impaired endothelium-dependent
vasodilatation to exercise capacity, and found a strong correlation between peak hyperemic
response and peak oxygen consumption (VO2peak) in patients with heart failure. Therefore, these
data suggest that patients with heart failure exhibit impairment in endothelium-dependent
vasodilatation following exercise induced hyperemia, which may contribute to the exercise
intolerance.
2.2.9.1.2 Skeletal Muscle Responses to an Acute Bout of Exercise
2.2.9.1.2.1 Skeletal Muscle Strength
Lipkin et al., [160] measured muscle strength in patients with severe heart failure and
found a 45% reduction in quadriceps strength compared to age-matched controls. In addition,
Magnusson et al., [155] have observed low muscular strength in patients with heart failure and
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attributed the reduced strength to a smaller muscle cross-sectional area. In contrast, Minotti et al.,
[154] found no difference in isometric strength between heart failure and controls, although there
was evidence of a marked decline in muscular endurance. This suggests that the specific tension
(i.e. tension per unit of cross-sectional area) may not be altered as a result of the disease.
Furthermore, Buller et al., [178] confirmed this finding showing no difference in maximal force
produced during 3 repetitions, but a marked decline in force production during prolonged knee
extension exercise in heart failure. In both studies the degree of muscle dysfunction as defined by
muscle endurance, correlated with peak oxygen consumption (VO2peak) as measured by cycle
ergometry [154,178]. Thus, reduced muscle strength in patients with heart failure is probably due
to skeletal muscle atrophy, rather than a change in the contractile apparatus. In contrast, the
impaired muscle endurance appears to reflect a qualitative change in skeletal muscle.
2.2.9.1.2.2 Skeletal Muscle Blood Flow
As previously stated a number of studies have reported reduced limb blood flow at rest in
heart failure [101,179]. In addition, there is substantial evidence that the increase in blood flow
to working muscle is attenuated for each given workload in heart failure [143,157]. In fact,
Wilson et al., [157] have reported reduced leg blood flow during submaximal and peak exercise
in patients with heart failure using the thermodilution technique. Furthermore, Sullivan et al.,
[143] have confirmed these findings and found a strong relationship between the leg blood flow
response to exercise, and peak oxygen consumption (VO2peak) and functional class. The failure of
skeletal muscle blood flow to increase normally during exercise appears to be primarily related
to an impaired vasodilatory capacity. In patients with heart failure, arteriolar vasodilatation is
impaired, as evidenced by a failure of leg vascular resistance to decrease normally with exercise
[101,157,180]. The mechanisms involved in the impaired metabolic vasodilatory capacity within
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skeletal muscle in heart failure include [158]; (a) excessive sympathetically mediated
vasoconstriction, (b) increased levels of angiotensin II and vasopressin, (c) chronic vascular
deconditioning, and (d) endothelial dysfunction.
Another explanation for the alterations in skeletal muscle perfusion observed in heart
failure patients may be related to the distribution of blood during exercise. It is generally
accepted that exercise is associated with an increase in sympathetic vasoconstrictor activity and
angiotensin II [181]. This increase in neurohumoral activation serves to increase vascular
resistance in non-working tissue and helps to increase arterial blood pressure. However, Wilson
et al., [175] have reported that patients with heart failure do not develop major re-distributions of
blood flow from non-exercising beds to exercising muscle. The mechanism for the failure to
shunt blood to working tissue was attributed to a reduced sympathetic vasoconstrictor activity.
Certainly, this hypothesis appears to go in the face of traditional views, suggesting that increased
sympathetic nervous system activity enhances vasoconstriction in heart failure. Irrespective of
the precise mechanism, the above studies provide convincing evidence that skeletal muscle
perfusion is altered in heart failure patients during exercise. It is therefore not surprising that
exertional fatigue in heart failure has traditionally been attributed to muscle underperfusion
[182].
2.2.9.1.2.3 Skeletal Muscle Metabolic Responses
Anaerobic metabolism occurs early during exercise in heart failure and is likely an
important cause of exercise intolerance. Studies using 31P-MRI have demonstrated that early
anaerobic metabolism occurs independently of reduced muscle blood flow [147,183]. In
addition, abnormalities in skeletal muscle metabolism occur in patients with heart failure when
compared with healthy individuals during exercise under ischemic conditions [147]. These
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skeletal muscle characteristics have important ramifications on substrate and oxygen utilization
during exercise. However, it appears that these metabolic alterations are independent of skeletal
muscle blood flow. In fact, studies demonstrating a greater increase in the inorganic phosphate
to phosphocreatine ratio, a measure of oxidative stress, and more pronounced drop in acid-base
balance (pH) during progressive forearm exercise in heart failure compared to healthy controls
despite similar forearm blood flows [159,183]. In addition, Massie et al., [184] explored the
metabolic responses in exercising muscle under ischemic conditions. In this study, it was
demonstrated that skeletal muscle metabolic responses of the flexor digitorum were still
markedly different in heart failure patients, when exercise was performed with a cuff
sphygmomanometer inflated to 250 mmHg. These data indicate an increased reliance on
anaerobic glycolytic metabolism and decreased oxidative phosphorylation during exercise in
skeletal muscle in heart failure compared to controls. This may have implications for
understanding the symptoms reported by heart failure patients after repeated submaximal efforts
during their daily activities.
2.2.9.1.3 Summary of the Acute Exercise Response in Heart Failure
Exercise capacity is one of the most powerful predictors of mortality in heart failure
[170,185-187]. Nearly all patients with heart failure suffer from rapid onset fatigue that results in
a markedly reduced exercise capacity. Yet, the physiologic responses to an acute bout of exercise
in heart failure are, for the most, characteristic to those observed in healthy normal. Close
examination of cardiac and circulatory responses in heart failure do reveal a marked decreased
reserve capacity from pre-exercise to maximal exercise conditions. The capacity to raise skeletal
muscle blood flow during exercise is reduced, secondary to changes in neurohumoral and
vascular responsiveness. It is thought that the decreased reserve capacity in cardiac output,
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stroke volume, heart rate, and vascular responsiveness contribute to the reduced skeletal muscle
blood flow and impaired exercise tolerance in patients with heart failure. Additional factors that
contribute to the early onset of fatigue in heart failure are an increased reliance on anaerobic
metabolic pathways, and impaired oxidative metabolism of skeletal muscle. Therefore, the
exercise intolerance characteristic of heart failure patients appears to be related to a change in
oxygen and nutrient delivery to the musculature, as well as a reduced oxidative capacity of
skeletal muscle.
2.2.9.2 The Response to Exercise Training in Heart Failure
The first report indicating that heart failure patients could safely participate and benefit
from a cardiac rehabilitation program dates to 1979 [188]. Since that study many randomized
clinical trials have been conducted and demonstrate that exercise-based cardiac rehabilitation
favorably improves exercise tolerance, disease-related symptoms, and quality of life in patients
with heart failure, without negatively impacting left ventricular function. No adverse exercise
training–related effects have been reported despite that these patients would appear to be at
higher risk for events given their left ventricular dysfunction and heightened state of sympathetic
activity. In fact, exercise training contributes to a reduction of the fatigue- and dyspnea-limiting
exercise intolerance that is common in these patients [189,190].
However, despite these consistent findings, the mechanism of the training response in
heart failure is not fully understood. It appears that the improvements in exercise capacity are
more related to reversing the peripheral compensatory abnormalities, rather than improvements
in cardiac function. Therefore, this section of this review will outline the response to exercise
training in heart failure. First, this section will present the information regarding (a) the
cardiovascular responses, and (b) the skeletal muscle responses.
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2.2.9.2.1 Cardiovascular Responses to Exercise Training in Heart Failure
2.2.9.2.1.1 Cardiac Output
Cardiac output shows either no change [182], or a small increase [191] following a period
of chronic exercise training. In the study by Sullivan et al., [182] patients exercised
approximately 60 min, 3-5 days/wk at 75% of peak heart rate reserve. Although there was a trend
toward an increase in maximal exercise cardiac output, indices of left ventricular function did not
change [182]. On the other hand, in a randomized cross-over trial by Coats et al., [191] exercise
training was associated with an increase in both submaximal and maximal cardiac output during
exercise in eleven patients with mild to moderate ischemic heart failure.
The increase in peak cardiac output was in large extent due to changes in stroke volume,
and was achieved at a greater absolute work load. The apparent differences between these studies
are difficult to interpret, but could be a function of several factors such as (a) etiology, severity
and duration of disease, (b) training modality and intensity, (c) length of the training program,
(d) method of cardiac evaluation, or (e) a combination of all the above. Therefore, Coats et al.,
[191] is the only study to report an enhanced stroke volume response to exercise following
training.
2.2.9.2.1.2 Heart Rate
Perhaps one of the most consistent response to exercise training is a reduction in resting
heart rate and at any given submaximal workload [192]. The reduction in resting heart rate is
thought to reflect a change in the balance between sympathetic and parasympathetic activity
towards greater dominance of the vagal nerve. The reduction in heart rate during exercise is,
generally, attributed to a larger stroke volume, secondary to myocardial hypertrophy [192] or an
increase in blood volume [193].
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In the study by Sullivan et al., [182] and Coats et al., [191] resting and submaximal
exercise heart rates also decreased in patients with heart failure following training. Finally, a
slight but significant increase in peak heart rate reserve was observed by Coats et al., [191].
2.2.9.2.1.3 Vascular System
Hornig et al., [194] are the first to suggest that a local exercise program can enhance
vasodilatory capacity in patients with heart failure. In this cross-over trial, patients participated in
4 weeks of training which consisted of handgrip exercise at 70% of peak handgrip strength for 30
min per day. Exercise training restored flow-dependent dilation in patients with heart failure.
Furthermore, a study by Hambrecht et al., [195] have reported that moderate-intensity aerobic
exercise training significantly improved endothelium-mediated vasodilation of the peripheral
vasculature after 24 weeks in patients with heart failure and that these changes were significantly
correlated with changes in peak oxygen consumption [195]. A similar study has shown that
lower-limb bicycle ergometer exercise training leads to a correction of endothelial dysfunction of
the upper extremity, indicating a systemic effect of local exercise training on endothelial
function [196].
Furthermore, there is a need for long-term exercise training for maintaining improvement
of vascular function; improvement of endothelial function after 4 weeks of handgrip exercise is
lost after the cessation of training, with a return to baseline vascular function after 6 weeks [194].
These results indicate that exercise training has the potential to reverse the deleterious
effects of increasing peripheral resistance and reducing oxygen delivery to the working skeletal
muscle caused by endothelial dysfunction, although the improvement in vascular resistance may
be more rapid and pronounced in subjects who are healthy rather than patients with heart failure
[197].
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2.2.9.2.2 Skeletal Muscle Responses to Exercise Training in Heart Failure
2.2.9.2.2.1 Muscular Function
Resistance training was not routinely prescribed to patients with heart failure because this
type of exercise was associated with undesirable and pathological cardiovascular responses
[198,199]. However, during the last decade, increasing evidence indicated that dynamic
resistance training alone [200-202] or in combination with aerobic exercise [203-205] is
beneficial and counteracts the negative peripheral side effects exhibited in patients with heart
failure. In addition, localized skeletal muscle training has been shown to improve symptoms of
heart failure and exercise capacity; even localized calf skeletal muscle training improves
oxidative capacity without changes in calf blood flow, and it significantly improved a subjective
fatigue score [206].
Finally, selective respiratory muscle training in 3 weeks improved respiratory muscle
endurance and strength, with an enhancement of submaximal and maximal exercise capacity in
patients with heart failure. Dyspnea quantified by the Borg scale was significantly reduced
during progressive isocapnic hyperpnea, and dyspnea during activities of daily living was
subjectively improved in most patients who underwent training [207].
2.2.9.2.2.2 Skeletal Muscle Blood Flow
There is evidence from both human and animal studies that exercise training may
improve skeletal muscle blood flow [182,208]. In fact, Sullivan et al., [182] have reported
significant improvements in peak leg blood flow and arterio- venous oxygen difference in heart
failure patients with significantly reduced left ventricular ejection fraction (24%), following 4-6
months of exercise training. The exercise prescription during this training protocol consisted of
approximately 60 min of cardiovascular activity performed 3-5 days/wk at 75% of peak heart
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rate reserve. The improvement in skeletal muscle blood flow is not related to improved central
hemodynamics and appears to be directly related to exercise capacity [209,210].
2.2.9.2.2.3 Skeletal Muscle Metabolism
Studies have reported on the ability of skeletal muscle to significantly improve metabolic
capacity following exercise training in patients with heart failure [211,212]. For example,
Minotti et al., [212] examined the ability of skeletal muscle to adapt in patients with a mean left
ventricular ejection fraction of 27%. Patients participated in a 28-day localized unilateral
forearm training program. Training consisted of multiple sets (8 min in duration) of wrist flexion
exercise performed 6 days/week. Following training, muscle bioenergetics, as assessed by 31PNMR spectroscopy, improved in the trained forearm, whereas muscle mass, limb blood flow and
cardiac output remained unchanged. In addition, the authors reported an impressive 260%
increase in muscle endurance measured as the number of minutes that a submaximal load could
be lifted until exhaustion [212].
In addition, Stratton et al., [213] have reported that after training there were significant
improvements in skeletal muscle responses to exercise with lesser phosphocreatine utilization,
higher muscle pH at submaximal workloads, and improvement in phosphocreatine reserve,
which is also an indicator of mitochondrial adenosine triphosphate synthesis rate. These findings
suggest that skeletal muscle abnormalities in heart failure are, in part, due to a deconditioning
process, and can be partially reversed through exercise training.
2.2.9.2.3 Summary of the Response to Exercise Training in Heart Failure
Therefore, there is growing evidence that exercise training may reverse many of the
peripheral abnormalities present in the heart failure patient. Exercise training may improve
autonomic function, skeletal muscle blood flow and localized oxidative capacity. Together, these
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changes may translate in an increased exercise tolerance, reduction in activity-related symptoms,
and improved quality of life. These findings assume added importance in light of previous
reports that exercise capacity is the most powerful predictor of survival of heart failure patients.
Whether exercise training can improve long-term functional and prognostic outcomes in heart
failure patients is presently uncertain. Furthermore, the improvement in exercise tolerance in
heart failure patients following training equals that achieved in controlled trials of ACEinhibitors [214]. Finally, since exercise tolerance is known to be an independent marker of
prognosis, an increased exercise capacity following training may itself indicate a prognostic
benefit.
2.3 Peripheral Arterial Disease
Just as with heart failure patients a major physiologic problem for patients with
peripheral arterial disease is a reduction in muscle blood flow. However in peripheral arterial
disease patients the cardinal symptom is pain on exertion that is normally relieved by rest. As the
disease progresses the pain may also occur at rest. In this section the following issues will be
addressed: (a) the definition, (b) the incidence and prevalence, (c) the etiology and
pathophysiology, (d) the cardinal symptoms, (e) the diagnostic tests and the prognostic value of
exercise testing, and lastly (f) the classification of peripheral arterial disease related to the degree
of symptom severity. This section will present information regarding the principal circulatory
and muscular compensatory adaptations in peripheral arterial disease patients. Finally, this
section will discuss the acute exercise responses, and the response to exercise training in
peripheral arterial disease patients. The purpose of this section is to increase the understanding of
the manner in which patients with peripheral arterial disease compensate to their reduction in
blood flow, and the potential ramifications for treatment strategies.
63

2.3.1 Definition
Peripheral arterial disease is defined as obstruction of blood flow through a section of the
arterial tree excluding the intracranial or coronary circulations [215]. In fact, peripheral arterial
disease is a chronic manifestation of systemic atherosclerosis in the lower limb distal to the
aortic bifurcation in which the arterial lumen of the lower extremities becomes progressively
occluded by atherosclerotic plaque [216]. As a result, the obstruction impedes blood flow to the
lower extremities that leads to a mismatch of oxygen delivery and metabolic demand that
becomes more evident during physical activity [215,217].
Peripheral arterial disease is mostly silent in its early stages but may manifest as
intermittent claudication when the luminal obstruction is greater than 50% [215] (see figure 2.3 ).
As the disease progresses, the symptoms typically intensify to pain at rest, with the potential for
frank tissue loss [218]. As a result, peripheral arterial disease patients have impaired function and
quality of life [219]. This is true even for persons who do not report leg symptoms. Furthermore,
peripheral arterial disease patients, including those who are asymptomatic, experience significant
decline in lower-extremity functioning over time [220].
2.3.2 Incidence and Prevalence
Peripheral arterial disease is a major cause of disability, loss of work, and lifestyle
changes in the United States [221]. In addition, peripheral arterial disease affects approximately
12 million persons in this country [222]. It is a prevalent but underdiagnosed and undertreated
disorder associated with significant morbidity and mortality [223].
The prevalence of peripheral arterial disease increases with advancing age, as
approximately 12 to 20% of people older than 70 years suffer this condition [224,225].
Furthermore, one half of all peripheral arterial disease patients older than 55 years are
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asymptomatic. Among the symptomatic, 40% experience intermittent claudication, and 10%
have critical limb ischemia [226].

Figure 2.3. Arterial obstructions exceeding 50% of the internal lumen diameter of a
peripheral artery, such as the superficial femoral artery (A), may result in IC. The
most common cause of such symptomatic obstructions is atherosclerosis, resulting
from a buildup of fatty, cholesterol-laden plaque within the arterial wall (B) [215].
The Rotterdam Study [227] assessed the age- and sex-specific prevalence of peripheral
arterial disease and intermittent claudication in a group of 7715 old individuals. The Rotterdam
Study reported that the prevalence of peripheral arterial disease in the elderly is high whereas the
prevalence of intermittent claudication is rather low, although both occurrences clearly increase
with advancing age. In fact, the same study showed a frequency of claudication ranging from 1%
in those 55 to 60 years of age to > 5% in those over age 80 [227].
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Finally, in the Cardiovascular Health Study [228], the ankle-brachial index, a frequently
used marker of peripheral arterial disease, was measured in patients older than 65 years of age at
a baseline examination. Those with an ankle-brachial index < 0.8 were more than twice as likely
to have had a myocardial infarction, angina, heart failure, stroke, or transient ischemic attack as
patients with normal values. Furthermore, cumulative data after 6 years of follow-up on 5888
patients showed that an ankle-brachial index < 0.9 was an independent risk factor for occult
cardiovascular disease, recurrent cardiovascular events, and mortality [229].
Despite its prevalence and cardiovascular risk implications, only 25% of patients with
peripheral arterial disease are undergoing treatment [230]. The risk factors associated with
peripheral arterial disease are similar to those for coronary heart disease and include increasing
age, diabetes mellitus, cigarette smoking, hypertension, elevated lipid levels, and elevated
homocysteine levels [217,231]. In addition, persons with peripheral arterial disease, compared
with those without, have 4 to 5 times the risk of dying of a cardiovascular vascular disease event,
resulting in a 2- to 3-times higher total mortality risk [217,229].
2.3.3 Etiology and Pathophysiology
Atherosclerosis (arteriosclerosis obliterants), a primarily systemic inflammatory process,
is the leading cause, more than 90%, of occlusive arterial disease of the extremities in patients
over 40 years of age [232,204, 205]. Peripheral arterial disease is the result of atherosclerotic
disease of the lower extremities, and it is one of the major causes of disability in middle age and
the elderly [233]. The segmental lesions responsible for the stenosis or occlusion are usually
localized in large and medium-sized blood vessels [234]. It is important to emphasize that
inflammation is currently considered to be a key factor in all stages of atherogenesis in nondiabetic as well as diabetic patients [235]. The histopathological basis of disease is identical to
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that seen in the coronary vasculature and other vascular beds [236]. In general, atherosclerosis
results from an excessive inflammatory and fibroproliferative response to numerous vascular
insults, which leads to alteration of the normal homeostatic properties of the endothelium [237].
The initial changes that precede the formation of atherosclerotic lesions occur in the
endothelium, and they include: (a) increased endothelial permeability to lipoproteins and other
plasma constituents, (b) up-regulation of leukocyte adhesion molecules, (c) upregulation of
endothelial adhesion molecules, and (d) migration of leukocytes into the artery wall [234,238].
These processes are mediated by many vasoactive molecules, cytokines, and growth factors
[237]. Afterward, if the inflammatory response cannot counteract or remove the insulting factors,
the inflammatory response will stimulate migration and proliferation of smooth muscle cells that
participate in the formation of fatty streaks in atherosclerosis along with lipid-laden monocytes,
macrophages (foam cells), and T lymphocytes [237,239].
The resulting inflammatory process leads to increased amounts of macrophages and
lymphocytes, and it promotes cholesterol and calcium deposition and, ultimately, the buildup of
plaque [232]. These macrophages and lymphocytes can emigrate from the blood and multiply in
the lesion and result in further damage and eventually lead to focal necrosis [237,239]. These
changes causes further enlargement and restructuring of the lesion, so it becomes covered by a
fibrous cap that overlies a core of lipid, a mixture of leukocytes, and necrotic tissue. The necrotic
core is the result of (a) apoptosis and necrosis, (b) increased proteolytic activity, and (c) lipid
accumulation [237].
The lesions may be stable, or they may develop a thin, unstable fibrous cap, that is caused
by continuing influx and activation of macrophages. As a result, the lesion is vulnerable to
ulceration [240]. Once the lesion ulcerates, the underlying plaque is exposed to the bloodstream,
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and the potential for thrombotic occlusion or embolization increases [241]. Therefore,
atherosclerosis is a multistage, multigenic, and very complicated inflammatory disease [239].
Indeed, during atherogenesis, growth factors, cytokines, lipids, and enzymes modulate critical
cell functions by inducing (a) lipid accumulation and oxidation, (b) cell-mediated inflammatory
response, (c) smooth muscle proliferation, (d) vasoconstriction, and (e) a prothrombotic
environment within the artery wall [237,240].
The primary sites where the lesions are located include the abdominal aorta and iliac
arteries (30% of symptomatic patients), the femoral and popliteal arteries (80 to 90% of patients),
and the more distal vessels, including the tibial and peroneal arteries (40 to 50% of patients)
[242]. In addition, the atherosclerotic lesions have a predilection for arterial branch points where
increased turbulence, altered shear stress, and intimal injury occur [232]. Typically, the
narrowing of a proximal artery was considered the only factor responsible for the reduced
oxygenation in the skeletal muscle. However, the hemodynamics limitations are poor predictors
of exercise performance among individuals with peripheral arterial disease [243].
In addition, the natural history of peripheral arterial disease is slow progression of
symptoms over time [244]; however, there is considerable variation within this overall pattern. In
most patients, the disease progression is benign [215]. A great majority of patients will remain
asymptomatic or with fairly stable symptoms; some may even show improvement. In that regard,
a large population study found that 5 years after diagnosis of peripheral arterial disease , 63% of
patients showed angiographic progression, but 66% still had no limiting intermittent claudication
[245]. Many patients will simply adjust or adapt their lifestyles to accommodate their
symptomatic limbs in the same way many patients with heart failure adjust their lifestyles to
their heart function [215].
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2.3.4 Symptoms
The symptoms and signs of peripheral arterial disease are displayed in table 2.7 [246].
The decreased blood flow to the legs caused by peripheral arterial disease may be mild or severe,
resulting in a broad range of symptoms. The symptoms may range from pain on exertion that is
normally relieved by rest, also known as intermittent claudication, which is the primary
manifestation of peripheral arterial disease [218,247], to pain at rest also known as critical limb
ischemia [216,248]. In the general population, only about 10% of persons with peripheral arterial
disease have the classic symptoms of intermittent claudication. About 40% do not complain of
leg pain, whereas the remaining 50% have a variety of leg symptoms different from classic
claudication [223,249].
2.3.4.1 Intermittent Claudication
Intermittent claudication is described as a cramp, ache, fatigue, tightening discomfort, or
frank pain located in the muscles of the buttocks, thighs, or calves [250,251]. Intermittent
claudication is the result of poor oxygenation of the muscles of the lower extremities, induced by
walking or exercise and relieved by rest [252]. Classic intermittent claudication, as defined by
the World Health Organization (WHO)/Rose Claudication Questionnaire, is calf pain that occurs
during exercise and ceases within 10 minutes of rest [253].
Intermittent claudication is usually reproducible, occurring at approximately the same
distance, pace, and grade from day to day, and resolves within 2 to 5 minutes with rest. The
location of the pain often corresponds to the level of stenosis [254]. For instance, patients with an
iliac lesion often experience claudication in the thigh or buttock, whereas popliteal lesions are
more often associated with calf claudication [216]. In addition, peripheral arterial disease
patients may develop Leriche syndrome, which includes (a) claudication, (b) impotency, and (c)
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global atrophy of the lower extremities due to aortoiliac obstructive disease [255]. Intermittent
claudication is present in less than 1% of individuals under age 50 and approximately 5% or
more of those older than age 80 [217].
Table 2.7 Symptoms and signs of Peripheral Arterial Disease
Symptoms and signs
Exertional leg pain and relief with rest
Cool or cold feet to palpation
Nocturnal and rest pain relieved with dependency
Absent pulses
Blanching or pallor on elevation
Delayed venous filling after elevation
Dependent rubor
Atrophy of subcutaneous fatty tissue
Shiny skin
Loss of hair on foot and toes
Thickened nails, often with fungal infections
Gangrene or non-healing ulcer

Intermittent claudication prevalence rates vary, but in a vascular laboratory population,
only 1/3 of peripheral arterial disease subjects reported classic WHO/Rose claudication [256]
[247]. This indicates that the remaining 2/3 of individuals with peripheral arterial disease are
reportedly asymptomatic or have atypical symptoms. Daily activity is reduced up to 45% in
patients with intermittent claudication, as compared with healthy subjects of similar age [251].
Although intermittent claudication incidence has declined since 1950, the mortality has remained
high and unchanged [11].
2.3.4.2 Critical Limb Ischemia
Critical limb ischemia is defined as limb ischemia that could occur during rest [216,217].
Clinically, ischemia in the limb at rest is manifested first in the cutaneous tissues of the foot,
where factors regulating perfusion differ from those governing calf muscle circulation, and
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reflexive sympathetically mediated vasoconstrictor activity may reduce foot blood flow even
under conditions of ischemia [255]. Critical limb ischemia is typically described as worse at
bedtime with horizontal positioning (and relieved by dependent positioning), or evidence of
distal tissue necrosis (non-healing ulcers, gangrene) [257]. It is a severe manifestation of
peripheral arterial disease, which threatens the viability of the extremity because arterial
perfusion is insufficient to meet even the basal metabolic demands of the tissue [258]. Other
symptoms of ischemia at rest include hypesthesia, cold sensitivity, muscular weakness, joint
stiffness, and contracture [255].
Normally, pain at rest indicates severe, often multilevel arterial occlusive disease. It
characteristically occurs as a dull, aching sensation in the toes or fore foot, or as a severe,
nagging burning at night with the patient lying supine [246,255]. The patient may hang the foot
or leg over the side of the bed or get up to walk around to obtain relief. Some patients with
severe rest pain sleep sitting in a chair with the legs dependent, resulting in edema [258].
Therefore, it has a profound effect on functional capacity and quality of life among the patients,
and it requires an aggressive management, which usually includes angiographic examination and
therapeutic intervention by percutaneous angioplasty or surgical revascularization. When these
are not feasible, gangrene commonly ensues leading to amputation [255]. Critical limb ischemia
results in some 150,000 amputations annually in the US, with perioperative mortality rates of 5–
10% for below-knee amputation and up to 50% for above-knee amputation because of comorbid
conditions [217]. Finally, the annual incidence of critical limb ischemia approximates 500 per
one million population [221]. Among patients with intermittent claudication, approximately 10%
progress to limb-threatening ischemia in 5 years, and 25% of those with critical limb ischemia
require amputation [244].
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2.3.5 Diagnostic Tests
This particular section will describe various diagnostic tools that are currently available
in the diagnosis and management of patients with peripheral arterial disease. However, the main
focus of this section is to present information regarding two of the most practical and frequently
used tests in the diagnosis of patients with peripheral arterial disease, the ankle-brachial index
test and exercise testing with the ankle-brachial index.
2.3.5.1 The Ankle–Brachial Index Test
The ankle-brachial index is a simple, inexpensive, non-invasive vascular tool that
correlates well with angiography disease severity and functional symptoms [259, 256]. Under
normal conditions, systolic blood pressure in the legs is equal to or slightly greater than the
systolic pressure in the upper limbs. In the presence of an arterial stenosis, a reduction in
pressure occurs distal to the lesion [223]. The ankle-brachial index, which is calculated from the
ratio of ankle to brachial systolic pressure, is a sensitive marker of arterial insufficiency. The
highest pressure measured in any ankle artery is used as the numerator in the calculation of the
index; a value greater than 1.0 is normal and a value less than 0.90 is abnormal [260].
Normally, an ankle-brachial index less than 0.90 is considered diagnostic of peripheral
arterial disease. There are three categories; (a) mild disease correlates with an ankle-brachial
index ranging from 0.70 to less than 0.90, whereas (b) moderate disease correlates with an anklebrachial index ranging from 0.40 to less than 0.70, and finally (c) severe disease is associated
with an ankle-brachial index less than 0.40 [221,261]. Patients with intermittent claudication
tend to have an ankle-brachial index in the range of 0.5 to 0.9, whereas those with critical
ischemia usually have an index of less than 0.50 [223]. The ankle-brachial index also has
prognostic significance because of the association with arterial disease elsewhere, especially
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coronary heart disease. Recent studies indicate an association of elevated ankle-brachial index
levels with increased all-cause and cardiovascular mortality [242].
2.3.5.1.1 Ankle-Brachial Index Technique
The ankle-brachial index measurement sites are displayed in figure 2.7. An ordinary
blood pressure cuff is positioned over the upper arm and inflated above systolic blood pressure.
Next, a Doppler ultrasonic velocity signal probe is placed over the brachial artery to detect the
resumption of blood flow with cuff deflation. Measurement of systolic blood pressure is repeated
on the other arm. The higher of the 2 systolic blood pressures is used in the calculation. The
measurement of the ankle systolic blood pressure is detected with the Doppler probe over the
posterior tibial artery and then over the dorsalis pedis artery. The higher value from the two
arteries is used into the calculation. The process should be repeated for the other leg. Finally, the
lowest ankle-brachial index between both legs is the ankle-brachial index that stratifies the
patient’s risk [217].
2.3.5.1.2 Limitations of Ankle-Brachial Index
In some patients with diabetes, renal insufficiency, or other diseases that cause vascular
calcification, the tibial arteries at the ankle become non-compressible. This leads to a false high
ankle-brachial index value. In those cases, additional measures would be necessary (e.g. a toebrachial index, pulse volume recordings or other noninvasive testing) [221].
2.3.5.2 Exercise Testing
The addition of ankle-brachial index measure with exercise testing provides more
information on the dynamics of claudication [262]. Studies have reported that exercise testing is
useful in those patients with claudication symptoms who have a normal ankle-brachial index or
normal pulse at rest [263]. The typical treadmill protocol for persons with peripheral
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arterial disease is either a graded or a constant load protocol [264]. The graded protocol utilizes a
fixed speed while grade increases every two or three minutes to a symptom limited maximal (or
“peak”) performance [265]. The constant load protocol has both speed and grade fixed, and it is
done on a treadmill allowing the patient to walk at a standard speed and grade for a predeterminated period (2 mph at 12% incline for 5 minutes) or until claudication appears [221].
Both types of protocol have shown very good reproducibility [266].
The next section is intended to present information regarding the prognostic value of these
diagnostic tools used in patients with peripheral arterial disease. This section will address the
outcomes of the ankle-brachial index technique, and then, the exercise testing with the addition
of ankle-brachial index. The prognostic value of exercise testing in peripheral arterial disease is
as follow:
2.3.5.2.1 Ankle-Brachial Index Test
Although not a direct measure of function, the ankle-brachial index is of key importance
to assess peripheral arterial disease severity [267]. The ankle-brachial index test is a non-invasive
measure that is made in the peripheral arterial disease patient first while resting in the supine
position, and second, post exercise (also supine) by assessing systolic blood pressure in the ankle
and arm with a Doppler ultrasonic instrument [264]. In addition, many studies have reported that
the ankle-brachial index decreases with age. In fact, the Rotterdam Study [227] showed that the
ankle-brachial index decreased sharply with advancing age. These investigators concluded that
the high prevalence of peripheral arterial disease and unfavorable cardiovascular risk profile of
patients with peripheral arterial disease, illustrates the need to explore the use of the anklebrachial index as a risk indicator in cardiovascular screening and risk profiling in medical
practice. Finally, the ankle-brachial index test also provides significant information regarding;
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(a) the disease progression, (b) the functional capacity, and (c) its role as predictor of
cardiovascular morbidity and/or mortality among peripheral arterial disease patients [221].
2.3.5.2.1.1 Disease Progression
The changes in the ankle-brachial index values over time represent a useful tool to
monitor disease progression [268]. For example, changes in the ankle-brachial index that exceed
±0.15 are considered to be outside the range of experimental error and indicate disease
progression [262].
2.3.5.2.1.2 Functional Capacity
Many studies have shown that the ankle-brachial index is independently linked with
impaired lower extremity functioning, even in asymptomatic patients. In that regard, the
Women’s Health and Aging Study [269] revealed that decreasing ankle-brachial index values
were associated with progressive worsening in functional scores, even after adjustment for age,
sex, race, smoking status, and comorbidities. For example, in asymptomatic women, lower
ankle-brachial index scores were associated with slower walking velocity, poorer standing
balance, slower time to arise, and fewer blocks walked per week. In addition, the Study of
Osteoporotic Fractures [270] showed that patients with an ankle-brachial index less than 0.90
had significantly lower hip abduction force, knee extension force, walking velocity, and number
of blocks walked than those with an ankle-brachial index of 0.90 or greater. Finally, other studies
have reported that progressive peripheral arterial disease is associated with muscle fiber loss,
poorer leg strength, and slower walking velocity [271].
2.3.5.2.1.3 Predictor of Cardiovascular Morbidity and/or Mortality
The Cardiovascular Health Study [229] was conducted among 5888 adults 65 years of
age or older in order to monitor for cardiovascular events after establishing a baseline
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cardiovascular disease and ankle-brachial index measurement. The results reveal that mortality
rate at 6 years was higher in those patients who had cardiovascular disease and a low anklebrachial index (<0.90) at baseline (32.3%), in contrast it was lowest in patients with neither of
these risks factors at baseline (8.7%). A study conducted by McKenna et al., [272] showed that
mortality from cardiovascular disease was highest among patients with an ankle-brachial index
less than 0.40 and lowest among patients with an ankle-brachial index of 0.85 to 1.50.
Interestingly, several studies had revealed the importance of the ankle-brachial index as a
predictor of cardiovascular mortality among asymptomatic peripheral arterial disease patients
[273,274]. The study by Criqui et al., [273] showed the survival curves based on mortality from
all causes among normal subjects and subjects with symptomatic and asymptomatic peripheral
arterial disease. This study confirms the overall poor prognosis with advancing age and the
alarmingly high risk in asymptomatic patients whose disease would not be detected clinically.
However, a hemodynamic measure such as ankle-brachial index should not be used as a primary
measure of the functional effects of an intervention such as exercise rehabilitation since the
correlation between ankle-brachial index and treadmill walking is often weak [264].
2.3.5.2.2 Exercise Testing
The exercise testing assessment has been considered the gold standard for evaluating
exercise performance in peripheral arterial disease patients [264]. Normally, in healthy subjects
ankle systolic blood pressure is maintained during moderate exercise. On the other hand, in
patients with claudication their ankle systolic blood pressure falls to low or is undetectable with
low level workloads and returns to baseline after a few minutes [262]. The two main measures
that are obtained from treadmill testing are pain-free walking time, also called initial claudication
distance and maximal walking time, also called absolute claudication distance [264,275]. Pain76

free walking time is the time a patient can walk before the onset of claudication, while maximal
walking time is the amount of time a patient can walk before being stopped by severe
claudication [251,264]. Finally, among patients with peripheral arterial disease the post-exercise
ankle-brachial index will drop significantly [263]. However, any pain or discomfort related to the
exercise while the ankle-brachial index remains normal or unchanged are not produced by
peripheral arterial disease [221].
2.3.6 Classification According to the Symptom Severity
Two major classification systems have been used to rate the symptom severity and to
assess the impact of intervention programs in peripheral arterial disease patients. The first one is
the older Fontaine system [276]. This system assigns patients to 1of 4 clinical stages (I-IV),
depending on the manifestation of clinical signs (see table 2.8).
Table 2.8 Fontaine’s classification
Stage
Stage I
Stage II
IIa

Clinical description and objective criteria
Asymptomatic peripheral arterial disease patients
Exercise-induced ischemia
Intermittent claudication, pain during walking
Relief of symptoms when standing
IIb
Compensated disease: walking distance > 100 m
Stage III Ischemia-driven symptoms at rest
IIIa
Ankle Pressure Index ≥ 50 mm Hg
IIIb
Ankle Pressure Index < 50 mm Hg
Stage IV Trophic ulcers and gangrene
IVa
Limited gangrene
IVb
Extensive gangrene

In addition, a new classification has now been proposed by Rutherford et al., [277]. It
comprises six clinical categories (see table 2.9), and its use is recommended by the TransAtlantic Inter- Society Consensus (TASC) Working Group for the diagnosis and assessment of
the progression of peripheral arterial disease [278].
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Table 2.9 Rutherford categories
Category
0
1

Clinical description
Asymptomatic
Mild claudication

2

Moderate claudication

3

Severe claudication

4

Ischemic rest pain

5

Minor tissue loss

6

Major tissue loss
(normally above the
metatarsal level)

Objective criteria
Normal treadmill test
Treadmill exercise limited to 5
min; ankle pressure after
exercise >50 mmHg, but at
least 20 mmHg lower than at
rest
Between Rutherford 2 and 3
disease
Treadmill exercise limited to
<5 min; ankle pressure after
exercise <50 mmHg
Ankle pressure <40 mmHg
and/or great toe pressure <30
mmHg; pulse volume
recording barely pulsatile or
flat
Ankle pressure <60 mmHg
and/or great toe pressure <30
mmHg; pulse volume
recording barely pulsatile or
flat

In summary, peripheral arterial disease is a major and growing public health problem
in the United States. In fact, peripheral arterial disease is a prevalent but underdiagnosed and
undertreated disorder associated with significant morbidity and mortality. Peripheral arterial
disease is a clinical syndrome that causes a reduction of blood flow to the lower extremities, and
it produces a mismatch of oxygen delivery and metabolic demand that becomes more evident
during physical activity.
The cardinal manifestation of peripheral arterial disease is intermittent claudication.
Finally, the Rutherford system is currently the recommended classification used to quantify the
severity of symptoms among peripheral arterial disease patients. The next section will present
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information regarding the principal circulatory and muscular compensatory adaptations in
peripheral arterial disease patients.
2.3.7 Compensatory Adaptations to Peripheral Arterial Disease
Peripheral arterial disease is defined as an obstruction of blood flow to the lower
extremity, due to atherosclerosis. Peripheral arterial disease is mostly silent in its early stages and
its symptoms progress slowly over time. Eventually, patients with peripheral arterial disease
might suffer from pain at rest and/or ischemic ulceration and gangrene due to hypoperfusion,
which is known as critical limb ischemia.
The primary pathophysiology of peripheral arterial disease is impaired perfusion that
forces a series of functional and structural modifications in the affected limb. These
compensatory modifications determine the functional ability of patients with peripheral arterial
disease. Thus the purpose of this section of the review is to discuss the compensatory
modifications associated with the disease. Particular focus will go toward discussing: (a) the
vascular compensatory adaptations, and (b) the skeletal muscle compensatory adaptations as a
result of peripheral arterial disease.
2.3.7.1 Vascular Compensatory Adaptations
Atherosclerosis is a disease of the large and medium sized arteries. The small arteries
such as the digital vessels generally are not affected in atherosclerosis, but, on occasion, may
become involved secondarily [279]. Traditionally, atherosclerosis research has mainly focused
on investigating risk factors for plaque development and its complications. However,
considerably less is known about compensatory phenomena of the vasculature in atherosclerosis.
In that regard, few experimental studies encouraged the hypothesis that vessels dilate in response
to atherogenesis, thereby restoring normal blood flow and delaying the onset of clinically
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important stenosis [280-282]. The vasculature is recognized as a complex organ capable of
sensing its environment (e.g. shear stress), transducing signals to effector cells or surrounding
tissue and responding to various stimuli by releasing local regulatory mediators such as growth
factors and vasoactive peptides [282-284].
Many studies have described atherosclerosis as a diffuse and progressive process with a
variable distribution and clinical presentation that is dependent on the regional circulation
involved [217,251,285]. Factors that may influence these differences include the size and
structure of the affected artery, local and regional flow, changes in microcirculatory alterations,
and end-organ damage.
Generally, the reduction of blood flow as a result of the atherosclerotic lesion would
favor the installation of distal modifications far away from the original stenotic vessel [251]. The
local blood flow control can be divided into two phases: (a) acute control, and (b) long-term
control. Acute control is achieved by rapid changes in local vasodilation or vasoconstriction of
the arterioles, metarterioles, and pre-capillary sphincters. This response occurs within seconds to
minutes in order to provide a rapid means for maintaining appropriate local tissue blood flow.
The long-term control results in slow changes in flow over a period of days, weeks, or
even months. These changes are the result of an increase or decrease in the physical sizes and
numbers of actual blood vessels [110]. Furthermore, the understanding of atherosclerotic
vascular disease has evolved most dramatically over the past 25 years with the growth of the
field of vascular biology [286]. With that in mind, the purpose of this section of this review is to
outline the major vascular compensatory adaptations in peripheral arterial disease. The topics
included in this section are: (a) large and medium-sized arteries, (b) collateral arteries, and (c)
microcirculatory disturbances.
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2.3.7.1.1 Large and Medium Sized Arteries
When a large or medium sized artery becomes occluded, secondary vascular channels
immediately develop around the blockage and allow, at least, partial resupply of blood to the
tissue below the blockage. Vascular loops above the blockage begin to dilate, and are in part
secondary to neural and/or metabolic relaxation of the smooth muscle surrounding the blood
vessels. Obviously, the compensation is less then optimal, but is able to maintain cellular
function under resting conditions. The compensation continues and within a few days may
eventually be sufficient to normalize flow under even low levels of activity [110].
Whereas the initial compensation is more than likely the consequence of rapid neural
changes and metabolic dilation, the long-term collateral formation more than likely involves
structural changes in the circulatory tree that contribute to vessel growth and enlargement [110].
In fact, it has been reported that compensatory enlargement of the vessel at the site of active
atherosclerosis effectively preserves normal lumen size [285]. However, whereas the
compensation is clearly aimed at improving blood flow to the compromised region, vascular
remodeling does alter the normal pressure/flow relationships. It is believed these alterations
contribute to the degree of disability the patient suffers [287]. In fact, it is not uncommon to
observe, within the same vessel, both a decrease in lumen size (due to advancing atherosclerosis)
and an increase in lumen diameter [288]. Consequently, the flow profile (from laminar to more
frequent turbulent flow), and vessel shear will change throughout the affected artery thereby
increasing the stress on an already vulnerable vessel.
2.3.7.1.2 Collateral Arteries
The importance of the collateral arteries was described in the previous section. However,
given its importance this section will describe in greater detail the underlying factors that
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contribute to the formation of these vessels. Collateral arteries may already be present in the
body, and are only stimulated and subsequently opened in times of need. However, collaterals
also “grow” as the need remains or the extent of the disease worsens.
Many factors are well known and accepted regarding collateral arteries [279]. The
collateral arteries consist of three components: the exit, mid-zone, and re-entry vessel [289]. An
example of an exit collateral would be the profunda femoris with the geniculate arteries
representing the reentry channel(s). Normally the mid-zone connecting the two will not be
visible on an arteriogram because of their small size. However, this is the zone that will undergo
the greatest change in diameter when ischemia develops. In fact, with acute arterial occlusion,
limb survival will often depend on the ability of the mid-zone collaterals to increase in diameter
and carry enough nutritive blood flow to permit limb survival [279]. The problems with
collateral arteries is that they present an increase in resistance to flow (due to their relatively
small size) which limits their capability of providing enough blood flow to reach the levels
necessary to prevent claudication from occurring. Thus, they may be sufficient for resting flow
needs but cannot respond to the added stress of exercise.
Another problem that is often encountered with collaterals is that when more than one set
of collateral arteries are in series in a limb with multisegmental obstructions, there is a significant
increase in the resistance to flow. Thus the peripheral vascular resistance rises further adding to
the vascular problems. For this reason multisegment arterial disease is nearly always more severe
than single-segment occlusion [287]. Indeed, it is the patient with multisegment disease who
presents the greatest challenges in management. Finally, anatomically, there are profound
differences in the collateral capabilities of some areas of the circulation that are important
hemodynamically [279]. For instance, the aorta and iliac arteries received their collateral arteries
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(called parietal) from intercostals and subcostal arteries. Visceral collaterals to supply the limb
can also come from the inferior mesenteric arteries that connect with the arteries of the pelvis;
however, they are not able to supply enough blood to the ischemic limb to prevent claudication
from occurring [279]. Below the knee the anatomic arrangement, in terms of potential collateral
flow, is much different. The blood supply to the gastrocnemius muscle is from a single source,
the sural artery. Within the muscle, the arteries branch much like those of a tree; however, and
most critically, there are relatively few arterial connections with the gastrocnemius muscle from
outside sources. In other words, it almost has an isolated blood supply. In contrast, the soleus
muscle is supplied by multiple side branches that freely communicate up and down the limb with
other branches that permit inflow in cases of chronic arterial obstruction [289]. These extensive
intercommunications are usually able to provide adequate levels of blood flow even in the
presence of extensive chronic arterial occlusion in the arteries below the knee. They are
particularly important when considering the problem of diabetic arterial disease, in which
extensive pathology in this area is very common [279].
2.3.7.1.3 Microcirculatory Disturbances
The components of the microcirculation (arterioles, capillaries, venules, and the
endothelial cells covering vascular structures) contribute to maintain the internal circulatory,
coagulative and metabolic homeostasis [110]. The endothelial cells are in the non activated state
(normal morphology) when the perfusion pressure is normal. In addition, the blood cells are in a
non secretory, non adherent state [290].
As a result, the blood vessels are able to deliver the proper amount of blood flow that is
plentiful in oxygen and substrates for energy production, in order to meet the metabolic
requirements of the skeletal muscle. The next section will present information regarding two of
83

the microcirculatory disturbances seen in patients with peripheral arterial disease. The topics
included are: (a) the endothelium and and (b) the blood cells.
2.3.7.1.3.1 The Endothelium
It is interesting to consider that the above-mentioned changes, in large part, aim to
improve blood flow to tissue, under difficult circumstances. In contrast, a consistent finding in
the literature is that patients with peripheral arterial disease have impaired endothelial function
[291-294]. Indeed, Edwards et al., [295] have reported that ischemic conditions promote
endothelial changes that favor platelet adhesion and subsequently activate the coagulation
cascade. Furthermore, Thomson et al., [296] revealed the presence of capillary endothelial
swelling in critical limb ischemia. In addition, studies in patients with peripheral arterial disease
have reported an increase in adhesion molecules [297] that when interacting with their counterreceptors expressed by circulating cells, favor the cell–cell adhesion. Raised plasma levels of
circulating adhesion molecules that further increase with exercise have been reported in patients
with intermittent claudication [298]. Finally, Boger et al., [299] reported that patients with
peripheral artery disease present impaired nitric oxide synthesis. These findings suggest that the
endothelial function is compromised. Clearly, this compensation is difficult to understand if one
considers that most changes aim to improve the situation. One could speculate that this in fact is
more a disease related factor rather than a compensation for the atherosclerosis. Certainly, this
fits with current thinking which strongly suggests that endothelial dysfunction precedes the
development of atherosclerosis.
2.3.7.1.3.2 The Blood Cells
Erythrocyte mean corpuscular volume is significantly correlated with the angiographic
score in peripheral artery disease patients [300]. Others also report increases in plasma viscosity
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with the progression of the atherosclerotic process in patients with peripheral arterial disease and
these findings correlate with the clinical stages of the disease [301]. Intuitively, this
compensation makes sense as the body attempts to improve its oxygen carrying capacity in a low
flow environment. However, this compensation also appears to come with negative
consequences as the apparent transport of oxygen from the heme to the myoglobin and into the
cell is compromised.
In addition, studies in patients with peripheral arterial disease have shown greater
leukocyte and platelet activation [302,303] that could lead to physical obstruction and/or the
release of toxic chemicals affecting the microcirculation. In addition, activated leukocytes and
platelets may adhere to the endothelium of pre-capillary arterioles and post-capillary venules,
through the action of adhesion molecules [297]. Activated leukocytes may deliver a variety of
noxious substances including proteolytic enzymes, oxygen free radicals, and leukotrienes. Then,
these products by inducing cell membrane peroxidation and endothelial damage, promote
vascular permeability, plasma leakage and consequent interstitial oedema [302]. The activation
of platelets produces the release of different products that may promote vasoconstriction and
fibrin formation and inhibit fibrinolysis [303].
In addition, increased vascular permeability in patients with peripheral arterial disease
has been reported by Hickey et al., [304]. Their results showed that in claudicant patients the
exercise-induced ischemia in the affected limb is accompanied by microalbuminuria. Blood
viscosity is an important determinant of blood flow, which in turn is determined by hematocrit,
blood cell deformability, and plasma viscosity. In the normal microcirculation, under high shear
stress and perfusion pressure, erythrocytes deform easily and thus pass easily through the
capillaries. In contrast, erythrocytes in patients with peripheral arterial disease deform less
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rapidly making their passage through the capillaries more difficult [305]. These changes would
lead to red cell aggregation, increased blood viscosity and reduced blood flow. Clearly more
work is needed to differentiate which of these observed changes are compensatory and which are
contributory to the disease progression.
2.3.7.2 Skeletal Muscle Compensatory Adaptations
2.3.7.2.1 Histologic and Biochemical Alterations in Skeletal Muscle
The reduction in blood flow in patients with peripheral arterial disease progress gradually
and ultimately leads to severe ischemic disease. As a result peripheral arterial disease patients
exhibit a variety of structural changes in skeletal muscle consisting of (a) neural modifications,
specifically denervation, (b) muscle fiber atrophy, and (c) selective loss of type II fibers relative
to type I fibers [306,307]. The result of these modifications is neuromuscular dysfunction,
contributing to the clinical course of the disease. For instance, Hedberg et al., [306] have
reported that peripheral arterial disease patients with critical ischemia have widespread
destruction of muscle fibers, which are replaced with non-contractile connective tissue.
Importantly, the destruction of muscle fibers appears to be, at least, for a period of time
during the disease progression somewhat selective. In fact, chronic ischemia in peripheral arterial
disease patients is typically characterized by denervation and a decreased type II fiber area.
Table 2.10 provides a very simplistic overview of the differences in muscle fibers [283].
Obviously; the changes are associated with muscle atrophy and a loss of muscle mass that
lead to functional impairment. In that regard, England et al., [308] have reported that ischemic
pain associated with peripheral arterial disease leads to lower extremity neuropathy. The
neuropathy causes partial denervation-reinervation, and it results in decreased muscular strength
and performance [309].
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Table 2.10 Skeletal muscle fiber types
Features

Type I

Type II

Color
Contractility
Function
Mitochondria density
Oxidative capacity
Glycolytic capacity
Enzymes

Red
Slow twitch
Postural
High
High
Low
Citrate synthase
Succinate dehydrogenase
Cytochrome oxidase

White
Fast twitch
Fine movement
Low
Low
High
Lactate dehydrogenase
Pyruvate kinase

These changes are seen in both motor and sensory nerves of peripheral arterial disease
patients with concurrent diabetic neuropathy, and they are also reported in non-diabetic patients
[310,311]. Furthermore, Eames and Lange [312] have reported sensory and motor impairment
weakness in claudicants, which has a detrimental effect on the biomechanics of walking [243].
On the other hand, peripheral arterial disease patients with less severe ischemia exhibit more
diverse skeletal muscle changes. For instance, selective loss of type II fibers [243] to no loss of
fibers [307], or an increase in the number of type I fibers [313]. In addition, some studies have
reported selective loss of type IIb fibers [314]. These changes can lead to greater strength
deficits in peripheral arterial disease patients due the fact that type II muscle fibers are larger,
stronger, and faster than type I muscle fibers.
Traditionally, the technique in the study of muscle fiber typing involves the examination
of myofibrillar adenosine triphosphatase activity. This technique allows for the classification of
muscle fibers in three distinct groups: (a) slow fibers or type I, highly fatigue resistant, (b) fast
fibers or type II, specifically type IIa or intermediate, and (c) fast fibers or type IIb or high
anaerobic capacity fibers [243,315,316]. Histologic changes in skeletal muscle in unilateral
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peripheral arterial disease patients were examined by Regensteiner et al., [243]. Their findings
indicated muscle fiber atrophy and decrease of the type II fiber cross-sectional area. Thus, the
histologic changes of muscles, especially type II fiber atrophy, may contribute to the reduced
exercise performance in peripheral arterial disease patients. However, there are other studies that
report no clear difference in fiber distribution and in diameter between diseased and nondiseased legs of patients with unilateral peripheral arterial disease [317,318]. One reason for
these conflicting results may be the heterogeneity of the muscle fiber composition. Furthermore,
muscle fibers are composed of a series of contractile proteins that have different molecular and
biochemical characteristics [319]. It means that more than one single myosin heavy chain
isoform may exist in a single fiber [320].
These myosin isoforms determine muscle fiber type and also reflect the functional state
of the ischemic muscle in peripheral arterial disease patients. The main myosin heavy chain
isoform of a slow fiber is the myosin heavy chain I, the fast fiber IIb mainly consists of myosin
heavy chain IIb, and the intermediate (IIa) contains mainly myosin heavy chain IIa. However,
Jaschinski et al., [321] have reported that in a single fiber different myosin heavy chain isoforms
exist; (a) a fiber I may be found in myosin heavy chain I and IIa; and (b) a fast fiber IIb may be
found myosin heavy chain IIa and IIb.
In that regard, Steinacker et al., [316] investigated for the first time, the expression of
myosin heavy chain isoforms in skeletal muscle of peripheral arterial disease patients. They
findings indicate a relative decrease of myosin heavy chain IIb and increase of myosin heavy
chain I, followed by a decrease of myosin heavy chain IIa with progressive ischemia (see figure
2.4). In addition, McGuigan et al., [315] have reported a significant reduction in myosin heavy
chain I isoforms in peripheral arterial disease patients compared with healthy individuals. The
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same study using the myofibrillar adenosine triphosphatase activity technique reported a
significantly reduced percentage of type I fibers and significantly increased percentage of type
IIa fibers. These investigators concluded that the conversion of type I (oxidative) to type II (nonoxidative) fibers limits the endurance capacity of peripheral arterial disease patients.

Figure 2.4. MHC isoform distribution between control patients and patients with PAOD
with clinical stage II, III, IV. In comparison with control patients, there was no change
of MHC isoforms in patients with PAOD II, but there was a significant decrease of
MHC IIb in PAOD III and IIa and of IIb in PAOD IV. MHC, Myosin heavy chain;
PAOD, Peripheral arterial obstructive disease [316].
2.3.7.2.2 Capillary Density
Studies in individuals free of disease indicate that capillary density is directionally
correlated with the oxidative capacity and endurance of a muscle group [322]. Patients with
peripheral arterial disease exhibit significant skeletal muscle abnormalities compared with
healthy controls [323]. Ironically, despite having a reduced aerobic capacity, the skeletal muscle
capillary density appears to be increased in patients with peripheral arterial disease, and the
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relative increase in vascular density appears to be proportional to the extent of skeletal muscle
hypoxia [323,324]. This response could be viewed as a potentially beneficial adaptation and an
attempt to compensate for the atherosclerotic lesions limiting blood flow upstream.
2.3.7.2.3 Metabolic Enzyme Activity
The literature appears to be quite clear in that patients with peripheral arterial disease upregulate skeletal muscle oxidative enzyme activity. It is believed the upregulation of skeletal
muscle oxidative enzyme activity in peripheral arterial disease patients is an adaptive response to
the reduced skeletal muscle blood flow [307,325]. Several studies have reported an increase in
the oxidative enzymes, citrate synthase and cytochrome oxidase in the calf muscles of peripheral
arterial disease patients [311,313,325]. The upregulation of oxidative enzymes is further
enhanced in claudicant patients who exercise regularly, suggesting the combination of hypoxia
and physical activity in stimulating enzyme activity. Interestingly, the histological and
biochemical features of skeletal muscle of peripheral arterial disease patients are not too
dissimilar from those seen in athletes [317]. However, studies using electron microscopy have
identified structural abnormalities in lower limb muscle mitochondria of peripheral arterial
disease patients [326]. For instance, Kemp et al., [327] reported that peripheral arterial disease
patients have twice the requirement for adenosine triphosphate than control subjects at the same
workload. This metabolic imbalance or reduced metabolic efficiency may provide yet another
glimpse into the mechanisms for the reduced functional ability seen in these patients. It appears
part of the problem resides with alterations in fat metabolism as evidenced by studies showing an
accumulation of acylcarnitine in claudicants [328]. The inability to move acylcarnitines across
the mitochondrial membranes may have significant consequences on overall muscle function
[329]. Finally, Hands et al., [330] have reported that peripheral arterial disease patients have
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slower recovery of high-energy phosphate substrate in the muscles which lead to a poorer
tolerance of exercise and a prolonged recovery time.
2.3.7.2.4 Muscle Metabolism
Muscle contraction depends on a continuous supply of energy. The adenosine
triphosphate-creatine system supplies energy only for short periods of time. The more efficient
way to produce adenosine triphosphate is through aerobic synthesis of adenosine triphosphate,
fueled by glucose and free fatty acids as the major substrates. However, when the oxygen supply
is limited, the anaerobic system will take command. In doing that, pyruvate is converted to lactic
acid rather that Acetyl-Coenzyme A. Resting conditions or light intensity activities utilize free
fatty acids as the main source of energy (β oxidation). If the intensity of the activity increases,
glycolysis will be activated using glucose as a substrate. Although the oxidation of free fatty
acids provides more adenosine triphosphate than glucose, the amount of oxygen required for
fatty acid metabolism is higher.
In patients with peripheral arterial disease any increase in activity levels would cause an
inequality between the oxygen supply and the demand. As a result, aerobic generation of
adenosine triphosphate becomes inadequate, and it forces anaerobic metabolism that increases
lactic acid production [331]. The ischemic muscle during exercise produces high levels of
inorganic phosphate as a consequence of a high rate of adenosine triphosphate and
phosphocreatine breakdown. Hence, the ratio of inorganic phosphates to phosphocreatine
increases to a greater extent than in the normoperfused muscle. It results in a higher reliance of
glycolytic metabolism to obtain the energy needed [290]. Kemp et al., [327] using 31P magnetic
resonance spectroscopy, found an increased accumulation of lactate and depletion of cellular
adenosine triphosphate during exercise in claudicants compared with normal subjects.
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The reduced vascular perfusion would be responsible for the reduction of adenosine
triphosphate synthesis. As a result, both the oxygen delivery (reduced mitochondrial oxidation)
and the washout of toxic metabolites from the skeletal muscle would be impaired [290]. Patients
with claudication have been shown to accumulate acetylcarnitine (thus reflecting AcetylCoenzyme A accumulation) and lactate (as a consequence of pyruvate dehydrogenase
inhibition). Interestingly, Hiatt et al., [332] found that there is an inverse correlation between
both plasma and muscle levels of acetylcarnitine and subsequent assessments of peak exercise
performance.
These findings were corroborated by the same Hiatt in a later study showing that
peripheral arterial disease patients exhibit an accumulation of lactate and intermediates of
oxidative metabolism (short-chain acylcarnitines) in skeletal muscle at rest [328]. These results
strongly suggest that in patients with intermittent claudication, altered carnitine metabolism may
be associated with the altered muscle energy metabolism. Furthermore, a study by Brevetti [333]
reported that patients with peripheral arterial disease with mild functional impairment have low
resting plasma levels of acetylcarnitine that normally increase with exercise, while the most
affected patients have elevated resting levels of acetylcarnitine and do not form these esters with
exercise. The plasma concentration of acetylcarnitine depends not only on the rate of formation
of Acetyl-Coenzyme A but also on the availability of carnitine to remove it from the
mitochondria pool.
Therefore, it is possible to assume that in peripheral arterial disease patients with
moderate to severe claudication, the overutilization of carnitine at rest (as reflect by the elevated
levels of acetylcarnitine) results in carnitine insufficiency. This condition would prevent to

92

provide sufficient carnitine to meet the increased metabolic demand induced by walking in
peripheral arterial disease [290]. In fact, these patients after carnitine supplementation showed an
increase in plasma acetylcarnitine as opposed to the decrease observed before treatment [333].
2.3.7.2.5 Oxygen Delivery to the Tissue
Normally, oxygen passes to the tissue via the capillaries. However, blood entering
capillaries is only 50% saturated [334], thus implying that one-half of oxygen gathered by the
lungs exits the circulation prior to arriving to the capillaries. Possible sinks for oxygen exiting
before the capillaries include oxygen shunting from arterioles to parallel venules, arteriolarcapillary oxygen diffusional shunting and periarteriolar tissue consumption.
Those observations were first reported by Duling and Berne [334]; they found that
significant amounts of oxygen exit the arteriolar network. Intaglietta et al., [335] using the
phosphorescence decay technology was able to evaluate the longitudinal vessel pO2 gradients (or
blood oxygen saturation gradients) and the perivascular pO2 tissue gradients that most likely
determine the rate of oxygen exit from blood vessels. Their results confirm that a major portion
of blood oxygen is delivered to the tissue by the arterioles.
In addition, Curtis et al., [336] reported that when endothelium is removed from the dog
hind limb, oxygen consumption decreases by 34%. In fact, endothelium is capable of metabolic
activity which can be 100-fold that of other cells [337]. The endothelium is responsible for the
synthesis and secretion of many vasoactive products (e.g. renin, prostaglandins, collagen, nitric
oxide, endothelin, and prostacyclin). Moreover, endothelial cells have an active actin/myosinbased contractile system that also may consume oxygen [338].
Therefore, the metabolic stress induced by ischemia would result in more oxygen
consumed by the endothelium and less becomes available to the metabolic requirements of the
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muscle. Finally, this pathophysiologic mechanism could contribute to the alteration of oxidative
machinery occurring in the skeletal muscle of patients with peripheral arterial disease.
2.3.7.3 Summary of Compensatory Adaptations in Peripheral Arterial Disease
In patients with peripheral arterial disease the vascular compensatory mechanism deals
more with an initial compensatory dilation and enlargement of the vessel at the site of active
atherosclerosis. It is due to neurogenic or metabolic relaxation of the smooth muscle surrounding
the blood vessels. Next, the opening of collateral vessels would try to normalize the blood
supply. The growth of these collateral vessels follows the principles of both acute (neurogenic)
and long-term (metabolic) blood flow control. Alterations in skeletal muscle include (a) selective
loss of type II fibers relative to type I fibers, (b) up-regulation of the oxidative enzyme activity,
and (c) increased capillary density. However, these changes seem to be proportional to the extent
of skeletal muscle hypoxia.
2.3.8 The Role of Exercise in Peripheral Arterial Disease
2.3.8.1 The Acute Exercise Response in Peripheral Arterial Disease
Usually, peripheral arterial disease patients with intermittent claudication do not exhibit
signs or symptoms of their disease at rest. It is not until a physiologic stress, such as exercise, is
introduced that they develop pain (claudication) due the insufficient blood flow able to reach the
muscles. Therefore, the purpose of this section is to review the effects of a single bout of
exercise on patients with peripheral arterial disease. In particular, this review will focus on: (a)
the vascular responses and (b) the skeletal muscle responses.
2.3.8.1.1 Vascular Responses to an Acute Bout of Exercise
The change in blood flow upon the transition from rest to exercise in a normal healthy
individual is regulated by multiple and redundant mechanisms, such as mechanical and/or non94

mechanical factors. The major factor that contributes to the initial blood flow change is the
muscle pump set up by the contracting musculature that moves blood into the veins and away
from the skeletal muscle. This is followed by a drop in pressure and an actual rapid inflow of
blood in between contractions. This phenomena is known as exercise hyperemia. The more
gradual rise in flow appears to be determined by the influence of metabolic and perhaps
endothelial factors. Interestingly, there are no studies which have examined the flow responses in
peripheral arterial disease patients. Given the stated changes in the vasculature and muscle mass
it is hypothesized that the blood flow transition is in part compromised and more than likely
cannot reach the same height for a given work load secondary to the blockage.
Therefore, it appears that most peripheral arterial disease patients with intermittent
claudication have relatively normal resting lower limb blood flow, and blood flow could increase
with exercise [339]. However, as exercise continues, arterial occlusions restrict further increases
in blood flow, and consequently oxygen delivery reaches a plateau [339]. The primary effect of
patients with peripheral arterial disease during a single bout of exercise is the development of
claudication pain in the lower extremity musculature due to the insufficient blood flow.
Interestingly, the ankle brachial index is reduced following an exercise session because
blood flow is shunted into the proximal leg musculature at the expense of the periphery and
distal areas of the leg [217]. In addition, Bauer et al., [340] have reported that the oxygen
consumption (VO2) kinetics at the onset of exercise are markedly slowed in patients with
peripheral arterial disease compared with control subjects. These investigators concluded that the
impaired VO2 kinetic responses in peripheral arterial disease patients appeared to be related to
the presence of vascular disease. Finally, the same investigators stated that further research is
needed to assess whether peripheral flow limitations or changes in the regulation of skeletal
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muscle oxidative function, or both, are responsible for the observed response in patients with
peripheral arterial disease.
2.3.8.1.2 Skeletal Muscle Responses to an Acute Bout of Exercise
Peripheral arterial disease leads to insufficient blood supply to the involved muscle,
which is especially aggravated during exercise, inducing an imbalance between supply and
demand to active muscles. Hemodynamic measures are poor predictors of symptom-limited
capacity despite the major role of decreased arterial blood flow in limiting exercise performance
[341]. Therefore, it indicates that alterations in skeletal muscle fibers may play an important role
in exercise capacity among patients with peripheral arterial disease. Next, this section will
review the major modification in skeletal muscle metabolism. Previous studies have shown that
peripheral arterial disease have alterations in the regulation of oxidative adenosine triphosphate
generation, abnormalities of electron transport chain enzyme activities, and an accumulation of
short-chain acylcarnitines in affected skeletal muscle [328,342].
The inherent delay to increase muscle oxidative metabolism in the face of increasing
adenosine triphosphate requirements has been termed “metabolic inertia,” and has been
hypothesized to be an important physiologic characteristic of the exercise response [343,344].
Indeed, it has been reported that contrary to the up-regulation of oxidative enzymes seen in
patients with peripheral arterial disease, these enzymes exhibit a low activity due to structural
abnormalities [345]. Thus, these modifications would limit the exercise tolerance in peripheral
arterial disease patients.
2.3.8.1.3 Summary of the Acute Exercise Response in Peripheral Arterial Disease
Peripheral arterial disease patients showed interplay between the metabolic and
hemodynamic factors that may contribute to the exercise impairment. The exercise performance
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of peripheral arterial disease is reduced because of the onset of claudication leg pain. Impaired
endothelial function is one mechanism that plays a role in limiting exercise capacity in patients
with peripheral arterial disease. The increase in capillary density among patients with peripheral
arterial disease may follow the metabolic hypothesis by Adair et al., [346] who suggest that the
blood vascular system adapts its structure to meet the maximum oxygen needs of the tissue cells
rather that the average tissue requirements. Muscle performance is compromised in patients with
peripheral arterial disease because of alterations in fiber type composition that limits the
endurance capacity of the muscle. The hypothesized mitochondrial dysfunction may result in less
efficient use of the extracted oxygen (less ATP per oxygen) and an accumulation of
intermediates that further disrupt metabolism. This means oxidative ‘capacity’ may be preserved
while mitochondria function under the non-optimal conditions resulting from the functional
abnormality.
2.3.8.2 The Response to Exercise Training in Peripheral Arterial Disease
Many prospective studies have demonstrated the benefits of exercise training in
peripheral arterial disease patients with intermittent claudication. The first randomized,
controlled trial of exercise training in persons with intermittent claudication demonstrated a
marked improvement in treadmill walking ability [347]. A meta-analyses [348] that examined
both nonrandomized and randomized trials showed that exercise training improved pain-free
walking time by an average of 180% and improved maximal walking time by an average of
120%.
Furthermore, a meta-analyses from the Cochrane Collaboration [349] that considered
only randomized, controlled trials concluded that exercise improved maximal walking distance
time by an average of 150%. Many trials have demonstrated the efficacy of walking
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rehabilitation compared to placebo, those outcomes reported an increase in pain-free and
maximal treadmill walking duration [347,350,351]. In addition, the improvement in walking
ability results in improvement in routine daily activities [352]. Regensteiner et al., [353] found
an improved capacity to perform routine daily activities after exercise training. Exercise training
has been shown to significantly improve (a) the onset of leg discomfort, or initial claudication
distance, and (b) the point at which the pain becomes unbearable, forcing the patient to stop
walking, or absolute claudication distance [354,355].
Patients participating in a supervised, structured exercise program had a 180% increase
in initial claudication distance, compared with a 40% increase in control groups [348]. On the
other hand, unsupervised exercise rehabilitation programs, often referred to as home programs,
have been carried out in addition to supervised ones. The majority of those called “home
programs”, have produced a more modest benefit or even have had a lack of benefit compared to
a supervised program. A recent meta-analysis by Degischer et al., [356] has reported a lack of
significant benefit from these programs. However, Wullink et al., [357] have suggested that a
home program with structured coaching might lead to exercise improvement. These findings
suggest that exercise training programs have a clinically important impact on functional capacity
among patients with peripheral arterial disease. Therefore, exercise training is one of the most
effective interventions available for the treatment of claudication as a result of peripheral arterial
disease. Despite its demonstrated effectiveness, supervised exercise rehabilitation has several
limitations, most notably the lack of available programs.
Recently, the Centers for Medicare and Medicaid Services have established a current
procedural terminology code for exercise rehabilitation in patients with peripheral arterial
disease (CPT 93668) [358]. Finally, despite numerous studies demonstrating the benefits of a
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supervised exercise program for treatment of claudication [359], there is a paucity of data on the
durability of results. Menard et al., [360] showed that continuation of an exercise program either
supervised or at home, is necessary for maintenance of the positive effects in the treatment of
intermittent claudication. In addition, patients who continue to exercise maintain a higher healthrelated quality of life and greater daily functional status than do those who discontinue training.
2.3.8.2.1 Vascular Responses to Exercise Training in Peripheral Arterial Disease
2.3.8.2.1.1 Blood Flow
Evidence from the literature suggests that an increase in the blood flow to the lower
extremity is uncommon [325,350,361-363]. The inability to increase lower limb blood leads to
exercise induced pain because the muscle’s metabolic demands exceed the body’s capacity to
deliver the needed energy substrate. It has been suggested that exercise in patients with
peripheral arterial disease improves maximal walking distance due to an absolute increase in
blood flow, possibly secondary to the growth of a collateral circulation. Studies on dogs [364]
with ligated femoral arteries have shown an increase in blood flow to the lower limbs after the
training intervention. However, many studies have shown that exercise training in patients with
intermittent claudication does not significantly improve leg blood flow [339,350,365,366].
Furthermore, a study by Gardner and Poehlman [348] found that the increase in lower limb blood
flow was small while exercise tolerance increased by over 100%. Tan et al., [367] reported that
exercise training improved exercise tolerance significantly without any increase in femoral blood
flow.
Finally, an increase in collateral vessel formation in relation to the leg muscle has been a
postulated mechanism for improvement in intermittent claudication symptoms after exercise.
Although, animal models of occlusive arterial disease [368-370] have shown that exercise
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training may also cause redistribution of blood flow from inactive to active muscles, that
response has not been evaluated widely in humans. One study showed that maximal calf blood
flow increased modestly with exercise, but this small improvement was not related with the
improvement in exercise intolerance [350]. Other studies have also varied results in terms of
whether leg blood flow increased or not and whether any increase observed was correlated to
improved walking ability resulting from exercise training [325,366].
In addition, the role of angiogenesis in improving walking ability after exercise
rehabilitation has not been well investigated in patients with peripheral arterial disease. The
mechanisms underlying endogenous angiogenesis are complex, possible pro-angiogenic stimuli
include reductions in oxygen tension or related metabolic alterations in the muscle, and increased
blood flow and muscle contraction [371]. In that regard, in healthy subjects, a single session of
exercise increased vascular endothelial growth factor mRNA expression in calf muscle [371].
However, that response has not been studied in patients with peripheral arterial disease. In
addition, the finding of increased vascular endothelial growth factor mRNA expression during a
bout of exercise suggests that vascular endothelial growth factor may be related to angiogenesis
[372]. Furthermore, that increase was related in a dose-dependent fashion to the degree of
metabolic stress [372].
Exercise training may be associated with transient hypoxia in the lower extremity which
would up-regulate vascular endothelial growth factor mRNA protein expression potentially
enhancing endogenous angiogenesis. In fact, Gustafsson et al., [373] have reported similar
finding for patients with heart failure. However, content of basic fibroblast growth factor,
another important angiogenic growth factor, does not seem to be altered in response to muscle
activity in hypoxic skeletal muscle [374,375]. In conclusion, the current evidence does not
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support the hypothesis that an increase in blood flow is a major mechanism to improve exercise
tolerance in patients with peripheral arterial disease.
Therefore, other mechanisms must play a role in the substantial improvements in function
and symptoms that occur in these patients when they receive exercise training. Therefore, it
would appear that there is not sufficient evidence to suggest that muscle blood flow is positively
affected.
2.3.8.2.1.2 Vascular Endothelial Function
Patients with peripheral arterial disease have impaired endothelial-dependent vasodilation
[292]. Indeed, Brendle et al., [376] found that endothelial-dependent vasodilation, ambulatory
function, and calf blood flow significantly improved after a 6 month exercise rehabilitation
program. Furthermore, arterial flow-dependent dilation is mediated by the endothelial release of
nitric oxide, which is increased with exercise training and may improve walking ability in
patients with intermittent claudication [377,378]. Therefore, it would appear that there is not
sufficient evidence to suggest that endothelial function is positively affected with training.
2.3.8.2.1.3 Blood Viscosity
Patients with peripheral arterial disease have a high incidence of abnormal blood
rheology [379]. The study by Pararajasingam et al., [379] showed that peripheral arterial disease
had a plasma viscosity in excess of the upper limit of normal (1.72). Exercise training in normal
subjects leads to a reduction in plasma viscosity [380] and a decrease in packed cell volume
[381]. The decrease in packed cell volume could lead to a reduction in blood viscosity and
improvement in blood flow. Studies in peripheral arterial disease patients have reported no
significant changes in the blood rheology after training [367,382]. Therefore, it would appear
that there is not sufficient evidence to suggest that blood viscosity is positively affected.
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2.3.8.2.2 Skeletal Muscle Responses to Exercise Training in Peripheral Arterial
Disease
2.3.8.2.2.1 Skeletal Muscle Metabolism and Oxygen Extraction
Elevated plasma acylcarnitine levels at rest have been associated with the functional
impairment in patients with peripheral arterial disease [332]. Additionally, exercise to
claudication pain has been associated with an increase in the plasma concentration of
acylcarnitines, which may reflect the disordered metabolic state of ischemic muscle [383].
Muscle oxidative metabolism in patients with peripheral arterial disease favors the accumulation
of acylcarnitines. A controlled, randomized trial conducted by Hiatt et al., [350] reported that a
12-week exercise training program for patients with peripheral arterial disease increased peak
exercise performance in all treated subjects, delayed the onset and progression of claudication
pain during exercise, and improved community-based walking ability.
These investigators also reported that the improvement in performance was correlated
with a change in carnitine metabolism (an index of cellular metabolism) and not to a change in
blood flow. In addition, the same investigators reported that after 12 weeks of training, there
were further increases in exercise performance determined from the training sessions and from
treadmill testing. At this point in time, treated subjects had an increase in peak oxygen
consumption possibly reflecting either an increase in muscle oxygen delivery or an improvement
in muscle oxidative metabolism [350]. The same Hiatt et al., [311] reported that 12 weeks of
treadmill training increased peak exercise performance in peripheral arterial disease patients.
Although this study did not find the "classic" mitochondrial training response (increase in citrate
synthase activity), the results confirm the relationship between skeletal muscle acylcarnitine
content and function in peripheral arterial disease, demonstrating that the response to treadmill
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training was associated with parallel improvements in intermediary metabolism. In addition,
studies have been reported that exercise training in patients with peripheral arterial disease leads
to lower lactic acid concentration than was recorded before training [351,384,385]. Many studies
have reported an improvement in oxygen extraction in patients with peripheral arterial disease
[311,347,350].
Exercise training is associated with an increase in muscle mitochondrial content [386],
and the increase in mitochondrial content correlates with the increase in oxidative exercise
capacity [387]. On the other hand, detraining or sedentary behaviors are associated with a
decrease in muscle mitochondrial content [388]. Peripheral arterial disease leads to a limitation
in physical activity, and an increasingly sedentary lifestyle. This level of physical activity might
be considered analogous to detraining, and thus would be predicted to be associated with a
decrease in mitochondrial enzyme activities. However, earliest observations have reported that
the expression and activity of several mitochondrial enzymes are increased in skeletal muscle
from limbs in patients with peripheral arterial disease [389]. Furthermore, the same findings have
been reported in recent studies that showed an increased mitochondrial content in the muscle of
patients with peripheral arterial disease [307,311,325]. This increased mitochondrial expression
appears to be a direct consequence of, and is proportionate to, the severity of the occlusive
disease. For instance, Jansson et al., [307] reported that bilateral gastrocnemius biopsies from
patients with peripheral arterial disease primarily in one leg demonstrate increased enzyme
activities in the limb with significant hemodynamic changes when compared with the lessaffected limb.
One could assume that the increased mitochondrial expression could be understood in the
context of compensation for impaired oxygen delivery [307]; it also suggested that the metabolic
103

signals leading to this enhanced expression may represent important factors in peripheral arterial
disease pathophysiology.
Although peripheral arterial disease is associated with increased mitochondrial content,
the regulation of mitochondrial enzyme activity may also differ from that in control subjects. In
fact, exercise training is a strong stimulus for mitochondrial proliferation in normal subjects.
However, exercise training in patients with peripheral arterial disease has not been uniformly
associated with enhanced mitochondrial activity. Indeed, some studies have documented
increased mitochondrial enzyme activities with training in peripheral arterial disease [325,363]
with others showing no increase despite achieving a systemic training response [311].
This suggests that the regulation of mitochondrial expression in peripheral arterial disease
may be under a different series of control factors compared with normal subjects. Despite the
limitation in oxygen delivery, changes intrinsic to the skeletal muscle might also contribute to
metabolic dysfunction. These findings support the concept that patients with peripheral arterial
disease develop a mitochondrial myopathy [390]. Finally, mitochondria in chronically ischemic
muscle have abnormal ultrastructure [391], extensively damaged DNA [392], altered expression
and activities of enzymes, and abnormally high intermediates of oxidative metabolism [273,332].
2.3.8.2.2.2 Skeletal Muscle Enzymatic Changes
Using muscle biopsies, before and after training, allowed the study of possible enzymatic
changes in peripheral arterial disease. In that regard, Lundgren et al., [393] have reported
significant increases in the levels of oxidative enzymes such as cytochrome oxidase and succinic
oxidase, with a very small rise in citrate synthase. The same study found that patients with a low
level of cytochrome oxidase (compared with normal) before training have a markedly improved
level on completion of an exercise [393].
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Perhaps, the low enzyme activity before training may result from reduced physical
activity, muscle fiber depletion or mitochondrial damage secondary to ischemia. These findings
would suggest that exercise training may reverse the low oxidative capacity of the muscle in
peripheral arterial disease patients.
2.3.8.2.3 Summary of the Response to Exercise Training in Peripheral Arterial
Disease
Although there is little doubt that an exercise program is an invaluable first line of
treatment for patients with peripheral arterial disease, the mechanisms of improvement in
claudication symptoms with exercise are not well understood. The physiological, metabolic, and
mechanical alteration produced by the exercise intervention presumably stimulates an adaptive
response that may reduce claudication symptoms.
Some of the proposed mechanisms for an increase in exercise tolerance include: increase
in leg blood flow, more favorable distribution of blood flow, improved hemorheological and
fibrinolytic properties of blood (e.g. reduced viscosity), greater reliance upon aerobic metabolism
because of a higher concentration of oxidative enzymes, less reliance upon anaerobic
metabolism, an improvement in the efficiency of walking economy and oxygen uptake kinetics,
increased free-living daily energy expenditure.
One set of mechanisms that is currently receiving attention is the role of blood flow and
associated factors. There is the possibility that angiogenesis, adaptations in peripheral blood flow
or changes in blood flow distribution may be a cause of improvement in walking after exercise
rehabilitation [371,372]. The role of angiogenesis in improving walking ability after exercise
rehabilitation has not been well investigated in patients with peripheral arterial disease and
provides an exciting possibility. Although animal models of occlusive arterial disease have
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shown that exercise training enhances collateral-dependent blood flow to the hind-limb muscles
[369], studies of that nature are limited in humans.
2.4 Protection vs. Optimization
The conditions so far, heart failure and peripheral arterial disease, have a common
underlying problem of reduced muscle blood flow and subsequent exercise intolerance.
However, the manner in which the body responds to the reduced blood flow is remarkably
different and warrants careful consideration. This review has outlined in great detail the different
physiological and morphological compensatory adaptations for both conditions. It is very
important that we understand these compensatory adaptations properly in order to provide the
most effective exercise prescription and avoid just prescribing a generic recommendation for
exercise that cannot be as effective.
The main purpose of this next section is to compare heart failure and peripheral arterial
disease in regard to the different pathophysiologic pathways to a common problem, the reduction
of blood flow to skeletal muscle. In doing so, this section of this review includes: (a) differential
adaptation to reduced blood flow, (b) indication for protection and optimization, (c) the
underlying mechanisms, and (d) the implication of an exercise program.
2.4.1 Differential Adaptation to Reduced Blood Flow
In the early stages of both diseases, the majority of patients are able to still perform
normal daily activities. However, the symptoms and signs are more evident when these patients
are exposed to stressful conditions, such as physical activity. Heart failure, as defined previously,
is a syndrome in which cardiac output is insufficient to meet metabolic demands. Although the
natural history of heart failure is punctuated by occasional episodes of acute decompensation
with overt systemic volume overload and pulmonary edema, the primary chronic symptoms in
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patients with heart failure are exertional fatigue and dyspnea. These symptoms are the primary
determinants of their health-related quality of life. Heart failure is characterized by a series of
compensatory mechanisms designed to maintain cardiac output and arterial pressure at a level
compatible with life.
The cardiac compensatory changes include (a) ventricular dilation to stretch the
sarcomeres (fast adaptation); (b) ventricular hypertrophy (slow adaptation) and aim to preserve
cardiac output. The circulatory changes include (a) autonomic nervous system activation (fast
adaptation); (b) humoral activation (intermediate to slow adaptation); (c) impaired vascular
responsiveness (slow adaptation), and aim to maintain blood pressure. Alterations in skeletal
muscle include (a) skeletal muscle atrophy (slow adaptation) and (b) impaired oxidative
metabolism (slow adaptation). Although speculative, it is thought that those mechanisms with an
intermediate to long-time constant eventually contribute to the severe clinical manifestations.
In contrast, peripheral arterial disease results from atherosclerotic occlusion that impairs
perfusion to the lower extremity. The two major clinical presentations of peripheral arterial
disease are intermittent claudication and critical limb ischemia. Normally, in patients with
intermittent claudication, arterial occlusive disease is manifested by insufficient blood flow
during exercise. On the other hand, in patients with critical limb ischemia, blood flow is
inadequate to meet the resting demands of the limb. Furthermore, peripheral arterial disease is
characterized by a series of compensatory mechanisms designed to increase the peripheral blood
flow. They include an initial compensatory dilation and enlargement of the vessel at the site of
active atherosclerosis. These changes are thought to be due to neurogenic or metabolic relaxation
of smooth muscle surrounding the blood vessels. Next, the opening of collateral vessels would
try to normalize the blood supply. The growth of these collateral vessels follows the principles of
107

both acute (neurogenic) and long-term (metabolic) blood flow control. Alterations in skeletal
muscle include: (a) selective loss of type II fibers relative to type I fibers, (b) up-regulation of the
oxidative enzyme activity, and (c) increased capillary density. However, these changes seem to
be proportional to the extent of skeletal muscle hypoxia.
2.4.2 Indication for Protection and Optimization
In terms of the heart failure condition, one can argue that the reduction in physical
performance secondary to the compensatory changes is an effort to protect the organism from
putting too much stress on a weakening organ. In other words, if the heart is failing, the body
does not want to add an additional stress to cause the heart to fail even more. Thus, exercise
intolerance in heart failure is a protective mechanism. Removal of these compensatory changes
could therefore be disastrous. Therefore, the patient is dealing with a double-edged sword. By
not being active the condition gradually worsens, by being potentially too active the patient will
cause further harm. In contrast, patients with peripheral arterial disease also aim to protect
themselves, but do so by optimizing blood flow and oxygen transport, in an effort to maintain
functionality. However, in peripheral arterial disease exercise intolerance is also a protective
mechanism, as the claudication pain with exercise is a warning signal that the tissue is
underperfused and at risk for damage and deterioration.
Therefore, two interesting questions come to mind that are relevant to this review and my
focus area. First, how does a muscle cell recognize that reduced blood flow is a consequence of a
failing heart or a femoral lesion? Second, what are the clinical implications of these differential
compensations, and how can this be addressed by the exercise physiologist?
These are clearly challenging questions. In regards to the first, there certainly must be a
series of mechanisms that need to be identified to help understand the phenomena. In addition,
108

there clearly must be interplay between organ systems to orchestrate such compensations,
thereby re-establishing the importance of the integrative physiologist. There are probably many
candidates that may help understand the compensations for heart failure. These include (a) the
neurohormonal system and (b) an altered balance between catabolism and anabolism. Without a
doubt the neuroendocrine milieu in heart failure is significantly altered, and in most cases
hyperactive in comparison to controls.
In heart failure, the impaired contraction and/or relaxation of the heart and disturbance of
central hemodynamics activate compensatory mechanisms, including the neuroendocrine
reaction, also called the neurohumoral response, which creates the self-perpetuating vicious
circle of heart failure. The low blood pressure reflexly stimulates the adrenergic and reninangiotensin-aldosterone systems, with increased peripheral vascular resistance and afterload.
Then, aldosterone excess promotes fluid retention, peripheral congestion and edema so that both
the preload and afterload also increase. Among these neuroendocrine responses, the ergoreflex
response is quite important in heart failure. In fact, these ergoreceptors, small myelinated and
unmyelinated afferents of the skeletal muscle (group III and group IV afferents), play the role of
a feedback control mechanism to maintain the homeostasis between muscle work and energy
supply to perform it. Stimulated by the metabolic state of the muscle, the ergoreceptors monitor
the effectiveness of the blood flow, and adjust the cardiocirculatory, ventilatory, and autonomic
responses to meet the increased metabolic needs of the contracting muscle. In addition, it has
been reported an enhanced activity of these receptors, which contribute to the excessive
neuroendocrine response [84,92,142]. Some of the possible metabolic products of a discrepancy
between blood flow and metabolism in the contracting muscle that have been shown to activate
the muscle afferents are potassium [394], a decrease in pH [395], prostaglandins [396], and
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blood flow itself [397]. This information is clear evidence of the role of the ergoreceptors as the
muscle cell that is able to recognize the reduction of blood flow as result of a failing heart.
In contrast, these neuroendocrine changes are typically not observed in peripheral arterial
disease. The main physiological cause for the manifestations of peripheral arterial disease is
linked to the insufficient oxygen supply secondary to reduced blood flow. It seems that the
candidate is the skeletal muscle itself. Many studies have reported that peripheral arterial disease
is associated with a skeletal muscle metabolic myopathy [325,398]. In fact, patients with
peripheral arterial disease with severe ischemia had the most defective oxidative function [399].
In addition, the combination of factors related to intensity and frequency of “ischemic insult,”
and possibly the ischemia reperfusion associated with it, may be responsible for defective
mitochondria [400]. The mitochondrial dysfunction may have two major negative consequences
in patients with peripheral arterial disease; (a) peripheral arterial disease mitochondria do not
have the capacity to produce as much adenosine triphosphate as normal skeletal muscle
mitochondria do, (b) dysfunctional mitochondria are a source of abnormally high levels of
reactive oxygen species, which may be independently injurious to the mechanisms that sustain
normal cellular structure and function. The end result of this process is a significant decrease in
energy production and a potentially increased level of destructive oxygen radicals in the skeletal
myocytes of patients with peripheral arterial disease [401]. This evidence would suggest that
independent of where the reduced blood flow is coming from, the major problem is the defective
mitochondrial function as a pathophysiologic component of peripheral arterial disease.
The next section will try to address the second question: what are the clinical implications
of these differential compensations, and how can this be addressed by the exercise physiologist?
In heart failure, these compensations are present in every step of the oxygen transport system,
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from the center (the heart, lung, central neural control) to the periphery (circulation,
neurohumoral status, reflexes, autonomic nervous system, and muscle metabolism). Therefore,
the complete system is under permanent stress due to the compensatory responses that are trying
to maintain function in these patients. As an exercise physiologist, it is important to have a better
understanding of these modifications in order to provide the best and appropriate exercise
program without producing further cardiovascular stress in these patients.
In contrast, in peripheral arterial disease, the greater compensations are in the periphery.
These compensations are trying to optimize blood flow and oxygen transport in order to maintain
and preserve function in these patients. The role of the exercise physiologist is also very
important in patients with peripheral arterial disease. It is necessary to know these modifications
in order to recognize how these patients will response to the different exercise activities. In
summary, it is very important that we understand these compensatory adaptations in heart failure
and peripheral arterial disease, to provide the best recommendation for exercise that fit the
condition of these individuals.
2.4.3 Underlying Signals and Mechanisms
This section will attempt a discussion to further understand the underlying signals and
mechanisms contributing to, and differentiating compensations between the disease states. The
section will also attempt to present information regarding the underlying mechanisms of exercise
intolerance in heart failure and peripheral arterial disease.
Heart failure is characterized by general muscular weakness, muscle atrophy, and
exercise intolerance that lead to reductions in functional capacity, ability to perform activities of
daily living, and health-related quality of life [402]. The cardinal symptoms limiting exercise
capacity in patients with heart failure are fatigue and/or dyspnea. The severity of exercise
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intolerance can be quantified by a variety of methods, semi-quantitative assessments, such as
interview (New York Heart Association classification) and surveys (Minnesota Living with
Heart Failure or Kansas City Cardiomyopathy questionnaires), and quantitative methods,
including timed walking tests (6-minute walk distance) and graded exercise treadmill or bicycle
exercise tests. However, the cardiopulmonary exercise testing on a motorized treadmill or a
bicycle ergometer provides the most accurate and reliable assessment of exercise tolerance [22].
Normally, heart failure patients exhibit reduced peak exercise oxygen consumption when
compared to normal individuals. Heart failure causes exercise-limiting changes in every step of
the oxygen transport system, from the center (the heart, lung, central neural control) to the
periphery (circulation, neurohumoral status, reflexes, autonomic nervous systems, and muscle
metabolism). The assessment of peak oxygen consumption gives insight into the
pathophysiology of exercise intolerance. Exercise intolerance will be closely related to one or
both of the parameters that influence peak oxygen consumption (i.e. cardiac output and
arteriovenous oxygen (a-vO2) difference). Indeed, it has been shown that fatigue arises from the
impaired cardiac pumping capacity delivering inadequate amounts of oxygen, leading to a
buildup of products of anaerobic metabolism within the exercising muscle [142]. The association
of heart failure and muscular function might propose that a reduction of blood flow to exercising
skeletal muscle would cause a demand-perfusion mismatch, leading to the symptoms and
reduced exercise capacity. In fact, patients with severe heart failure distribute only approximately
50% to 60% of total cardiac output to the exercising skeletal muscles, compared with
approximately 90% of total cardiac output in healthy individuals [151].
However, in patients with more established heart failure, the major determinants of
diminished work capacity appear to be reduced skeletal muscle perfusion during exercise and
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alteration in skeletal muscle histology and biochemistry. In these patients, reduced exercise
capacity cannot be explained by clinical measures of heart failure (e.g. left ventricular ejection
fraction) [173]. In fact, improvement of cardiac output with an infusion of dobutamine improves
the femoral vein flow of patients with heart failure, but does not alter muscle performance [403].
These results suggest that nutrient delivery to skeletal muscle may not simply equate to total
blood flow, and abnormal nutrient delivery may be caused by maldistribution of blood during
exercise. Muscle metabolism and contractile performance correlate with the extent of nutritive
flow and inversely with non-nutritive flow [404]. In addition, alterations in the regulation of
vascular activity by the sympathetic nervous system and increased noradrenaline may contribute
to abnormal nutritive delivery [142]. Therefore, the problem appears to reside in the periphery.
Indeed, the problem may be secondary to the inability to shunt blood to the working muscle, to
distribute the blood within muscle, or to utilize the available oxygen. A recently proposed
hypothesis argues that peripheral skeletal muscle is the source of the signals which disrupt
normal patterns of cardiorespiratory control [141]. This hypothesis is known as the muscle
hypothesis.
In patients with heart failure the neurohormonal activation and the altered balance
between catabolism and anabolism (in favor of catabolism) contribute to disease progression and
the transition from non-wasted heart failure to cardiac cachexia [309]. In addition, the ergoreflex
(a peripheral reflex originating in skeletal muscle sensitive to products of muscle work) is
overactive in heart failure patients and contributes significantly to impaired exercise tolerance
[405]. Indeed, a clear association exists between symptom severity, New York Heart Association
functional class, muscle wasting, [309] and ergoreflex overactivity [406]. In addition, a recent
study by Piepoli et al., [152] has reported: (a) a significant association between peripheral muscle
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wasting and enhanced muscle reflex, (b) a strong relationship between more advanced cardiac
cachexia and muscle reflex overactivity, which is consistent with the concept that syndrome
progression is related to peripheral maladaptive changes in the muscles, and (c) the ergoreflex
assessment in 1 limb (arm) is associated with lean tissue loss measured in a different limb (leg),
consistent with a systemic activation of the muscle reflex system in heart failure patients. These
authors concluded that the downward spiral of dysregulation in exercising skeletal muscle
suggested by the muscle hypothesis is similar to the larger picture of other vicious cycles in heart
failure in which the physiological responses initially appear adaptive but turn maladaptive over
time.
In contrast, patients with peripheral arterial disease suffer exercise-induced limb pain, or
claudication. Indeed, claudication is associated with significant functional disability and
impairment of quality of life. Claudication typically limits maximal walking capacity to
approximately 50% of that in age-matched controls [332]. As a result peripheral arterial disease
patients face inability to perform a variety of occupational and recreational physical activities.
Despite the clear role of decreased arterial flow in claudication, hemodynamic limitations in the
limb are poor predictors of the degree of claudication-associated impairment [331,341].
Furthermore, invasive revascularization does not completely normalize exercise performance
[407], and interventions such as exercise rehabilitation (which do not alter hemodynamics) have
established efficacy [350]. Therefore, one could suggest that additional factors distal to the
arterial obstruction may contribute to the pathophysiologic pathway seen in patients with
peripheral arterial disease.
Many investigators have reported evidence that peripheral arterial disease is associated
with a skeletal muscle metabolic myopathy [325,326,342,408-410]. Their findings suggest that
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in addition to reduced oxygen supply, suboptimal energy production from defective
mitochondria may be a factor in peripheral arterial disease pathogenesis. Over the last decade a
number of studies have documented that mitochondria in chronically ischemic muscle have
abnormal ultrastructure [326], damaged DNA [411], altered enzyme expression and activity, and
abnormally high intermediates of oxidative metabolism [325,342]. These studies evaluated the
mitochondria characteristics using fixed or frozen muscle samples. Other laboratories have used
phosphorus 31 magnetic resonance spectroscopy [398,409,412] to study the bioenergetics of
chronically ischemic skeletal muscle during various types of exercise. These in vivo studies of
mitochondrial function demonstrate an intrinsic defect in mitochondrial respiration, similar to
that in the mitochondrial myopathies [323,413]. In summary, the skeletal muscle abnormalities
include: (a) alterations in mitochondrial expression, (b) accumulation of metabolic intermediates,
(c) altered control of mitochondrial respiration, (d) enhanced oxidative stress, and (e) somatic
mitochondrial DNA mutations [319].
2.4.4 The Implication of an Exercise Program
Patients with heart failure have poor clinical status and impaired exercise capacity due
both to cardiac limitations (significant left ventricular impairment) and to peripheral
maladaptations of the skeletal musculature. The latter include the reduction of peripheral blood
flow and impaired perfusion as well as deficiencies in skeletal muscle function, morphology and
metabolism. These skeletal muscle disturbances increase cardiovascular stress, deteriorate
symptoms and reduce further exercise capacity [156,414]. Since the late 1970s, several studies
have reported that exercise training can induce favorable physiological adaptations and improve
symptoms, clinical outcome and quality of life [70,195,415,416]. The majority of these studies
were based on aerobic exercise, which was traditionally the main exercise mode in rehabilitation
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programs. Recently, it has been reported that muscle strength [417] was a better predictor of
long-term survival than workload or peak oxygen consumption (VO2peak) in patients with severe
congestive heart failure, indicating the importance of maintaining a normal skeletal muscle mass
in order to improve the outcome of these patients. Therefore, resistance training programs would
allow training the peripheral muscles effectively without producing great cardiovascular stress.
In that regard, dynamic resistance training, based on the principles of interval training, alone
[200-202,418] or in combination with aerobic exercise [203-205] is beneficial and counteracts
the negative peripheral side effects seen in patients with heart failure.
In contrast, peripheral arterial disease is an obstructive condition where the flow of blood
through peripheral arteries is impeded. During periods of increased oxygen demand (e.g.
exercise), peripheral limb ischemia occurs, resulting in the sensation of muscle pain termed
claudication. As a result of claudication, subjects’ ability to exercise is greatly reduced affecting
their quality of life [252,419]. Many treatment options for patients with peripheral arterial
disease exist; however, exercise training is an effective and low-cost means of improving
functional ability and quality of life. Recently, a Cochrane Review supported the role exercise
training has in the symptoms of peripheral arterial disease [349], specially improving walking
ability in these patients. In addition, Gardner and Poehlman [348] published a meta-analysis of
training studies conducted in patients with peripheral arterial disease. Their recommendations
appear to have formed the basis of exercise prescription for patients with peripheral arterial
disease. These investigators concluded that the most effective training program included training
sessions > 30 minutes in duration, at least three times a week, over a period of 27 weeks or more
[348]. In regard to the intensity they stated that the program must include training to near
maximal pain levels. In addition, few research studies have compared the use of different
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training modes in improving walking ability in patients with peripheral arterial disease. The use
of resistance [351,353], stair-climbing [420], pole-striding [421] and less specific modes of
training including flexibility [422] and gymnastics [423] have been complemented with, or in
place of, treadmill walking in an attempt to improve walking ability in patients with peripheral
arterial disease. The effectiveness of each type of training appears to vary; however, few
statistical comparisons analyzing the effectiveness of walking training to other training modes
have been made. However, the use of different modes of exercise training has become an
important research topic. Indeed, some elderly people are not able to, or are not comfortable
with, exercising on treadmills [424]. In addition, the use of training modes other than walking
could improve the adherence of subjects to training programs by removing the discomfort of
claudication during exercise.
2.5 Conclusion
In conclusion, in both diseases, heart failure and peripheral arterial disease, which
essentially have a common underlying problem of reduced muscle blood flow and subsequent
exercise intolerance, the manner in which individuals respond, adapt, and compensate to the
disease is highly variable. This review was intended to outline how the different physiologic
systems attempt to compensate for the problems incurred by the pathophysiologic pathway of
heart failure and peripheral arterial disease. These “compensatory changes” are critical to
understand as they to a large degree contribute to the clinical course of patients afflicted by these
two diseases. Finally, this is critical as we need to move from generic exercise programs to
individualized targeted treatment plans that may be more effective in their delivery, and
subsequently help to maintain and preserve functional ability in these patients.
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Chapter 3
High and Low Volume Resistance Training and Vascular Function
3.1 Introduction
The addition of resistance training guidelines to the 1998 American College of Sports
Medicine (ACSM) position stand was the result of overwhelming evidence of the health and
functional benefits associated with this type of training [425]. Resistance training not only
impacts strength and endurance, but also contributes to the maintenance of functional ability,
prevents osteoporosis, sarcopenia and disabilities [425-427]. Resistance training also reduces
cardiovascular risk factors [426]. The mechanisms through which resistance training reduces
cardiovascular disease risk are currently not clear. One hypothesis is that resistance training
improves vascular function. Data from our laboratory and others show regional vascular
adaptations when a localized training stimulus is used [5,428,429]. Importantly, these
adaptations occur within 4 weeks of training.
Few studies have examined the effects of whole-body resistance training on vascular
function. Those that have studied this issue reveal mixed results. For example, Rakobowchuk et
al., [430] reported peripheral arterial remodeling following intense resistance training. However,
they did not find changes in the reactivity of the artery. Maiorana et al., [431] did not find any
vascular modifications following resistance/aerobic training. In contrast, Green et al., [432]
reported improvements in nitric oxide-mediated vascular function, following 8 weeks of
resistance/aerobic training in patients at risk for and with coronary artery disease. Those findings
were further confirmed in type II diabetics [433]. One study reported a decrease in vascular
function following high-intensity resistance training [434]. The reasons for the mixed results are
probably multifactorial and include: training duration, intensity, volume, and specificity. We
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hypothesized that vascular function would be modified following short-term, whole-body circuit
weight training (CWT) and that the improvements would be greater in individuals performing
high volume compared to low volume training.
Consequently, the aim was to examine the influence of two volumes of CWT on reactive
hyperemic blood flow (RHBF), venous capacitance (VC) and outflow (VO) in younger
individuals.
3.2 Methods
3.2.1 Subjects and Experimental Protocol
Thirty-five individuals were recruited. The majority of participants were untrained and/or
novices to weight lifting. Those with disease were excluded. Following explanation of the
details, participants signed an informed consent approved by the Institutional Review Board of
the host institution. The study was a prospective, randomized trial, consisting of 5 weeks of
CWT. The experimental procedures consisted of two separate visits performed before and after
training.
3.2.2 Experimental Procedures
3.2.2.1 Visit 1: Strength Measures
Handgrip strength was examined in the non-dominant arm, using a dynamometer (model
78010, Lafayette Instruments; Lafayette, IN) and determined from the average of 3 maximum
voluntary contractions (MVC). A one repetition maximum (1RM) was used to determine knee
extension and bench press strength, using standard nautilus equipment. To eliminate interobserver variability the same investigator performed these procedures before and after training.
Prior to the measures participants were familiarized with the procedures and instructed on the
correct techniques.
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3.2.2.2 Visit 2: Vascular Function
Participants were refrained from food, alcohol or caffeine for 12 h, and rigorous physical
activity for 24 h before the procedures. Prior to the measures, blood pressure cuffs were
positioned around the non-dominant upper arm and wrist, and a mercury-filled strain gauge
placed around the forearm 10 cm distal to the olecranon process. The strain gauge was connected
to a plethysmograph (EC-5R system, Hokanson; Bellevue,WA, USA). The forearm was
extended and slightly supinated and supported by a foam block. Following the set-up the
participant was allowed to rest for 15 min. The technique is noninvasive, and based on the
assumption that alterations of pressures in strategically placed cuffs allows for examination of
the rate of change in limb volume thought to reflect vascular function [435].
Resting forearm blood flow was obtained as follows: First, hand circulation was occluded
for 1 minute by inflating the cuff at the wrist to 240mmHg. Forearm blood in-flow was obtained
using a venous occluding pressure of 7 mmHg below diastolic blood pressure [4]. Forearm VC
and VO were measured after an additional 5 min of venous occlusion. Then, RHBF was
examined after 5 min of forearm arterial occlusion achieved by inflating the upper arm cuff to
240mmHg [4]. Vascular indices were then determined as described above. Throughout the
experiment heart rate and blood pressure were obtained.
Data analysis was performed as follows: Resting blood flow was recorded at a paper
speed of 5 mm/sec and values were derived from the slope drawn at a best-fit tangent.
Calculations were made as a function of 60 sec divided by the horizontal distance (mm) needed
for the slope to rise vertically from baseline to the top of the recording paper and multiplied by
the full chart range. Forearm VC was calculated as the vertical distance (mm) representing the
change in volume graph following 5 min of venous filling [436]. Forearm VO was derived from
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a tangent line representing the vertical drop in the volume-graph from the excursion line and
drawn at 0.5 second and 2 sec following the release of the venous occlusion pressure [436,437].
Forearm RHBF was recorded at a paper speed of 25 mm/sec.
Analyses were performed using a slope drawn at a best-fit tangent to the curves of the
first 3 pulse flows post cuff release. The RHBF was then calculated from 60 sec multiplied by
the paper speed (25 mm/sec) divided by the horizontal distance (mm) needed for the volume
slope to increase by 20 mm vertically [4]. All vascular indices are expressed in ml · 100 ml
tissue-1 · min-1. Previous work from our laboratory indicated adequate stability and
reproducibility of this technique [4].
3.2.2.3 Training Intervention
The CWT was performed in 1 hr sessions, 3 days/wk for 5 wks, consisting of 8 stations.
The high volume group was encouraged to complete 3 sets/station, while the low volume group
performed 1 set/station. For each station, participants performed 2 or 3 exercises, using sets of 8
to 12 reps performed to voluntary muscular fatigue.
Initial intensity was set at 60% of 1RM or as tolerated. After each station, passive static
stretches were performed. Training load was increased by 5-10% for the next session when
participants were able to perform 12 reps. Training load, number of reps, and ratings of
perceived exertion (Borg scale) were recorded, to document the tolerance and progression of
training.
The circuit included: Station 1: biceps curl, triceps extension, and punch-outs; Station 2:
knee flexion, knee extension, and calf raises; Station 3: pull backs, pull over; Station 4: squats,
and step lunges; Station 5: bench and military press; Station 6: row, and pull down; Station 7:
pull and jerk, and sit-ups; and Station 8: Back extension: McKenzie exercises [438].
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3.2.3 Statistical Analysis
Statistical analyses were performed using SPSS (11.0). Group values are expressed as
mean ± SD. Pre-training group differences were examined using independent t-tests. Differences
in training volume across the 5 wks were examined using a 2 (high and low volume) * 5 (wks of
training) analysis of variance with repeated measures. The influence of training on vascular
function and strength was examined using two separate multivariate analyses (MANOVA).
Alpha was set a priori at 0.05.
3.3 Results
3.3.1 Participant Characteristics and Intervention Results
The average age of the participants was 22±1.89yrs. Weight, height, BMI, resting systolic
and diastolic blood pressure, and resting heart rate were not statistically different between
groups. The participants’ characteristics are presented in Table 3.1.
Table 3.1 Participants characteristics
Group
Mean
SD
Age (years)
Low Volume
21
1.84
High Volume
22
1.85
Weight (kg)
Low Volume
74
14.39
High Volume
85
28.45
Height (cm)
Low Volume
168
9.64
High Volume
173
9.38
2
BMI (kg/m )
Low Volume
26.2
4.44
High Volume
27.9
7.00
Rest SBP (mmHg)
Low Volume
118
10.31
High Volume
120
9.48
Rest DBP (mmHg)
Low Volume
65
9.04
High Volume
65
9.86
HR rest (bpm)
Low Volume
61
11.49
High Volume
65
7.07
BMI, body mass index; Rest SBP, resting systolic blood pressure; Rest DBP,
resting diastolic blood pressure; HR rest, heart rate at rest.
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One participant from the low volume group did not finish the training due to lack of
compliance. No injuries or significant problems were reported. The progression and volume of
training are presented in Figure 3.1. Over the 5 wks of CWT the high volume group increased
the training volume by 62%, from 3219 (Wk 1) to 5236 lbs (Wk 5). The low volume group
increased the training volume by 68%, from 2707 (Wk 1) to 3997 lbs (Wk 5).
Table 3.2 Changes in strength measures (pre and post) in both groups
Group
Low volume

Test
Mean
SD
Handgrip (kg)
Pre
22.39
9.80
Post
25.4*
10.76
High volume
Pre
28.02
12.98
Post
33.37*
14.01
Bench press (kg)
Low volume
Pre
56
35.97
Post
70.91*
38.41
High volume
Pre
60.93
32.62
Post
71.97*
37.42
Knee extension (kg) Low volume
Pre
79.38
31.56
Post
112.44*
36.46
High volume
Pre
94.04
34.35
Post
123.53*
36.21
Pre, pre-training measures; Post, post-training measures; *p<0.05 vs. Pre
3.3.1.1 Visit 1: Strength Measures
The MANOVA revealed significant increases in all strength measures. However, no
significant differences in strength gains were observed between the groups. The strength
measures are presented in Table 3.2. The mean absolute and percent change in strength for
handgrip strength was 3.89±4.57 kg (+15.59%), knee extension 30.62±12.52 kg (+ 35.31%), and
bench press 12.4±8.81 kg (+21.03%).
3.3.1.2 Visit 2: Vascular Function
Results for forearm vascular measures are presented in Table 3.3. The MANOVA
revealed no significant changes in forearm RHBF, VC and VO.
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3.4 Discussion
The aim was to examine the influence of different volumes of CWT on forearm vascular
Function including RHBF, VC and VO among young individuals. Our findings indicate
significant and similar increases in strength for both groups. In contrast, group averages for
vascular function did not change following five weeks of CWT. Overall changes in strength for
this study averaged 24%. These improvements are consistent with previous studies. In fact, the
2002 ACSM [439] position statement on progression models in resistance training indicate that
muscular strength increases approx. 40% in untrained and 20% in moderately trained individuals
over periods ranging from 4 wks to 2 yrs. The initial gains in strength are believed to be due to
neural changes [439]. These adaptations include: improvements in muscle activation and
coordination, enhanced muscle fiber recruitment, and improved muscle contraction synergism
[440,441]. It is not until ~6 wks into training that muscle hypertrophy becomes obvious and
contributes to the strength gains [442]. This study was not designed to measure muscle mass or
size, but, forearm circumference did not change.
The average values for the vascular measures were similar to those found in previous
studies [4,5], and similar to a low fitness group studied in our laboratory [4]. In addition, the
forearm RHBF values are in agreement with others [429,443]. It was hypothesized that vascular
function would be modified following CWT and that the improvements would be greater in
individuals performing higher volume training. It is important to understand the rationale for the
hypothesis. First, the selection of the training duration stems from studies conducted in our
laboratory and by others indicating short-term handgrip exercise training results in improved
vascular function [5,428]. For example, Alomari et al., [5] reported a unilateral improvement in
vasodilatory responsiveness after 4 wks of handgrip training. The training protocol consisted of
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20 min/session performed 5 days/wk at 60% of MVC. After training, RHBF improved by ~21%
[5]. Studies conducted by others report similar increases (~ 20% to 30%) in RHBF following
short-term localized forearm training [429,443]. Given these findings we hypothesized that
whole-body CWT for 5 wks would be a sufficient stimulus to induce vascular changes.
Table 3.3 Results for the pre and the post forearm blood flow measures
Group

Test

Mean

SD

Rest BF
Low volume
(ml/100ml/min)
High volume

Pre
2.45
0.75
Post
2.76
0.86
Pre
3.14
0.99
Post
3.15
0.83
Rest VC
Low volume
Pre
3.11
0.67
(%)
Post
3.48
0.81
High volume
Pre
3.21
0.95
Post
3.34
0.87
Rest VO
Low volume
Pre
38.92
7.82
(ml/100ml/min)
Post
40.78
7.94
High volume
Pre
36.83
11.26
Post
39.29
9.82
RHBF
Low volume
Pre
20.69
6.50
(ml/100ml/min)
Post
21.67
4.76
High volume
Pre
23.05
5.95
Post
22.71
5.24
Rest BF, resting blood flow; Rest VC, resting venous capacitance; Rest VO,
resting venous outflow; RHBF, reactive hyperemia blood flow.
Second, the issue of volume of training stems from the lack of predictability in the
vascular responses among the available studies. For example, Rakobowchuk et al., [430] noted
an increase in mean brachial artery diameter following intense whole body resistance training.
Their participants completed 60 sessions (2/3 sets of 10-12 repetitions, and finished with 4-6 reps
with loads exceeding 90% of 1 RM) conducted 5 days/wk for 12 wks. In addition, they reported
an increase in RHBF thought to be the result of increased capillarization. However, they did not
find changes in the reactivity of the peripheral artery. Maiorana et al., [431] did not find any
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vascular modifications following 8 wks of resistance/aerobic training in middle-age men. Their
training consisted of aerobic activities (70 to 85% of peak heart rate) and 7 strength training
exercises (55 to 65% of MVC), designed to minimize the involvement of the arms. Training was
conducted 3 days/wk. Finally, Bond et al., [434] reported a decrease in leg RHBF following 4
wks of training consisting of 6 sets*15 MVC’s of the calf, 4 days/wk. The authors attributed the
decrease in peripheral hemodynamics to an increase in calf volume. Clearly the lack of
predictability in the vascular responses between studies could, in part, be a consequence of
different training volumes.
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Figure 3.1. Average volume of weight lifted (lbs) across the training weeks. Values
are mean + SD. * = p < 0.05 as compared to Week 1; † = p < 0.05 as compared to the
low volume group.
The present study is the first to examine the influence of different training volumes on
vascular function. As shown in figure 3.1, the training volume increased significantly, with both
groups noting a 60% change. In addition, the training volume was approx. 25% greater for the
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high volume group from wk 1 through 5. Despite the evidence in training progression and
difference in volume, no group changes were apparent for any of the vascular measures under
study. Thus, the stated hypothesis was rejected. Several factors may have contributed to the
present findings. These factors will be discussed briefly.
The first factor may be the training stimulus and localization. Our previous handgrip
studies [5,6] included protocols that were quite intensive (20 min sessions, 4 or 5 days/wk) and
very specific to a region. The current study may not have been able to achieve the specificity or
localization needed to trigger vascular adaptations.
A second factor concerns the length of training. Despite our previous work and
expectations, the relative short period of training may not have been enough to promote changes
in muscle mass and/or capillarity density in the region of interest. Arguably, vascular adaptations
may not occur until there is evidence of a change in muscle mass. In fact, changes in the crosssectional area of muscle appear to contribute to an increase in capillary density [442]. Perhaps,
the length of training was not enough to allow the structural changes that accompany muscle
hypertrophy to occur. Moreover, Rakobowchuk et al., [430] noted peripheral arterial remodeling
at 6 wks into training. Thus, the present study may have been on the verge of peripheral changes,
but fell short.
A third factor may be the population under study. The participants were healthy students
without overt disease. Generally, improved vascular function following training is observed in
individuals who have reduced vascular function prior to training. For example, Green et al.,
[432] reported that an 8 wk resistance/aerobic training improved endothelium-dependent nitric
oxide-mediated vascular function in both conduit and resistance vessels in patients at risk for and
with coronary artery disease. Those findings were further confirmed in type II diabetics [433]
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and patients with heart failure [204]. Interestingly, in this study those individuals with RHBF’s
below the 50th percentile (i.e. <23 ml/100ml/min, n=19) before training had a 17% greater RHBF
response after training (Pre: 17.41±4.03; Post: 20.30±4.55 ml/100ml/min, p=0.006), independent
of group assignment. Similarly, those with the lowest values for VO (i.e. <39.5 ml/100ml/min,
n=17) also had significant improvements after training (Pre: 30.58±6.46; Post: 36.11±8.38
ml/100ml/min, p=0.013). We are cautious in the interpretation of these findings due to: (1)
paired t-tests were used for these sub analyses, (2) there was no control group, as this was not the
focus of the study, and (3) there were no associations between the observed strength gains and
vascular changes. Despite this, the improvements in this sub-group are not too dissimilar from
previous reports [5,429]. Thus, it appears individuals with evidence of low vascular function may
respond favorably to CWT.
3.4.1 Conclusion
In conclusion, short term CWT using high and low volume training resulted in
significant, yet, similar increases in strength. In contrast, group averages for vascular function
did not change following CWT. Interestingly; those with the lowest pre-training vascular
measures did have significant increases in forearm RHBF and VO, independent of group
assignment.
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Chapter 4
Relationship between Vascular and Physical Function in Individuals with Peripheral
Neuropathy
4.1 Introduction
Peripheral neuropathies are a wide range of diseases affecting the peripheral nerves.
According to the 108th Congress report, 20 million Americans suffer from the disease [7]. In fact,
peripheral neuropathy affects more people than several other well-publicized pathologies,
including diabetes mellitus (17-18 million), coronary heart disease (13.2 million), and asthma
(15 million) [444]. The prevalence of peripheral neuropathy increases significantly in the older
adult population and nearly one-third of all diabetics suffer from this condition [7].
Irrespective of the etiology, it appears that pathological changes associated with the
disease are in many cases consistent with ischemia, secondary to vascular insufficiencies [8]. In
fact, the literature has clearly established that chronic ischemia contributes to demyelination or
axonal degeneration [445], which consequently, gives rise to a variety of symptoms including
reduced or altered sensation, pain, muscle weakness, and chronic fatigue. The progression of
peripheral neuropathy, generally, follows a distal to proximal pattern, with symptoms usually
beginning in the toes before the fingers. Eventually, patients with peripheral neuropathy develop
gait abnormalities and subsequent decrements in balance [446]. As a result, a large number of
individuals with peripheral neuropathy suffer from a reduction in daily physical activity and
reduced quality of life [447].
Importantly, in a recent 2-year follow-up on individuals with lower-extremity peripheral
arterial disease (PAD), baseline leg symptoms and ankle brachial index (ABI) were strong
predictors of the degree of functional decline [219]. Moreover, PAD patients reportedly have
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worse nerve conduction velocity in the legs, considered a clinical marker of peripheral
neuropathy, than individuals without PAD [243], suggesting a link between vascular deficiencies
and neural function. Thus, it appears that vascular impairments contribute to the functional
decline in patients with PAD. Ultimately, it is thought that functional decline leads to loss of
independence and disability [448].
Interestingly, despite evidence of functional deterioration and increased risk of falls in
patients with peripheral neuropathy [449,450], and studies reporting nerve damage in patients
with chronic ischemia [445], few studies have examined the link between vascular and motor
function in peripheral neuropathy patients. In one such study, patients with PAD coupled with
diabetes exhibited greater lower extremity dysfunction compared to PAD patients without
diabetes. The apparent differences were, at least, in part secondary to poorer neuropathy scores
[256]. Given the association between physical function and independence, understanding those
factors that may contribute to a loss of functional ability and mobility in individuals with
peripheral neuropathy is critical.
Therefore, the purpose of the present investigation was to examine the relationship
between measures of vascular (both arterial and venous) and physical function (mobility and
lower extremity strength) in individuals with peripheral neuropathy. It was hypothesized that
individuals with evidence of greater vascular function also would exhibit greater physical
function among this population.
4.2 Methods
4.2.1 Participants
Individuals with peripheral neuropathy were recruited from the greater Baton Rouge
metropolitan area. The participants were referred to us with the diagnosis of peripheral
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neuropathy by their respective physicians. No distinction was made for the types of peripheral
neuropathy. The inclusion criteria for the study was (a) ability to maintain an upright posture for
at least one minute voluntarily; (b) ability to walk at least 20 yards independently; (c) willingness
to participate in the study; and (d) a diagnoses of bilateral peripheral neuropathy. Individuals
were excluded from participation if there was (a) a history or evidence of central nervous system
dysfunction; (b) musculoskeletal deformity which could influence gait and balance; (c) a history
or evidence of vestibular dysfunction; (d) a history of angina; (e) evidence of plantar ulcer; (f)
unstable disease (e.g. uncontrolled diabetes mellitus, Arthritis, coronary artery disease, etc.); and
cognitive impairment defined as a score of less than 25 on the mini-mental state exam [451].
Following explanation of all the details of the study, each participant signed an informed consent
approved by the Institutional Review Board.
4.2.2 Measurements
4.2.2.1 Peripheral Sensory Testing
Plantar cutaneous pressure sensitivity was assessed using the 5.07 gauge SemmesWeinstein monofilament (North Coast Medical, Inc). The monofilament exerts 10 g of force at
the tip upon buckling and has been used in both clinical and research settings. While there is no
widespread consensus as to the optimal protocol, reduced sensitivity as measured by this
monofilament has been correlated to common symptoms of peripheral neuropathy [452].
The fiber was applied to 5 sites on the plantar surface (i.e. the great and fifth toes, the
first and fifth metatarsal, and the heel). The fiber was applied for 1.5 s and pushed to an angle of
90o. The order of the test sites was randomized to help prevent anticipation of the test by the
participant. The participant indicated when he or she felt the fiber. If the participant exhibited
any sign of foot ulcers, the testing sites were moved to the perimeter of the ulcer. All testing was
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performed by the same technician. Data was recorded as a “0” for no sensation, or a “1” if the
monofilament was sensed.
4.2.2.2 Vascular Assessment
Vascular function of the lower leg was assessed using strain gauge plethysmography at
rest and after 5 min of arterial occlusion. Specific measures included resting arterial inflow (AI),
vascular capacitance and conductance, venous outflow volume and half time (VOt1/2), and
reactive hyperemic blood flow (RHBF).
Prior to the vascular assessments participants were instructed to refrain from food,
alcohol or caffeine for 12 h, and rigorous physical activity for 24 h. Upon arrival to the vascular
laboratory, the participants were placed on an examination table and segmental pressure cuffs
were positioned around the lower thigh and ankle [453]. In addition, a blood pressure cuff was
positioned in the standard position around the upper arm to obtain blood pressure measures
continuously. The data was collected using an automatic blood pressure device (Datascope
Accutorr 4, Datascope Corp. Paramus, NJ).
Subsequently a mercury-filled strain gauge was positioned around the widest girth of the
lower leg. The position was marked and kept constant throughout the experiments. The strain
gauge was connected to a plethysmograph (EC-5R system, Hokanson; Bellevue,WA). The leg
was extended and slightly supinated and supported at least 10 cm above the level of the heart by
foam blocks, but ensuring the strain gauge was not impeded, in order to provide the most
comfortable arrangement for the participant. Following the set-up procedures, participants were
allowed to rest for 25 minutes. Resting in-flow was measured in triplicate as follows. First, foot
circulation was occluded for 1 minute prior to the assessment by inflating the cuff at the ankle to
240mmHg. Then, the segmental pressure cuff on the thigh was inflated to 7 mmHg below
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diastolic blood pressure, measured at the arm. Arterial in-flow was then recorded three times for
10 seconds with 10 seconds between each recording. Following an additional 2 minutes of
maintaining the segmental thigh cuff at the previous determined pressure, venous capacitance
was obtained. Subsequently, venous outflow was measured after release of the thigh pressure
cuff for 20 seconds.
Patients were then given another 5 minutes of rest prior to initiating the hyperemic test.
Following this rest period the thigh cuff was inflated to at least 60mmHg above systolic blood
pressure for 5 minutes. In the fourth minute foot circulation was again occluded for 1 minute by
inflating the cuff at the ankle to 240mmHg. Upon release of the thigh pressure cuff to a pressure
equal to 7 mmHg below diastolic blood pressure, reactive hyperemic blood flow was measured
in triplicate for 10 seconds, with 10 seconds between each measure.
Data were analyzed using a customized computer program (Matlab; Mathworks, Natick,
MA, U.S.A.). Resting arterial in-flow was calculated from the entire slope, 10 seconds in length,
of the volume change over an interval of 10 seconds and the mean of three consecutive
measurements was used to determine the average arterial in-flow. Recordings with significant
movement artifact were excluded. Resting vascular resistance was calculated as mean arterial
pressure / average in-flow. Resting vascular conductance was the reciprocal of vascular
resistance or average in-flow / mean arterial pressure. For both assessments, vascular resistance
and conductance, a blood pressure measure taken at that point was used for the analysis. Venous
capacitance was determined through visual inspection of the position of the recording needle on
the plethysmograph. Using a standard scale developed by the manufacturer an overlay is placed
over the recording paper. The distance from the base of the graph to the position of the mark at
the end of 2 minutes represents the relative venous capacitance.
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Reactive hyperemic blood flow was calculated from the slope of the volume change over
each 10 seconds interval. This allows for the determination of peak and the average reactive
blood flow response across the three measurements. In order to assess the timing characteristics
of the venous outflow, venous outflow data were fitted to an exponential curve using the least
mean square optimization method and processed by using Solver plug-in within the Microsoft
Excel environment. The Venous outflow half time (VOt1/2) were calculated based on the time
constant of the simulated exponential curve of each testing session.
4.2.2.3 Physical Function Assessment
On a separate day, participants were evaluated in a series of tests for functional capacity,
mobility, and lower extremity strength. At least five minutes of rest was provided in between
each test, while at least two minutes of rest was provided between trials of applicable tests. The
reliability of the functional testing protocol in this study has been reported elsewhere, and was
found to be high for patients with peripheral neuropathy. The protocol used is outlined below.
The Six-Minute Walk test was administered using a standardized protocol outlined by the
American Thoracic Society [73]. Briefly, cones were placed 30m apart along a well-lit indoor
hallway. Participants walked as far as possible in 6-min by walking back and forth around the
cones. The distance covered was recorded to the nearest meter. Specific pre- and within-test
participant instructions can be found in the American Thoracic Society statement [73].
Maximum walking distance traveled in 6 minutes (6MWD), to the nearest meter, was recorded
and used for analysis.
In order to examine balance and coordination a timed up- and-go test (TUG) was
implemented, using a previously established protocol [454]. The TUG-test is a useful test in
detecting mobility impairment [455]. Briefly, a firm chair with arm rests was placed in the
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middle of a well-lit, indoor hallway. In front of the chair, a distance of 3 m was marked on the
floor and a large cone was placed on the opposite end from the chair. The test began with the
participant seated with their back against the chair, arms in lap, and feet just behind the distancemarker on the floor. Instructions were to stand up using the arm rests if needed, walk safely to
and around the cone, walk back to the chair, and sit all the way back in the chair as fast as
possible. The timer was started on the work “go,” and stopped when the participant’s back
touched the back of the chair. The average time to complete each of 2 separate trials was
recorded and used for analysis.
Isokinetic knee extensor peak torque and knee flexor peak torque were measured with the
Biodex isokinetic dynamometer (Biodex Medical, Shirley, New York). Participants sat in the
Biodex chair with the back rest fixed at 85 degress. Subjects were secured using pelvic and torso
straps to minimize extraneous body movements that may influence testing performance. To
further minimize such effects, participants were instructed to hold the Biodex handgrips during
the procedure. The lateral femoral epicondyle was used as the reference point for matching the
axis of rotation of the knee joint with that of the dynamometer resistance adapter. The lower limb
was attached to the resistance adaptor to allow full knee extension and flexion to approximately
100 degrees.
A warm-up procedure consisting of five isokinetic knee extension and flexion
movements at 60 o/s was initially completed. A 10s rest period was given in between each trial.
Participants were instructed to kick and pull their leg lightly during the first trial, and increase
the amount of produced force with each trial so as to generate at or near maximal force during
the fifth trial. Following a 3-min rest period, the maximal strength test was completed.
Participants repeated warm-up procedures (5 trials, 10s rest between trials), only with specific
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instructions to “push/pull your lower limb as hard as you can, remembering to breathe out
normally during the trial.” During all maximal trials, verbal encouragement and concurrent
visual feedback from a computer monitor were provided to facilitate maximal values. Peak knee
extension (KE) and knee flexion (KF) torque (N·m) were recorded for each trial. Values from the
three best trials for each movement were averaged and used for analysis.
4.2.3 Statistical Analyses
Statistical analyses were performed using SPSS for Windows (version 11.0). Data are
presented as means and SD. To examine the associations between age, measures of vascular and
physical function, Pearson product moment correlation coefficients were calculated.
Associations between the monofilament scores and various measures were examined using a
Spearman rank correlation. To further appreciate the influence of the vascular indices on motor
function, analyses of variance were used to compare participants classified according to tertiles
on the performance scores, or in the case of the six minute walk test the clinically relevant score
of 400m. Finally, potential differences in vascular and motor function based on certain groupings
(e.g. etiology, gender, duration of disease) were determined using analyses of variance or
independent t-tests. Significance was tested at the 95% confidence level (p≤0.05).
4.3 Results
4.3.1 Participant Characteristics
A total of 59 individuals with peripheral neuropathy participated in all aspects of this
study. Participant characteristics are presented in Table 4.1. Forty-one percent of the participants
were women, and 59% men. Seventy percent of the participants were over the age of 65.
The oldest participant tested was 87years old, and the youngest was 39 years old. The
duration of the diagnosis ranged from 6 months to 20 years, with ~60% of the participants
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suffering from peripheral neuropathy less than 5 years. The etiology of peripheral neuropathy
was idiopathic in approximately 56% of the subjects. Thirty-one percent had Type II Diabetes
Mellitus, 7% of patients suffered from chronic low back pain, and 5% of patients with
neuropathy were cancer survivors. Thirty percent of the patients had a BMI greater than 30kg·m2

, and 40% had stage I hypertension on the basis of systolic blood pressure (SBP > 130mmHg).
Table 4.1 Participant characteristics
Minimum Maximum
Age (yr)
39
87
Disease duration (yr)
.5
20.0
Height (m)
1.50
1.96
Weight (kg)
43.64
150.00
BMI(kg·m-2)
16.43
47.94
Systolic Blood Pressure (mmHg)
95
175
Diastolic Blood Pressure (mmHg)
52
95
Resting Heart Rate (bpm)
42
116
Pulse Pressure (mmHg)
34
97
Monofilament Test Score
0
5
m = meters; kg = kilograms; bpm = beats per minute

Mean
69
5.50
1.70
83.96
28.78
130
72
71
57
2.47

SD
12
4.24
0.10
21.78
6.29
17
11
12
12
1.43

4.3.2 Peripheral Sensory Test
The majority of patients reported partial sensation on the peripheral sensory tests. Ten
percent of patients reported no sensation at any of the sites tested, and only 5% of participants
reported no diminished sensation at any of the sites. The sites that yielded the greatest sensitivity
were the big toe and fifth toe (~64% of participants reported sensing the monofilament). The site
of the heel yielded the lowest sensitivity, with ~16% of patients sensing the monofilament. The
duration of disease was significantly associated with the sum of the scores on the peripheral
sensory test (r=-0.48, p=0.002).
No significant relationships were found between the reactive hyperemic responses or
VOt1/2 and the sum of the sensory test scores. However, there were significant associations
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between vascular conductance (r=0.44, p=0.01), the TUG (r= -0.37, p=0.03) and the sum of the
sensory tests.
4.3.3 Vascular Assessment
The average values for the blood flow indices at rest and following occlusion are
presented in Table 4.2. The average resting inflow was 2.48±1.17 mL·100mL-1 ·min-1. Post
occlusion reactive hyperemia values significantly decreased (p=0.0001) with each measure from
a peak hyperemic response of 26.93±13.44 mL·100mL-1 ·min-1, immediately after cuff release, to
17.23±8.58 mL·100mL-1 ·min-1 at the second and 13.72±7.59 mL·100mL-1 ·min-1 at the third time
point.
Group comparisons based on etiology, gender, or disease duration did not reveal
significant differences in any of the blood flow indices, even when the diabetic patients were
compared to all others. In addition, there were no correlations between age and any of the inflow
measures. In contrast there was a significant association between age and VOt1/2 (r=0.31,
p=0.02). Finally, Table 4.3 reveals several significant associations between RHBF, venous
volume, VOt1/2 and vascular conductance.
4.3.4 Physical Function Assessment
The average scores for the physical function tests are shown in Table 4.4. No differences
in performances scores were noted for the different etiologies and disease duration. Men were
significantly stronger for KE (Men: 141±73; Women: 80±20 N·m, p=0.001) and KF (Men:
70±30; Women: 39±10 N·m, p=0.001), but no differences were noted for the 6MWD and TUG.
In addition, there were significant associations between age and each of the functional
scores (Age vs. 6MWD: r= -0.34, p=0.01; Age vs. TUG: r= 0.33, p=0.01; Age vs. KE: r= 0.51,
p=0.001; and Age vs. KF: r= 0.50, p=0.001). Finally, Table 4.3 shows several associations
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between the performance scores. A particular strong association was noted between 6MWD and
TUG (r=0.79, p=0.001), whereas there were no significant relationships between TUG and
measures of leg strength.
Table 4.2 Blood flow indices at rest and following occlusion
-1

-1

Minimum
0.96
13.46
0.00
8.00
0.60
8.46
7.52
0.08

Maximum
6.29
109.85
4.00
58.00
3.25
73.62
51.18
0.69

Mean
2.48
45.43
1.57
31.26
1.31
26.93
19.36
0.30

Arterial Resting Inflow (mL·100mL ·min )
Vascular Resistance (AU)
Venous Capacitance (mL·100mL-1 ·min-1)
Venous Volume (mL·100mL-1 ·min-1)
VO t1/2 (s)
RHBF Peak (mL·100mL-1 ·min-1)
RHBF Average (mL·100mL-1 ·min-1)
Peak Vascular Conductance
(mL·100mL-1 ·min-1)
AU = arbitrary units of resistance; VO t1/2 = venous outflow halftime; s = seconds;
RHBF = reactive hyperemia blood flow

SD
1.17
22.01
0.90
12.37
0.51
13.44
8.58
0.15

4.3.5 Associations between Vascular and Physical Function
The associations between the vascular indices and physical function are presented in
Table 4.3. In particular the associations between peak RHBF responses and the TUG (Peak
RHBF= 37.88 - 1*TUG; r=-0.31, p=0.024) and the 6MWD (Peak RHBF= 8.65 + 0.05*6MWD;
r=0.37, p=0.007) are of interest. Specifically, as shown in Figure 4.1 individuals in the top
tertiles of the TUG had significantly higher peak RHBF responses compared to the lowest tertile
[≤9.02s, RHBF: 30.97±12.56 mL·100mL-1 ·min-1; 9.02-10.88s, RHBF: 28.88±15.99 mL·100mL-1
·min-1; >10.88s, RHBF: 19.88±8.10 mL·100mL-1 ·min-1 , p=0.04].
Those with a 6MWD score <400m had lower RHBF compared to those who walked
>400m (see Figure 4.2) [<400m, RHBF: 23.47±10.52 mL·100mL-1 ·min-1; >400m, RHBF:
30.65±15.05 mL·100mL-1 ·min-1, p=0.05]. In addition, peak vascular conductance was also
significantly related to the TUG (Peak Vascular Conductance = 0.50 – 0.02*TUG; r=-0.38,
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p=0.007) and 6MWD (Peak Vascular Conductance = 0.50 + 0.001*6MWD; r=0.44, p=0.001),
showing similar differentials based on the tertiles and 400m threshold as for the peak RHBF
response (see Figure 4.3 and 4.4). Finally, a significant association between VOt1/2 and KF
(VOt1/2 = 1.67 - 0.01*KF; r=-0.37, p=0.01) and KE (VOt1/2 = 1.67 - 0.01*KF; r=-0.37, p=0.01)
was observed, with those in the top tertile exhibiting faster VOt1/2 (see Figure 4.5) [>77N·m,
VOt1/2: 1.01±0.31s; 36-77N·m, VOt1/2: 1.54±0.64s; <36N·m, VOt1/2: 1.38±0.40s, p=0.004].
Table 4.4 Physical function scores
Minimum Maximum
Mean
SD
6MWD (m)
98
570
373
106
Timed up and go (s)
6.20
33.25
11.00
4.26
KE (N·m)
23.67
327.17
104.71
56.83
KF (N·m)
10.20
151.57
51.38
25.09
6MWD = 6 minutes maximal walking distance; m = meters; s = seconds;
KE = knee extension; N·m = newton-meter; KF = knee flexion
4.4 Discussion
The purpose of the present investigation was to examine the relationship between
measures of lower leg vascular and physical function in individuals with peripheral neuropathy.
The present data, indeed, support a link between measures of vascular and physical function in
individuals with peripheral neuropathy. Specifically, individuals in the lowest tertile of the TUG
and those with a 6MWD score <400m had significantly lower peak RHBF responses and peak
vascular conductance compared to the other groups.
In addition, individuals in the top tertile of KE and KF exhibited faster VOt1/2 than the
other tertiles. These findings fit “The Disablement Pathway” and suggest that lower motor
function may, in part, be a consequence of deterioration of peripheral vascular function in
individuals with peripheral neuropathy.
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4.4.1 Vascular Assessment
The use of venous occlusion plethysmography is a powerful tool to study limb blood flow
in humans. In general, the study of blood flow responses following occlusion indicates that
younger, fitter, and healthier individuals exhibit greater flow responses, suggesting better
vascular function.

Figure 4.1. Association between peak reactive hyperemia blood flow (peak RHBF)
responses and the timed up and go (TUG) tertiles.* indicates significant difference from
other tertiles (p=0.01)
To that extent, peak RHBF responses in the present study were ~17% lower than values reported
for a group of healthy individuals in the same age range, and ~18% and 29% higher than a group
of heart failure and PAD patients [153,456], using the same analyses techniques.
Although beyond the scope of this paper, a lower than expected peak RHBF response
suggests alterations in the main factors that govern reactive hyperemia. More recently,
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TUG

KE

KF

Venous
Cap
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Con

Venous
Vol
t1/2

Venous
Outflow

RHBF
avg

RHBF
peak

Peak
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0.79
1
0.001
KE (Torque)
0.29
-0.13
1
0.029
0.321
KF (Torque)
0.38
-0.23
0.89
1
0.004
0.088
0.001
Venous Cap
0.01
0.11
0.27
0.24
1
(mL·100mL-1 ·min-1) 0.938
0.414
0.046
0.09
Vasc Con
-0.28
0.30
0.07
0.03
0.44
1
(mL·100mL-1 ·min-1) 0.037
0.023
0.618
0.83
0.001
Venous Vol
0.04
0.03
0.29
0.34
0.71
0.53
1
(mL·100mL-1 ·min-1) 0.790
0.840
0.032
0.010
0.001
0.001
Venous Outflow
-0.19
0.20
-0.28
-0.34
0.14
-0.02
0.13
1
t1/2(s)
0.176
0.138
0.037
0.01
0.321
0.885
0.329
RHBF avg
0.16
-0.05
-0.01
-0.03
0.43
0.28
0.56
0.30
1
(mL·100mL-1 ·min-1) 0.239
0.748
0.98
0.845
0.002
0.043
0.001
0.030
RHBF peak
0.37
-0.31
-0.06
-0.05
0.24
-0.01
0.39
0.23
0.88
1
(mL·100mL-1 ·min-1) 0.007
0.024
0.69
0.708
0.085
0.98
0.003
0.09
0.001
Peak Vasc Con
0.44
-0.38
-0.05
-0.08
-0.09
-0.10
0.56
0.25
0.78
0.93
1
(mL·100mL-1 ·min-1) 0.001
0.009
0.775
0.633
0.588
0.536
0.001
0.128
0.001
0.001
6MWD = 6 minutes maximal walking distance; m = meters; TUG = timed up and go; s = seconds; KE = peak knee extension
torque; KF = peak knee flexion torque, Venous Cap = venous capacitance; Vas Con = vascular conductance, Venous Vol = venous
volume; RHBF avg and RHBF peak = reactive hyperemia blood flow average and peak; Peak Vasc Con = peak vascular
conductance.

TUG (s)

6MWD (m)

6MWD

Table 4.3 Correlations between vascular and physical function

researchers have also used peak limb vascular conductance immediately after a period of cuff
arterial occlusion as an indirect measure of the structural limitations placed on limb muscle blood
flow [457]. The values for peak vascular conductance, in the present study, were considerably
lower than those reported for a group of men free of overt disease [457].

Figure 4.2. Association between peak reactive hyperemia blood flow (peak RHBF)
responses and the maximal walking distance cut-off points. Difference is significant at
p=0.05
Thus, a lower than expected peak vascular conductance in these patients could reflect, in
part, structural changes related to the arterial vasculature of the limbs (e.g. a reduction in
vascular density and or number) that limit the extent of vasodilation. Together, these findings
suggest that the arterial vasculature in individuals with peripheral neuropathy is compromised.
Such a compromised system could certainly contribute to the progression of the disease. In fact,
the literature provides significant evidence that conditions of acute and chronic ischemia
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contribute to changes in peripheral nerve function and structure [445]. In fact, Laghi Pasini et al.,
[445] reported a strong correlation between severity of nerve damage and stage of vascular
insufficiency. It is not currently known what underlying mechanisms may contribute to
deterioration of peripheral nerve function, but an increase in intracellular calcium [458], and/or
reduced oxygen species [459] could disrupt myelin and lead to axonal fiber degeneration.
In regards to venous circulation, several investigators have reported a reduction in venous
function with advancing age [460] and in patients with heart failure [461]. It is not clear what
mechanisms are involved in this reduced function, but impaired muscle activation and
generalized deconditioning may be involved. In addition, it is important to consider the changes
in the structure and function of the vasculature and peripheral nerves as a result of the aging
process. In that regard, Fu et al., [460] reported an age-related decline in venous filling and
emptying. It is not known if the progression of peripheral neuropathy may accelerate the decline
in venous function, or if a decrease in venous function contributes to the progression of the
disease. Given the important contribution of the venous system in metabolic waste removal and
end-diastolic volume, changes in this part of the circulation may be quite significant in terms of
overall vascular function. The present data confirms an association between venous outflow half
time and age in individuals with peripheral neuropathy.
4.4.2 Physical Function Assessment
A decline in functional performance in individuals with peripheral neuropathy is widely
accepted, although the rate of decline and contributing mechanisms are much less understood.
The six-minute walk test is an easily implemented test that determines the maximum distance a
person can walk in 6-min. This test is a valid measure of “functional capacity” as it evaluates the
integrated response of all systems involved during physical activity [73].
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It is therefore frequently used in both elderly and diseased populations, and was therefore
chosen for the current study. The total group average for the 6MWD (373±106m) in this study
appears to be quite typical for those seen in patients with heart failure [64], indicating significant
functional limitations. Importantly, based on the literature indicating that a walking distance less
than 400 meters is associated with higher prevalence of institutionalization, morbidity, mortality,
hospitalization and transplantation [462], the results of the present study suggest 50% of the
neuropathy patients are at elevated risk for complications.

Figure 4.3. Association between peak vascular conductance and the timed up and go
(TUG) tertiles. * indicates significant difference from slowest tertile (p=0.003).
† indicates significant difference from middle tertile (p=0.05)
The TUG test has been suggested to be a measure of basic mobility skills [454]. The test
assesses the time it takes a participant to stand up from a chair, walk around a cone 3 m away,
walk back to the chair, and sit down. Data regarding norms and threshold scores for the TUG-test
are available but are somewhat conflicting. For example, Steffen et al.,[463] reported average
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TUG-test times on a group of 60 to 69 years old men and women around 8sec. Bischoff et al.,
[455] recommended the need for early evaluation and intervention for community-dwelling
elderly women between 65-85years of age, who scored above 12 s on the TUG-test. Others
identified a cutoff point of 24 s as a parameter that significantly predicted falls during a 6-month
follow-up period. In the present study, 26% of participants scored above the 12s mark,
suggesting these patients may be at elevated risk.

Figure 4.4. Association between peak vascular conductance and the maximal
walking distance cut-off points. Difference is significant at p=0.007
Maximal isokinetic knee strength is a common measure of muscular strength and thus
chosen for the current study. It has been shown to decline with advancing age [464,465]. The
average KE for this cohort (104.71±56.83 N·m) is approximately 10% lower than those reported
for 60 to 69 year old individuals participating in NHANES 1999-2000 [465]. In addition, the
average KF in the present study (51.38±25.09 N·m) is 17% lower than those reported for men
and women aged 70 to 79 years from the Health, Aging, and Body Composition Study [464].
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These data suggest that patients with peripheral neuropathy have lower than expected leg
strength. Lack of measurement of muscle mass, composition, or more sophisticated tests to
examine neural recruitment, prevents speculation regarding the underlying mechanisms
involved.

Figure 4.5. Association between venous outflow halftime (VOt1/2) and peak knee
flexion torque (KF) tertiles. * indicates significant difference from other tertiles
(p<0.05)
4.4.3 Associations between Vascular and Physical Function
The major focus of this study was to examine the relationship between measures of lower
leg vascular and physical function in individuals with peripheral neuropathy. The data are
consistent with the stated hypothesis that individuals who have greater peak RHBF responses
and vascular conductance following occlusion have higher scores on the TUG and 6MWD tests.
In contrast, no significant associations were noted between the measures of vascular reactivity
and knee flexion and extension.
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It is important to notice the relationship between peak RHBF responses, vascular
conductance and the 6MWD. Both vascular indices studied provide evidence of the ability of the
vasculature to respond to an increase in metabolic demand (i.e. 5 minutes of occlusion).
Arguably, the physiologic demands associated with the walking test would also serve to
challenge the vasculature, and consequently individuals who have evidence of vascular
impairments would have a reduced motor capacity. Importantly, this study used 400 m as the
differentiating point. Studies have indicated the prognostic value of this threshold as it relates to
institutionalization, morbidity, mortality, hospitalization and transplantation [462]. It is
interesting to speculate that the increased risk in patients with peripheral neuropathy, who score
below 400m on the walk test, may in part be secondary to diminished vascular function.
It is also important to notice the relationship between peak RHBF responses, vascular
conductance and the TUG-test. The TUG-test is a basic test used to examine mobility and
balance. Arguably performance of the TUG-test is a more complex interplay between
physiological systems than the walk test. It is generally accepted that the TUG-test does not
focus on independent effects of organ impairments, such as low muscle strength, decreased
balance and other impairments, but measures the interaction of these factors on the performance
of activities of daily living. It is not clear what influence a diminished vasculature has during the
TUG-test in the peripheral neuropathy patients. However, we speculate that the initiation and
subsequent continuation of a movement pattern is very much dependent on the ability to
immediately increase blood flow to the working muscle. A major factor in the acute rise in
muscle blood flow is the muscle pump, and subsequent distribution of cardiac output toward the
working muscle. Thus, if the factors involved in the initial rise in blood flow with the onset of
activity are impaired this could result in the increase time needed to perform the TUG-test. We
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are unaware of studies that have examined blood flow at the onset of exercise in peripheral
neuropathy, but do recognize that such responses are blunted in the elderly. Thus, we encourage
further studies to explore the link between muscle blood flow and functionality in the peripheral
neuropathy patient.
The lack of significant associations between peak RHBF responses, vascular conductance
and the isokinetic strength tests was not surprising. The strength tests probably are more specific
in regards to the physiologic systems involved in the movement (e.g. muscle mass and neural
innervation), and more than likely does not rely heavily on the delivery of blood to perform the
test. In contrast, both KE and KF were significantly related to the VOt1/2. These findings further
confirm data from our laboratory suggesting that muscular fitness is related to venous function.
The associations suggest the contribution of the venous system to motor function is beyond the
typical role as a “passive volume reservoir”. Importantly, the venous system is controlled
primarily by the sympathetic nervous system. Generally, patients with chronic degenerative
conditions tend to be hyperadrenergic. It is certainly possible that muscle deconditioning in some
patients with peripheral neuropathy contributes to modifications in venous function.
We remain cautious in our interpretations considering the limitations inherent to a cross
sectional design and the lack of causality presented. It is also recognized that the lack of
longitudinal data regarding vascular and physical function and many other important factors in
individuals with peripheral neuropathy are not accounted for in the present study. However, the
present observations are unique in a sense that it is the first study to establish a link between
vascular and physical function in patients with peripheral neuropathy, and consequently
contributes to the existing literature in identifying several unique aspects that warrant further
discussion and research.
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It is also recognized that the present data do not elucidate possible mechanisms why
individuals with the variables under interest are linked. The lack of a mechanistic approach in the
current study prevents more sophisticated speculation regarding the development of possible
preventive or compensatory interventions. However, given data indicating that exercise training
can improve vascular function [433] we hypothesize that physical training may be an excellent
way to preserve functional ability and independence in certain patients with peripheral
neuropathy.
In summary, the present findings strongly suggest that diminished vascular function
contributes to a decrease in physical function in individuals with peripheral neuropathy. These
findings are particularly interesting in light of recent data that clearly indicates that lower
cardiorespiratory fitness is a significant predictor of dependence [466] and that ABI is a strong
predictor of the degree of functional decline in patients with PAD [219].
The newly published “International Classification of Impairments, Disabilities, and
Handicaps” (ICF) by the World Health Organization (www.who.int/classification/icf)
emphasizes the influence of human body function and structure on the level of functioning,
activity and participation. People with peripheral neuropathy have little activity and participation
due to limited by mobility, and this in turn have a negative effect on their quality of life. The
recognition of a relationship between vascular and physical functions enables us to further
investigate the mechanisms that underlie the functional limitations. These future studies may
provide us the information necessary for the development of effective interventions.
4.4.4 Conclusion
The purpose of the present investigation was to examine the relationship between
measures of leg vascular and physical function in individuals with peripheral neuropathy. The
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results support a relationship between measures of vascular and physical function where
individuals with greater physical function scores exhibited more favorable measures of arterial
inflow and venous outflow. The lower physical function may, in part, be a consequence of
deterioration of peripheral vascular function in individuals with peripheral neuropathy.
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Chapter 5
Effects of an Acute Bout of Exercise on Nitric Oxide Bioavailability, Oxidative Stress, and
Anti-oxidant Defense Markers in Trained Individuals
5.1 Introduction
The endothelium controls vascular tone, coagulation, and inflammatory responses.
Indeed, normal endothelial function includes control of antithrombotic and thrombolytic activity,
vascular architecture and permeability, leukocyte interactions with the vessel wall, and vascular
tone regulation during rest and exercise [237]. Vascular endothelial cells play an important role
in maintaining cardiovascular homeostasis primarily through the release of protective bioactive
substances, the most widely studied being nitric oxide [467]. The capacity of the endothelium to
release nitric oxide has been recognized as an important surrogate marker of general endothelial
health [468]. Cardiovascular diseases, diabetes, aging, and smoking, among other factors, have
been associated with reduced vascular endothelial nitric oxide function [469]. In addition,
disturbances of nitric oxide bioavailability have been suggested to play a key role in vascular
dysfunction and the development of atherosclerotic lesions [470].
Nitric oxide is a labile, lipid soluble gas synthesized in endothelial cells from amino-acid
L-arginine through the action of endothelial nitric oxide synthase [471]. Three distinct nitric
oxide synthase isoforms have been identified: (a) neuronal nitric oxide synthase (type I), (b)
inducible nitric oxide synthase (type II), and (c) endothelial nitric oxide synthase (type III) [470].
There are two major compartments for nitric oxide metabolism; the blood plasma and the
red blood cells compartment. The major immediate breakdown product of nitric oxide in human
plasma is nitrite. Plasma nitrite can be taken up by red blood cells, where it is oxidized in a
hemoglobin-dependent manner to nitrate, which may subsequently redistribute into plasma
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[472]. The term ‘free radical species’ summarizes a variety of highly reactive molecules that can
be divided into different categories, e.g. reactive oxygen species, reactive nitrogen species, and
reactive chlorine species [473]. In addition, oxidative stress species, more generally, reactive
oxygen species, as well as reactive nitrogen species, are products of normal cellular metabolism
[474]. Indeed, reactive oxygen species and reactive nitrogen species are well recognized for
playing a dual role as both deleterious and beneficial species, since they can be either harmful or
beneficial to living systems [475].
The beneficial effects of reactive oxygen species occur at low/moderate concentrations
and involve physiological roles in cellular responses to noxia; for example in defense against
infectious agents and in the induction of a mitogenic response [474]. On the other hand, the
harmful effect of free radicals causing potential biological damage is termed oxidative stress and
nitrosative stress [476]. Therefore, oxidative stress refers to the situation of an imbalance
between the production of free radicals and the antioxidant defense mechanisms.
In addition, Davies et al., [477] have reported that free radicals are formed also in
response to physical exercise. In fact, there is significant evidence that an acute bout of exercise
results in a significant increase in oxidative stress markers [478]. Interestingly, we are aware of
only one study that has examined markers of oxidative stress and anti-oxidants molecules in
conjunction with nitric oxide bioavailability [479]. This is particularly important as nitric oxide
can neutralize or become neutralized by reactive oxygen species. The neutralizing capabilities of
nitric oxide may to some extent protect the endothelial environment, but excess reactive oxygen
species may also reduce the other functions of nitric oxide, thereby increasing vascular
vulnerability [470]. The study by Di Massimo et al., [479] evaluated the ratio between
nitrite/nitrate or NOx, as a marker of nitric oxide bioavailability. Their results indicated an
153

increase in NOx and oxidative stress markers, and a decrease in total antioxidant systems from
baseline to peak exercise, returning to baseline values within 24 hrs. These findings suggest that
endothelial balance may be altered with acute exercise. However, it is well known that plasma
nitrate levels are influenced by a variety of nitric oxide synthase- independent factors (dietary
intake, saliva formation, denitrifying liver enzymes, and inhaled atmospheric gaseous nitrogen).
Furthermore, Lauer et al., [470] have reported that nitrate and/or NOx do not generally
represent useful markers of endogenous nitric oxide production. According to Lauer et al.,[470] a
better marker of nitric oxide bioavailability is the nitric oxide stored on the hemoglobin of the
red blood cells; nitrosylated hemoglobin. Indeed, this marker has been suggested to have a
potential role in transport and delivery of nitric oxide [480].
Given the current shortcomings in the literature regarding our understanding of
endothelial balance, the purpose of the present study was to examine the effects of an acute bout
of exercise on nitric oxide bioavailability, oxidative stress markers, and anti-oxidants markers at
three time points, before, at peak exercise, and at 20 minutes into the recovery phase in aerobic
trained individuals. It was hypothesized that an acute bout of exercise would result in a decrease
in nitric oxide bioavailability and an increase in oxidative stress markers from baseline to peak
exercise, with a gradual return to baseline in the recovery phase. In addition, on the basis of
previous investigations [479] it was hypothesized that the total anti-oxidants markers would
decrease from baseline to peak exercise, and return to pre-exercise levels in recovery. It was
speculated that the changes in the biological markers of nitric oxide, oxidative stress, and antioxidant defenses, in part, reflect the endothelial responses to an acute bout of exercise and
represent a marker of the ability to maintain endothelial balance during and following physical
stress. In addition, this study also examined the effects of acute exercise on vascular reactivity,
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defined as brachial artery flow mediated dilation. It was hypothesized that vascular reactivity
would decrease from baseline to immediately after 30 minutes of high intensity cycling, and
return to pre-exercise levels within 20 minutes of recovery.
5.2 Methods
5.2.1 Participants
Aerobically trained individuals were recruited to participate in this study. Individuals
with any unstable manifestations of cardiovascular, metabolic, orthopedic, neurological disease,
or at risk for adverse responses to exercise, and/or taking any medication which may affect
cardiovascular function were excluded from participating. The current study was reviewed and
approved by the Louisiana State University Institutional Review Board.
5.2.2 Experimental Design
The study was a prospective design consisting of two separated visits. Both visits
involved a bike time trial of 30 minutes. During the first visit, prior to, at peak exercise (30min)
and at 20 minutes in recovery blood samples were obtained for the purpose of examining
reactive oxygen species, anti-oxidants, and nitrosylated hemoglobin. In addition, gas analyses
were used for the determination of oxygen consumption, carbon dioxide production, and
ventilation. During visit two, vascular reactivity of the brachial artery was assessed prior to,
immediately following peak exercise and at 20 minutes in recovery.
5.2.3 Experimental Protocol
5.2.3.1 Visit 1
Participants reported to the laboratory, and were provided with the details, risks, and
potential benefits of the study. Following explanation and signing of the informed consent the
participant was provided a short questionnaire to determine the training status of the individual.
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Given the participants were all trained the questions dealt specifically with their average volume
of training per week, and schedule of competition, and their rankings.
After the assessment a nurse clinician placed an indwelling catheter in an antecubital vein
for the purpose of blood sampling. After securing the catheter the participant was given the
opportunity to relax for approximately 15 minutes before the initial sample was obtained.
Subsequently, the participant was asked to mount their bicycle which was placed in a
high performance, microprocessor controlled indoor trainer (Race Mate Compu Trainer). The
participant was then fitted with head-gear for the purpose of gas analyses and a Polar heart rate
monitor. After a brief calibration period heart rate and blood pressure were assessed, and the
breath-by-breath respiratory gas analyses system (Sensormedics software, Yorba Linda, CA)
started, and baseline measures obtained for five minutes. Then the time trial commenced with the
participant pedaling at a speed of 80 to 90 revolutions per minute. Resistance was increased over
the first 5 minutes to achieve 80 to 85% of the participant’s estimated heart rate reserve.
Throughout the test breath-by -breath measures of oxygen consumption, carbon dioxide
production, and pulmonary ventilation were obtained. In addition, before, during and after the
test, heart rate, blood pressure, and ratings of perceived exertion were obtained at five minute
intervals using a standard sphygmomanometer, Polar heart rate monitor, and Borg’s perceived
exertion scale (RPE, Borg’s 20-point scale) [481], respectively.
Blood sampling was performed prior to, at peak exercise (30min) and at 20 minutes in
recovery, from an antecubital vein. Each sample was approximately seven milliliters (7 mL).
Following each draw the sample line was flushed with saline. Prior to the second and third draw
approximately 2 to 3 ml were drawn and discarded to prevent any saline in the sample to be
analyzed. Following each draw approximately 3 ml of blood was immediately treated with
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specific spin trap probes and subsequently frozen in liquid nitrogen and kept at -80°C for
analyses. The remaining sample was centrifuged and separated and subsequently frozen for the
analyses.
5.2.3.2 Visit 2
Participants reported to the laboratory and were placed on an examination table in
preparation for the assessment of brachial artery reactivity prior to, immediately following peak
exercise and at 20 minutes in recovery. Following a 15 minute resting period, ultrasound images
were obtained using high resolution ultrasonography (Hewell Packer, Sonos 2000, 7.5-MHz
linear array transducer). Images were obtained in the longitudinal view, approximately 4 cm
proximal to the olecranon process, in the anterior/medial plane, with the participant's arm
immobilized and slightly supinated. Image depth was initially set at 4 cm, and gain settings were
adjusted to provide an optimal view of the anterior and posterior intimal interfaces of the artery
and kept constant throughout. Subsequently, brachial artery reactivity was tested by inflating a
blood pressure cuff, positioned approximately 1 cm distal to the olecranon process, to 240 mm
Hg for five minutes. Images were obtained immediately before forearm occlusion, and
continuously from the final 30 seconds of occlusion until three minutes following the release of
the blood pressure cuff.
After the vasoreactivity test, the participant was asked to mount their bicycle which was
again placed in a high performance, microprocessor controlled indoor trainer (Race Mate Compu
Trainer) and the bike was properly calibrated. The time trial commenced with the participant
pedaling at a speed of 80 to 90 revolutions per minute. Resistance was increased over the first 5
minutes to achieve 80 to 85% of the participant’s estimated heart rate reserve. Before, during and
after the test, heart rate, blood pressure, and ratings of perceived exertion were obtained at five
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minute intervals using a standard sphygmomanometer, Polar heart rate monitor, and Borg’s
perceived exertion scale (RPE, Borg’s 20-point scale) [481], respectively.
Immediately following the time trial the participant was again re-positioned on the
examination table, and the exact same procedures were used to examine brachial artery
vasoreactivity. This test was then again conducted at 20 min in recovery.
5.2.3.3 Data Analyses
The blood markers that were analyzed include: (a) reactive oxygen species, including
peroxynitrite, (b) specific endogenous anti-oxidants such as the enzymes glutathione, glutathione
peroxidase and catalase, (c) nitrosylated hemoglobin, a method for in vivo nitric oxide detection.
It is important to emphasize that nitrosylated hemoglobin have been reported as indicator of the
potential role in transport and delivery of nitric oxide [480]. The biochemical variables were
analyzed using the electron paramagnetic resonance (EPR) spectroscopy.
EPR has the potential to provide unique information on free radicals and other species
with unpaired electrons, because of its unique ability to detect unpaired electron species (reactive
oxygen species, nitric oxide) [482]. In fact, EPR is the most direct and unambiguous method to
measure free radicals and thiols [483]. Under some circumstances the concentration of these
species or their magnetic properties may make it difficult to measure them directly with EPR.
Consequently, a technique termed “spin trapping” has been developed in which a detecting
molecule ( usually termed a “spin trap”, e.g., a nitrone or nitroso compound) is added to the
system, which, upon reaction with a free radical, can form a product that is another free radical
that is considerably more stable that the initial radical [484]. The concentration of nitrosylated
hemoglobin was recorded with an X-band EPR spectrometer. The amount of detected nitric
oxide was determined from the calibration curve for intensity of the EPR signal of erythrocytes
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treated with known concentrations of nitrite (1–25 µM) and Na2S2O4 (20 mM) [485].
The quantification of reactive oxygen species was as follow: cyclic hydroxylamine 1hydroxy-3-carboxy-pyrrolidine (CP-H) was used for the quantification of reactive oxygen
species. During the reaction of CP-H with reactive oxygen species (lifetime more than 4 h),
reducing agent-resistant nitroxide radicals are formed. The amount of trapped reactive oxygen
species was obtained by quantifying the concentration of the corresponding nitroxide radical 3carboxyproxyl (CP). Quantification of reactive oxygen species released from blood samples
(non-stimulated reactive oxygen species formation) was performed after incubation at 37°C for
30 min using 500 µM CP-H and the low-field component of electron spin resonance spectra in
50 µl quartz capillaries (Noxygen Science Transfer & Diagnostics GmbH, Elzach, Germany)
[486].
All brachial artery imaging and analyses were conducted in accordance with the
Guidelines set forth by the Brachial Artery Reactivity Task Force [487]. Images were analyzed
using specifically developed edge-detecting software (Medical Imaging Applications, LLC).
Visual inspection was used to ensure consistent selection of the blood-vessel interface. Arterial
diameters were calculated as the mean distance between the anterior and posterior wall at the
blood vessel interface, with the image in diastole, defined as the peak of the r-wave. Brachial
artery flow mediated dilation was defined as the absolute (mm) and percent change in vessel
diameter from rest to peak dilation, as seen at 45, 60 and 90 seconds following cuff release. The
resolution of the brachial image in the current study allowed for a caliper accuracy of 0.028mm.
The reproducibility of this technique in our laboratory has yielded average mean differences in
brachial artery diameter change for days, testers, and readers of 1.91%, 1.40%, and 0.21mm
respectively, with intra-class correlation coefficients of 0.92, 0.94, and 0.90, respectively [488].
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5.2.4 Statistical Analysis
Data was analyzed using SPSS for Windows (version 15.0). Data was expressed as mean + SD.
To examine the changes in nitrosylated hemoglobin, total reactive oxidative stress, peroxynitrite
and anti-oxidant molecules between baseline, after exercise and during recovery data were
analyzed using ANOVA with repeated measures. A value of p<0.05 was considered statistically
significant.
5.3 Results
5.3.1 Participants Characteristics
Ten aerobically trained men (Age 33.3 ±7.3 years; Height 73.38 ± 2.72 inches; Weight
188.75 ± 17.32 lbs) participated in the study. The majority of the athletes were either regionally
or nationally ranked triathletes. Two of the athletes were strictly cyclists, one was an
ultradistance runner. All athletes had been involved in regular training for at least 3 years, but the
majority had over 5 years of competitive training experience.
5.3.2 Exercise Measures
The group averages for oxygen consumption, ventilation, and respiratory exchange ratios
during the final 10 minutes of the bike trial conducted in visit 1, were 38.51±6 ml/kg/min,
106.55±25.89 l/min, and 1.05±0.04U, respectively. In addition the average heart rate over the
course of the bike trial was 160±12 bpm, and the target heart rate was achieved approximately 5
minutes into the trial for all participants. The average heart rate over the course of the second
bike trial was 157±13 bpm, and was not significantly different from the bike trial in visit 1.
5.3.3 Biochemical Variables
The group averages for all the biochemical variables are presented in Table 5.1. Group
averages for production rate of reactive oxygen species increased from baseline (0.06±0.02
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Units/uL) to peak exercise (0.10±0.05 Units/uL), and return to pre-exercise values after 20
minutes or recovery (0.05±0.03 Units/uL). The group average for peroxynitrite increased from
baseline (0.24 ±0.81 Units/min) to peak exercise (0.31±0.11 Units/min) and returned to preexercise levels after 20 minutes of recovery (0.23±0.10 Units/min).
Table 5.1 Biochemical variables
Biochemical variable
Baseline
Reactive Oxygen Species
0.06±0.02
(Units/uL)
Peroxynitrite
0.24 ±0.81
(Units/min)
Glutathione Peroxidase
97.63±19.28
(nmoles/mg protein/min)
Glutathione assay
13.58±1.52
(nmoles/mg protein)
Catalase assay
5.90-05±2.30
(Units/mg protein/min)
Data are presented as mean ± SD., *p<0.05

Peak exercise

Recovery

0.10±0.05*

0.05±0.03

0.31±0.11*

0.23±0.10

71.94 ±15.93*

100.16 ±25.81

10.62±4.69

18.96±4.37

3.27-05±0.84

5.40-05±1.76

The average for the anti-oxidant glutathione peroxidase decreased from baseline
(97.63±19.28 nmoles/mg protein/min) to peak exercise (71.94 ±15.93 nmoles/mg protein/min)
and returned to pre-exercise values at 20 minutes after recovery (100.16 ±25.81 nmoles/mg
protein/min). The average for the anti-oxidant glutathione was 13.58±1.52 nmole/mg protein at
baseline, 10.62±4.69 nmole/mg protein at peak exercise, and 18.96±4.37 nmole/mg protein after
20 minutes of recovery. In addition, catalase average was 5.90-05±2.30 Units/mg protein/min at
baseline, 3.27-05±0.84 Units/mg protein/min at peak exercise, and 5.40-05±1.76 Units/mg
protein/min into the recovery phase. However, there were no significant changes in glutathione
and catalase.
Unfortunately at this moment we are not able to report the results for the nitrosylated
hemoglobin measurements as was intended due to technical difficulties when the samples were
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analyzed using the electron paramagnetic resonance spectrometry. The major reason was the
insufficient sensitivity of the electron paramagnetic resonance spectrometry used to detect
nitrosylated hemoglobin under basal conditions. The same equipment was used previously to
detect easily approximadetely 400 nM of nitrosylated hemoglobin in rodent blood. However, in
order to detect nitrosylated hemoglobin in human blood (40 - 100 nM) it is required to increase
the sensitivity of equipment up to 10 times. Several strategies were attempted to allow for a
representation of this variable but as of yet to no avail. In particular red blood cells’ packing
through a second centrifuge period was attempted but the sensitivity remained too low for
accurate detection.
5.3.4 Brachial Artery Diameter and Vascular Reactivity
Group averages for the brachial artery diameters before, immediately after and 20
minutes in recovery are depicted in Table 5.2. Group averages for the combined averages for
brachial artery flow mediated dilation (BAFMD) at 45, 60 and 90 seconds post release are also
presented in Table 5.2.
The repeated measure ANOVA for brachial artery diameters yielded a significant main
effect (p=0.0001) indicating a significant increase in brachial artery diameter after forearm
occlusion. However, the ANOVA also revealed a factor by condition effect (p=0.009) indicating
that the increase in brachial artery diameter post-occlusion was only seen in the pre-bike trial and
at 20 minutes after the bike-trial. In contrast, no significant changes in brachial artery diameter
were observed immediately after the time trial, even though there were no significant changes in
the pre-occlusion diameters between conditions.
The ANOVA for brachial artery reactivity yielded a significant condition effect
(p=0.002), with a significant blunted response immediately post bike trial (BAFMD = 0.38%),
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compared to pre bike trial values (BAFMD = 5.24%), and 20 minutes in recovery (BAFMD =
3.93%), indicating a temporal pattern of reactivity.
Table 5.2 Brachial artery diameter and vascular reactivity
Vascular measure
Base Diameter (mm)
45sec Post release (mm)
60sec Post release (mm)
90sec Post release (mm)
BAFMD (%)

Pre
Bike Trial
4.43±0.36
4.60±0.38*
4.64±0.40*
4.67±0.38*
5.24±2.78

Immediately post
Bike Trial
4.68±0.21
4.64±0.24
4.70±0.22
4.71±0.20
0.38±1.17**

20 min after
Bike Trial
4.58±0.23
4.69±0.27*
4.79±0.17*
4.77±0.23*
3.93±1.47

Data are presented as mean ± SD., *p<0.05 vs. base; **p<0.05 vs. Pre Bike and
20min Post Bike trial
The ANOVA for brachial artery reactivity yielded a significant condition effect
(p=0.002), with a significant blunted response immediately post bike trial (BAFMD = 0.38%),
compared to pre bike trial values (BAFMD = 5.24%), and 20 minutes in recovery (BAFMD =
3.93%), indicating a temporal pattern of reactivity.
5.4 Discussion
The major purpose of this study was to examine the effects of an acute bout of exercise
on nitric oxide bioavailability, oxidative stress and anti-oxidants markers, and brachial artery
reactivity. Specifically these dependent measures were examined before, at peak exercise, and at
20 minutes into the recovery phase, in aerobically trained individuals. The two major unique
outcomes of the present study indicate a significant increase in the production rate of reactive
oxygen species and peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at
peak exercise. In addition, brachial artery reactivity revealed a temporal pattern, with a blunted
response immediately after exercise, but near complete recovery after 20 minutes of recovery.
These findings support the a-priori hypotheses, and suggest an acute bout of exercise contributes
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to a significant rise in reactive oxygen stress on the vasculature, which can in part be buffered by
anti-oxidants systems, but may cause temporary blunting of arterial reactivity.
5.4.1 Exercise Measures
The present study utilized a time trial to examine the effects of exercise on pro- and antioxidants and vascular function. The exercise protocol in the present study was similar to the
study by Shing et al., [489]. The average oxygen consumption (VO2) during the bike trial in visit
1 was 38.51±6 ml/kg/min. This average was lower than the subjects in the study by Shing et al.,
[489] who reported a VO2 average of 44.60 ml/kg/min among their participants. The differences
in the VO2 average may in part be due to an older population in the present study (Age= 33 ±7.3
years), compared to Shing et al., [489] (Age= 25±4 Years). Interestingly, a study by Laursen et
al., [490] aimed to compare the cycling performance of cyclists and triathletes found that cyclists
may be able to perform better than triathletes in cycling time-trial events. This finding is
important in trying to explain the VO2 differences. As mentioned before, the participants in the
study by Shing et al., [489] were all trained cyclists, whilst the majority of the participants in the
present study were triathletes.
Regardless whether the VO2 averages are somewhat lower than perhaps expected, the
heart rate responses were consistent with an 80 to 85% of the participant’s heart rate reserve. In
doing so, all the participants were exercising at the same intensity, which mimicks a competitive
ride as reported by most of the riders. The decision to use the heart rate reserve method in this
population is based on work done by Lounana et al., [491]. These investigators stated that the use
of percentage heart rate reserve is a better indicator of exercise intensity among cyclists. Finally,
the findings that the averages heart rate did not show significant differences between the bike
time trials; provides strong evidence that both tests were performed equally as planned.
164

5.4.2 Reactive Oxygen Species
This study found that the production rate of reactive oxygen species and the pro-oxidant
peroxynitrite increased from baseline to peak exercise and then returned to pre-exercise values
after 20 minutes of recovery. Previous studies that have investigated oxidative stress markers
among trained individuals report similar trends. For example, Shing et al., [489] found an
increase in biomarkers of oxidative stress among trained cyclists after high-intensity exercise.
The major aim of the study by Shing et al., [489] was to determine the influence of consecutive
days of high-intensity aerobic bike exercise on oxidative stress markers. The blood samples were
taken 10 minutes before and 5 minutes after the exercise. Their results indicated a significant
increase (18%) in plasma malondialdehyde post-exercise. In addition, Lovlin et al., [492]
investigated the relationship between exercise intensity and lipid peroxidation in moderately
trained males. These investigators reported that maximal exercise resulted in a 26% increase in
plasma malondialdehyde post-exercise. These previous studies clearly show a similar pattern,
albeit to a lower magnitude, as reported in the present study, where the production rate of
reactive oxygen species increased 66%, and peroxinitrite 29%, from baseline to peak exercise.
Interestingly, the production rate of reactive oxygen species and peroxinitrite were not different
from baseline values at the 20 minutes mark in recovery. This stands in contrast with several
studies which report that secondary measures of oxidative stress remain elevated for a period of
time after exercise. For example, Michailidis et al., [493] reported that lipid peroxidation, as
measured by thiobarbituric acid reactive substances was elevated immediately and up to 3 hours
after 45 minutes of running on a treadmill at an intensity corresponding to 70-75% of subjects’
VO2max. The subjects in the study by Michailidis et al., [493] were low to moderately trained
.Further confirmation that secondary measures of oxidative stress remain elevated comes from a
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study by Alessio et al., [494]. These investigators also reported an elevated (46%) in plasma
thiobarbituric acid reacting substances among moderately trained individuals after 30 minutes
submaximal exercise. Participants in a study by Watson et al., [495] utilized trained individuals
who ran for 30 minutes at a submaximal speed corresponding to 60% of their VO2max. Again,
Watson et al., [495] reported that plasma lipid peroxidation, as measured by F2-isoprostanes
concentration (marker of oxidative stress) was significantly higher after the submaximal bout of
exercise (38%), and remained significantly elevated one hour into recovery (31%). However, the
findings in the current study were similar to those observed by Steensberg et al., [496]. Those
investigators reported that the concentration of plasma F2- isoprostanes increased approximately
1.6-fold in response to a treadmill exercise, but declined towards pre-exercise values within the
first hour of recovery. Obviously the differences in observations between studies are often
secondary to study design, study population and methodological issues, and are therefore
difficult to reconcile. However, the present study is particularly unique in that the production rate
of reactive oxygen species was a direct measure rather than a secondary marker of oxidative
stress.
In fact, it is important to recognize that many of the referenced studies have indeed used
secondary biomarkers to report oxidative stress (e.g. plasma malondialdehyde, thiobarbituric
acid reactive substances, and F2-isoprostanes). Arguably a major problem with those studies and
methods is that the measures of oxidative stress are indirect and reflect tissue damage rather than
production of oxidative stress. Consequently, many of those studies lack specificity. For
example, it is well-known that thiobarbituric acid reactive substances react with a wide variety of
compounds, including sugars and DNA [497]. Indeed, there is concern about the validity of
thiobarbituric acid reactive substances assay in detecting lipid perodixation in vivo, because
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thiobarbituric acid reactive substances assay is not specific to malondialdehyde, and lipid
peroxidation is not the exclusive source of malondialdehyde [498]. Furthermore, oxidation
products are typically present at low levels in biological material. Finally, normal concentrations
of F2-isoprostanes in human plasma have been proposed to range from 5 to 40 pg·mL-1 [499].
However, the clinical significance of concentrations outside this range has not been described
because no direct casual relationship between F2-isoprostanes and exercise performance has been
found [499]. Such assays therefore are prone to artifacts and cannot provide strong evidence of
the actual oxidative stress in vivo [497].
The unique contribution of the present study is that the production rate of reactive oxygen
species was examined before, at peak exercise, and 20 minutes after recovery. This is the first
such study in exercising humans, and may represent a more direct method of determining the
total pool of reactive oxygen species produced under stressful conditions, such as an acute bout
of exercise. However, some caution is needed at this point. The present study reports the
production rate of reactive oxygen species as measured from the red blood cell. Obviously future
studies must determine if a change in the production rate in the red blood cell is indeed a
reflection of other physiological systems that may also produce oxidative species at a high rate
during exercise. In addition, the rate of production of the reactive oxygen species is not taken in
real-time but is measured after obtaining a blood sample and immediately adding the sample to a
buffer and frozen in liquid nitrogen.
Given these possible limitations, it must also be appreciated that reactive oxygen species
can be produced during exercise from several potential cellular sources. Some sources may be
more important that others in a certain organ, at a specific time, or with a specific exercise mode.
However, these sources are not mutually exclusive and can be activated simultaneously [500]. In
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fact, extensive reviews regarding the sources of reactive oxygen species during exercise [501]
clearly suggests a major source of free radical production during exercise is the mitochondrial
electron transport chain [497]. Indeed, superoxide is produced during the oxidation of reduced
nicotinamide adenine dinucleotide to oxidize nicotinamide adenine dinucleotide [502]. Under
normal metabolic conditions, it has estimated that for every 25 oxygen molecules reduced by
normal respiration, one free radical is produced [503]. Given that the rate of whole body oxygen
consumption during exercise may increase 10–15 fold, and oxygen flux in an active muscle may
increase about 100 fold [504], the rate of production of several oxidative species is sure to rise.
With this rise in production a greater number of these species are sure to leak out of the electron
transport chain [503] and leave surrounding tissues vulnerable to their damaging effects. Several
candidates of oxidative species have been identified, including hydrogen peroxide, hydroxyl
radicals, and others [505]. Approximately 4% of electrons that enter the respiratory chain lead to
the formation of superoxide, whereas hydrogen peroxide is produced after the spontaneous or
superoxide dismutase-catalyzed dismutation of superoxide as well as many others enzymatic
reactions. Unlike superoxide, which remains at the site of production, hydrogen peroxide can
diffuse across membranes and through the cytosol [506].
More recently, nitric oxide has also been linked to the formation of pro-oxidants. In fact,
at higher levels of production, nitric oxide reacts with radicals such as superoxide to form
peroxynitrite, a powerful pro-oxidant [507]. Interestingly in the present study a significant rise in
the production rate of peroxynitrite was seen from pre- to peak exercise, and returned to preexercise levels at 20 minutes into recovery. This provides direct evidence of a significant rise in
pro-oxidants during exercise, probably subsequent to a higher production of both nitric oxide and
superoxide.
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In addition to mitochondrial production of oxidative species, some studies have reported
an extramitochondrial source of free radicals. There is significant amount of information on
putative reactive species that could contribute to exercise-induced oxidative injury or postexercise vascular injury [497]. Central to such oxidative damage are xanthine dehydrogenase and
oxidase and calcium. For instance, Vina et al., [508] have hypothesized that activation of
xanthine oxidase could be important in the generation of free radicals during exercise. Xanthine
dehydrogenase is found mainly in endothelial cells of blood vessels and in skeletal and cardiac
muscle [497]. Xanthine dehydrogenase may convert nicotinamide adenine dinucleotide to
reduced nicotinamide adenine dinucleotide, whereas xanthine oxidase utilizes oxygen and
xanthine, a purine degradation product, to produce superoxide and hydrogen peroxide. In
addition, xanthine oxidase catalyzed reactions have been well established as one of the major
sources of free radical generation in the ischemia and reperfused heart [509]. Duarte et al., [510]
pointed out that the endothelium might contribute to muscle damage induced by exercise. These
investigators stated that the xanthine oxidase located in capillary endothelium is one of the
possible sources for the production of reactive oxygen species. In addition, Vina et al., [511]
showed that inhibition of xanthine oxidase with allopurinol protects against exercise-induced
oxidation of glutathione in humans.
Finally, an increase in the release of calcium by pro-oxidants stimulates calciumdependent enzymes such as calcium-dependent proteases, nucleases, and phospholipases, which
subsequently trigger apoptosis of the cells [512]. Once calcium efflux has been triggered, a series
of common pathways of apoptosis are initiated, each of which may be sufficient to destroy the
cell [512]. Given the rise in the production rate of pro-oxidants from the red blood cell as shown
in this study, this is yet another extramitochondrial source of free radicals. Future studies must
169

determine if the production rate of free radicals from the red blood cell is indeed similar, or at
least a reflection of other free radical generating sources.
It is important to reflect on the necessity of the production of reactive oxygen species in
the human body. Certainly not all effects of these pro-oxidants are negative. In fact they can be
beneficial to living systems [475]. The beneficial effects of reactive oxygen species occur at
low/moderate concentrations and involve physiological roles in cellular responses to noxia; for
example in defense against infectious agents and in the induction of a mitogenic response [474].
On the other hand, the harmful effect of free radicals may contribute to biological damage and is
termed oxidative stress [476]. Indeed, these radicals can cause damage to cardinal cellular
components such as lipids [513] proteins [514] and nucleic acids [515].
In summary the present study indicates a significant rise in pro-oxidants with exercise in
trained individuals, which is quickly resolved within 20 minutes of recovery. These data suggest
a potential increase in vulnerability to oxidative stress with exercise, but only for a limited time
perhaps indicating a significant ability to buffer against oxidative species.
5.4.3 Anti-oxidants
It is, indeed, imperative to emphasize that oxidative status is controlled by a wide
spectrum of exogenous and endogenous anti-oxidants [473]. In general, the body has adequate
anti-oxidant reserves to cope with the production of reactive oxygen species under most normal
physiological conditions. For example, the system consists of anti-oxidant vitamins, glutathione
and thiols, and anti-oxidant enzymes [502]. Each of these anti-oxidants plays a unique role in the
cell and complements each other functionally. Furthermore, inter-organ transport of certain antioxidants is likely to occur. These anti-oxidant protection systems preserve homeostasis for
normal cell functions at rest and perhaps during mild exercise [501]. However, when reactive
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oxygen species production is excessive, or anti-oxidant capacity insufficient, oxidative stress will
develop, potentially leading to cellular damage. Indeed, the extent of oxidative damage during
physical exercise is determined not only by the level of free radical generation, but also by the
defense capacity of anti-oxidants.
The possible mechanisms by which anti-oxidants protect against pro-oxidants are
complex and multifactorial [516], and they may include; (a) prevention of reactive oxygen
species formation, (b) interception of reactive oxygen species attack by scavenging the reactive
metabolites and converting them to less reactive molecules and/or by enhancing the resistance of
sensitive biological targets to reactive oxygen species attack, (c) avoiding the transformation of
less reactive oxygen species (e.g., superoxide ) to more deleterious forms (e.g., hydroxyl), (d)
facilitating the repair of damage caused by reactive oxygen species and triggering the expression
of genes that encode anti-oxidant proteins, and (e) providing a favorable environment for the
effective functioning of other anti-oxidants (e.g., as a cofactor or by acting to maintain a suitable
redox status) [517]. Therefore examination of a disturbance in the equilibrium status of prooxidant/anti-oxidant reactions in living organisms is quite important to determine the organism’s
vulnerability [474].
As discussed above, the present study clearly indicates that the oxidative stress increases
with exercise, but quickly returns to pre-exercise levels suggesting the overall exposure to the
pro-oxidants is short. Importantly this study also reports that some anti-oxidant systems are
modified during and after exercise. In fact, glutathione peroxidase concentrations decreased from
baseline to peak exercise and then returned to pre-exercise values at 20 minutes of recovery.
However, no such changes were noted for catalase and glutathione. The manner in which antioxidants operate will be briefly discussed in this next section. Glutathione (gamma171

glutamylcysteinylglycine) is a tripeptide of glycine, glutamic acid and cysteine that plays a
central role in metabolic pathways, as well as in the anti-oxidant system of most aerobic cells.
Indeed, glutathione is the most abundant non-protein thiol source in the cell and serves multiples
functions in protecting tissues from oxidative damage and keeping the intracellular environment
in the reduced state [518]. Glutathione acts as an anti-oxidant both intra- and extracellularly and
is required as a coenzyme by a variety of enzymes including glutathione peroxidase, glutathione
S-transferase and thioltransferase [502]. In the red blood cell, the reduced form of glutathione is
vital in maintaining hemoglobin in a reduced state and hence protecting the cells from oxidative
damage [519]. In addition, glutathione is involved in detoxification of hydrogen peroxide
through glutathione peroxidase. Glutathione peroxidases are selenoenzymes which catalyze the
reduction of hydroperoxides in the presence of glutathione. Hydrogen peroxide, a reactive
oxygen species, is a harmful by-product of many normal metabolic processes. In order to prevent
damage, it must be quickly converted into other, less dangerous substances [520]. Both,
glutathione peroxidase and catalase (an intracellular enzyme) are frequently used by cells to
rapidly catalyze the decomposition of hydrogen peroxide into less reactive gaseous oxygen and
water molecules [520]. In addition, glutathione peroxidase and catalase provide the primary
defense against reactive oxygen species generated during exercise, and activities of these
enzymes are known to increase in response to exercise in both animal and human studies [521].
In regard to our findings, previous studies [522] have also reported a decrease in
glutathione peroxidase after an acute bout of exercise. For example, the study by Bloomer et al.,
[523] reported a decrease in glutathione peroxidase immediately following exercise, and it
returned to pre-exercise values at 60 minutes into the recovery phase. This study was conducted
among trained individuals performing an aerobic cycling activity for 30 minutes. The same
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investigators [523] suggested that after exercise, hepatic glutathione (coenzyme for glutathione
peroxidase formation) supply may not be sufficient to match the enhanced use resulting in
reduction of blood glutathione concentration. In addition, the decrease in anti-oxidant enzyme
activity observed may reflect allosteric downregulation of the enzymes in addition to enzyme
inactivation attributable to overwhelming oxidative stress. Indeed, Elosua et al., [524] have also
shown that there is a transient decrease in whole-blood glutathione peroxidase after 30-min
exercise cycling bout, and a tendency to recover the basal values within two hours. These
investigators [524] concluded that exercise-induced reactive oxygen species production leads to
the consumption of enzyme activity with a subsequent rebound recovery. Clearly, the above
studies reported a decrease in glutathione peroxidase immediately after an acute bout of exercise.
Furthermore, in the present study, the anti-oxidant catalase did not exhibit significant
changes after the acute bout of exercise. This finding is consistent with most of the previous
studies concerning muscle catalase [500]. However, studies that have examined the effect of a
single bout of aerobic exercise on blood catalase activity have reported mixed results. Some of
them have reported an increase [522], whilst others reported no differences [478]. It is important
to notice that our study was performed by aerobically trained individuals that did not exhibit
significant changes in the anti-oxidant catalase. On the contrary, those studies that have reported
an increase in catalase after an acute bout of exercise [522] were done among untrained
individuals performing exhaustive aerobic exercise of moderate duration. The discrepancy
among the results may be explained by the trained status of the participants. Indeed, several
studies have found that trained individuals responded differently to oxidative stress induced by
an acute exercise bout compared with untrained subjects [478]. In that regard, Vollaard et al.,
[498] suggested that the degree of oxidative stress may be attenuated by chronic aerobic and
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anaerobic training, through an increase in endogenous anti-oxidant production, a decrease in free
radical generation, or a combination of both processes. Furthermore, individuals engaged in
long-term heavy exercise become more resistant to oxidative stress mainly due to the adaptation
of their anti-oxidant defense systems [521].
In addition, Chakraborti et al., [525] have reported that an acute bout of exercise
increases the activities of anti-oxidant enzymes, including glutathione peroxidase and catalase in
skeletal muscle, heart and liver, which may result in a transient reduction in their blood
concentration. Indeed, plasma and muscle glutathione peroxidase content may be decreased
eventually during prolonged exhaustive exercise when hepatic glutathione reserve is diminished
and glutathione peroxidase use exceeds glutathione uptake [526]. Finally, Chakraborti et al.,
[525] concluded that the threshold and magnitude of activation appear different among enzymes
and tissues. The mechanisms by which anti-oxidant enzymes are activated within a relatively
short period of time during exercise are largely unknown. However, reactive oxygen species
have long been postulated to stimulate the expression of anti-oxidant enzymes [504].
The findings of the present study suggest that the anti-oxidant defenses among
aerobically trained individuals are critical in the efforts to buffer the increase in the rate of
production of pro-oxidants. In addition, the present findings clearly show a significant rebound
effect following exercise in aerobically trained individuals. However, understanding the
mechanisms involved in the increased anti-oxidant enzyme activity during exercise remains a
great challenge. Obviously, further studies are needed to determine if this apparent rebound is
similar in less trained individuals or those who are older or suffering from chronic disease.
Evidence of the beneficial effect of physical exercise on minimizing oxidative stress might be
related to increased anti-oxidant defenses [527]. In the same manner, Franzoni et al., [528] have
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demonstrated that chronic endurance training is associated with increased plasma anti-oxidant
activity in young and older men.
In summary, the current study suggests that some anti-oxidant defenses in aerobically
trained individuals are critical in the efforts to buffer the increase in the rate of production of prooxidants. However, it appears that some anti-oxidant systems are depleted at peak exercise, but
rebound to pre-exercise levels within 20 minutes of recovery in aerobically trained individuals.
5.4.4 Brachial Artery Diameter and Vascular Reactivity
A unique objective of this study was to determine the effects of an acute bout of exercise
on brachial artery diameter and reactivity. The basis for this examination was evidence from
other studies that an acute assault to the vasculature results in a transient reduction in vascular
function as defined by brachial artery flow mediated dilation. For example, several studies
indicate that a single high fat [529] and or high glucose meal [530], cigarette smoke [531], and
mental stress [532] transiently blunt vascular function.
Interestingly, no studies have examined the effects of an acute bout of exercise on
vascular function in trained individuals, despite significant evidence that chronic exercise
training improves vascular health. So the idea that chronic consumption of high fat, high glucose,
tobacco, and mental stress may have a chronic detrimental effect on the vasculature, chronic
exercise training appears to benefit vascular health. Thus the examination of potential factors that
may be produced during an acute bout of exercise may eventually provide insight about the
manner in which exercise may protect the vasculature. To that extent the discussion so far has
centered on the effects of an acute bout of exercise on pro- and anti-oxidants. This section of the
discussion will center on the vascular responses. The unique finding of the study is a transient
reduction in brachial reactivity at peak exercise which is restored within 20 minutes.
175

This is the first study to show a blunted response in brachial vascular reactivity
immediately following acute exercise in aerobically trained individuals. In fact, only one other
study [533] has reported on post exercise vasoreactivity. In that study the authors report a 2.3
fold reduction in brachial vascular reactivity among persons with intermittent claudication
following a single bout of maximal treadmill exercise. Interestingly along with the reduction in
vasoreactivity (from 8.5±0.9 to 3.7±0.8%, p<0.01), the authors found an increased plasma levels
of thiobarbituric acid-reactive substances (from 1.93±0.06 to 2.22±0.1 nmol/ml, P<0.02) and of
soluble intercellular adhesion molecule-1 (from 282±17 to 323±19 ng/ml, P<0.01). More
importantly, vitamin C prevented the acute, systemic impairment in endothelial function induced
by maximal exercise, suggesting a role for anti-oxidant therapy [533]. In fact, these investigators
recommend that there is a need for future studies aimed at assessing whether chronic oral
treatment with anti-oxidant agents improves systemic endothelial function in patients with
intermittent claudication.
The potential mechanism that a change in pro-oxidant/anti-oxidant balance could mediate
vascular reactivity is obviously pertinent to the current study as well, and will be discussed in
greater detail in the next section of the paper. However, prior to this discussion it is also critical
to discuss additional factors which could have contributed to the temporal pattern, of
vasoreactivity during and following exercise.
Generally vasoreactivity as defined by brachial artery flow mediated dilation is thought to
be in part controlled by endothelial derived vasodilators (esp. nitric oxide), local metabolites,
autonomic influences, and structural components of the vessel [534]. To that extent, a change in
or utilization of nitric oxide immediately after exercise could indeed affect vasoreactivity.
However, it is important to appreciate that previous data from this laboratory consistently reports
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a significant inverse relationship between arterial diameter and vasoreactivity [535]. Given the
evidence that the brachial artery diameter after exercise was larger than the pre-exercise
diameters (p<0.05) would in part explain why the reactivity would be less. However, this does
not fully explain the loss of reactivity as the brachial diameters immediately after exercise were
not significantly different from the 20 minute recovery mark.
Probably the major factor that contributed to a larger artery immediately after exercise is
a dramatic increase in blood flow and/or flow velocity. In fact, Tanaka et al., [536] reported that
the brachial artery is exposed to an increase in blood flow even though work is performed by the
lower extremities. This augmented blood flow, through local regulatory mechanisms, causes
vasodilation; which can persist for at least one hour after cessation of exercise [537], depending
on the exercise intensity. Thus one could argue that the reason for the reduced vasoreactivity
immediately after exercise is due to the artery being close to its “maximal” physiological value.
The lack of response may therefore be a consequence of a “ceiling effect”, rather than other
factors.
In summary, the present study indicates that brachial artery reactivity revealed a temporal
pattern, with a blunted response immediately after exercise, but near complete recovery after 20
minutes of recovery. These findings are consistent with other studies that report that certain
stressors may contribute to decreased vascular performance for a period of time. Future studies
are necessary to further determine why exposure to some stressors (e.g. high triglyceride, and
hyperglycemic meals, and cigarette smoke) causes vascular erosion, and other stressors (such as
exercise) contributes to improved vascular function. Within such an exploration it is
hypothesized that the maintenance and/or return to a favorable balance of pro- and anti-oxidant is
critical.
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5.4.5 The Connection between Pro- and Anti-oxidants and Vascular Reactivity
In a recent provocative review by Deanfield et al., [9] perturbations to endothelial
homeostasis was suggested as a major factor in the development of arterial disease. A major
point of discussion within the review was endothelial activation. Endothelial activation [9] was
defined as a switch from a quiescent phenotype toward one that invokes activation of molecular
machinery that result in the expression of chemokines, cytokines, and adhesion molecules
designed to interact with leukocytes and platelets and target inflammation [538]. The
fundamental change involved in this process is a switch in signaling from a nitric oxide-mediated
silencing of cellular processes toward activation by redox signaling. Reactive oxygen species in
the presence of superoxide dismutase, lead to generation of hydrogen peroxide, which, like nitric
oxide, can diffuse rapidly throughout the cell and react with cysteine groups in proteins to alter
their function [9]. However, because of the different chemistry involved, this results in very
different consequences, such as phosphorylation of transcription factors, induction of nuclear
chromatin remodeling and transcription genes, and protease activation [9]. It is intriguing that
endothelial nitric oxide synthase, which normally helps maintain the quiescent state of the
endothelium, can switch to generate reactive oxygen species in appropriate circumstances as part
of endothelial activation [9]. This is termed endothelial nitric oxide synthase uncoupling, and
results in superoxide formation if the key cofactor tetrahydrobiopterin is not present or
generation of hydrogen peroxide if the substrate L-arginine is deficient [539]. The ability of
endothelial nitric oxide synthase to regulate both the quiescent and activated endothelial
phenotype puts this enzyme at the center of endothelial homeostasis [9], and the maintenance of
vascular health. In fact, it is hypothesized that prolonged and/or repeated exposure to factors that
ultimately exhaust the protective effect of endogenous anti-inflammatory systems within
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endothelial cells, will contribute to endothelial dysfunction, loss of endothelial cell integrity,
accelerated cell senescence, and detachment into the circulation.
Central to this paper is the manner in which an acute bout of exercise can alter
endothelial homeostasis. This information is thought to be critical in developing a better
understanding of how chronic exercise may help maintain vascular health as implied from the
available literature [540]. The present study clearly shows an increase in the production rate of
reactive oxygen species and to some extent a reduction of anti-oxidant systems at peak exercise.
In fact, examination of the ratio between glutathione peroxidase and reactive oxygen species (Pre
Exercise: 1701±485; Peak Exercise: 669±221; 20 min Recovery: 2093±1543, p<0.05), and
glutathione peroxidase and peroxynitrite (Pre Exercise: 515±415; Peak Exercise: 225±71; 20 min
Recovery: 471±143, p<0.05) shows a significant decline in these ratios at peak exercise,
suggesting a significant change of the balance of pro-oxidant/anti-oxidants, in favor of oxidative
stress. Purportedly such a change in oxidative stress may be sufficient to trigger endothelial
activation, and contribute to a more vulnerable endothelial environment. Obviously, it is
recognized that the derived ratio within this study, is merely a gross measure of the balance of
pro-oxidant/anti-oxidants, and only serves as a point of illustration. However, the fact the present
study also shows an association between the levels of glutathione peroxidase and brachial artery
flow mediated dilation (r=0.578, p<0.05), and reactive oxygen species and brachial artery flow
mediated dilation (r=-0.431, p<0.05) certainly keeps the hypothesis alive that the prooxidant/anti-oxidant balance is a critical component in maintaining vascular reactivity.
Theoretically the ability of an acute bout of exercise to trigger endothelial activation
seems to defy intuition; in the face of a plethora of evidence of the benefits of exercise on the
cardiovascular system is undeniable [541]. Thus, the current finding beckons the question how
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chronic exercise protects the vasculature. Obviously, the present study was not designed to
answer this question, but future study designs should attempt to examine this directly. However,
it is perhaps within the discretion of this paper to speculate how chronic exercise may eventually
produce a protective endothelial environment. Using this discretion, it is perhaps important to
revisit Selye’s theory of stress-response-adaptation [542]. Applied to vascular physiology this
theory suggests that an acute exercise stress, when applied to the vascular system, will initially
contribute to a period of reduced function. However, if the exercise stress is repeated over a
period of time, the vasculature adapts to allow for an increased delivery of blood flow to active
skeletal muscle, thereby contributing to a greater functional ability. Thus the initial decline in
vascular performance with acute exercise could be a consequence of a perturbation of endothelial
homeostasis. In fact, the exercise-induced endothelial activation may serve as a significant
trigger for vascular modification, similar to exercise-induced mRNA activation, which may lead
to skeletal muscle hypertrophy [543]. Typically, when exercise-induced activation is too frequent
or infrequent, too excessive or not intense enough, or too long or not long enough the process
may lead too insufficient adaptations or maladaptation. It is subsequently no surprise that the
optimal dose-response for exercise training among different populations is not entirely
understood.
However, it is interesting to consider studies that reported less evidence of oxidative
damage among trained individuals [516]. Moreover, Leeuwenburgh et al., [497] reported that an
acute bout of exercise in untrained subjects’ increased oxidative stress considerably. These
studies imply that chronic exercise training may in fact create an environment that allows for the
maintenance of endothelial balance. Future studies are needed to further appreciate this
speculation. It is intriguing that the subject’s in the present study showed a considerably rebound
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effect in recovery from exercise, in terms of pro-oxidant/anti-oxidant balance and vascular
reactivity. This suggests that the exposure to oxidative stress was significant but short-lived in
these subjects. Further data is needed to appreciate whether this rebound is different in less
trained individuals. In addition, it is intriguing to speculate what might be seen in individuals
who already have endothelial activation pre-exercise, due to risk factors, or disease, or in older
individuals. Thus this study may have set the stage for a series of additional experiments with
endothelial homeostasis as its focus.
In that regard, a review by Lum et al., [544] acknowledged that acute and chronic oxidant
stress to the vascular endothelium is a serious causative factor of vascular endothelial
dysfunction (or “endothelial activation”), and plays an important role in the pathophysiology of
several vascular diseases. Indeed, endothelial activation may endanger normal synthesis and
release of nitric oxide by endothelial cells. However, under ‘normal’ physiological conditions,
reactive oxygen species production is low and the endogenous anti-oxidant systems are sufficient
to maintain the pro-oxidant/anti-oxidant balance. This vital action would uphold superoxide
production and elimination under tight control, thus preventing the breakdown of nitric oxide
[545]. On the other hand, in disease states in which the production of reactive oxygen species is
increased and/or the anti-oxidant capacity of the vessel is decreased, nitric oxide is transformed
to peroxynitrite, resulting in inhibition of endothelial-dependent relaxation [546].
Interestingly, it has been reported that reactive oxygen species are also frequently
elevated in patients with one or more cardiovascular risk factors, for example in smokers or in
patients with hypercholesterolemia [545]. Thus one could argue that the increased production of
reactive oxygen species in individuals at risk for disease or already with a disease is a key
component in the pathogenesis of endothelial activation. In addition, one could speculate that
181

any further overwhelming exposure to oxidative stress may compromise seriously the already
tenuous pro-oxidant/anti-oxidant balance in these individuals.
Likewise, there is a growing amount of evidence that aging is associated with increasing
systemic imbalance between the generation and the scavenging of pro-oxidants [546].
Furthermore, it has been proposed that increased oxidative stress may play a role in premature
aging [547]. It is important also to emphasize that a progressive impairment of endothelial
vascular function, nitric oxide related, is a peculiar aspect of the physiological aging process
[548]. Thus it seems to be an important interaction between age-associated pro-oxidant/antioxidant balance and the ability of vasculature to preserve nitric oxide bioavailability. Once again,
one could suggest that endothelial activation, as reported in disease states, is also a keystone in
the age-associated changes in humans.
Arguably, it could be speculated that conditions where endothelial activation is already
present (e.g. end-stage chronic diseases) oxidative stress on the vasculature is chronic rather than
acute. Such a condition could lead to a chronic imbalance and place individuals at great risk for
the consequences of such imbalance. In such situations the use of exercise may in fact be
counterproductive as it would merely add to the oxidative stress rather than serve as a stimulus
for adaptation. However, given the plethora of evidence of the beneficial effects of chronic
exercise in many disease states [549] the threshold where exercise training is harmful appears to
be set quite high.
In summary, the present study reports a significant increase in pro-oxidants, a decrease in
anti-oxidants, suggesting a change in the environment that may trigger endothelial activation.
Moreover, the study reports a blunted brachial artery reactivity at peak exercise. Interestingly,
the decline in pro-oxidants and return to pre-exercise levels for anti-oxidants and vasoreactivity
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implies a rapid return of endothelial homeostasis, within 20 minutes after exercise within these
trained individuals. Therefore, the present study provides an excellent model to study the
dynamic balance between pro-oxidant challenge and anti-oxidant defense in the biological
system.
5.4.6 Limitations of the Study
As with all studies, certain limitations prevent stronger inferences at this time. Generally,
limitations are a consequence of the study design, study population and methodologies. The
present study limitations within each of those categories will be briefly discussed.
In regards to the study design, there is no doubt that the use of only three measures to
detect a pattern in biological systems is a limitation. A true detection of a temporal pattern of any
system must involve more data points. However, due to feasibility issues this first ‘look-andsee’-study elected to examine three time points. It is recognized future studies are needed to
examine the inferred pattern discussed within this paper with greater care.
In regards to the selected participants, this study is certainly limited in scope. A stronger
design may have been one that compared individuals with different fitness levels or a wider age
range. The basis of the selection was one of convenience in terms of recruitment, finances, and
internal review board concerns. Despite this limitation, the current study did find consistency
within the responses among the subjects. Clearly this consistency in the response gives the study
a lot more strength. It is also important to understand that the selection of the participants was
done with the knowledge that the participants were willing to push themselves through an
arduous protocol that involved blood sampling at high levels of exercise. It was thought that this
strategy may allow for the greatest chance to see a consistent response as these athletes are
generally used to such high levels of performance. Obviously, it is important to take the next step
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and examine these responses among a greater number of populations where vascular issues can
be of major concern as it relates to physical performance.
Finally, the inability to accurately quantify the changes in nitrosylated hemoglobin, due
to technical difficulties experienced with the electron paramagnetic resonance spectroscopy
equipment, merely allows us to indirectly discuss what is believed to be happening with
endothelial balance. Several strategies were attempted to allow for a representation of this
variable but as of yet to no avail. Nevertheless, it is important to reinforce that this study is
reporting peroxynitrite, (interaction of superoxide with nitric oxide). This biochemical variable
may in some way provide some insights of the activities of superoxide and nitric oxide. Although
these limitations, the present findings regarding the dynamics of the pro-oxidant /anti-oxidant are
quiet exciting and deserve future follow up.
5.4.7 Conclusion
The major purpose of this study was to examine the effects of an acute bout of exercise
on nitric oxide bioavailability, oxidative stress and anti-oxidants markers, and brachial artery
reactivity. Specifically these dependent measures were examined before, at peak exercise, and at
20 minutes into the recovery phase, in aerobically trained individuals.
The two major unique outcomes of the present study indicate a significant increase in
reactive oxygen species and peroxynitrite, and a decrease in the anti-oxidant glutathione
peroxidase at peak exercise. In addition, brachial artery vasoreactivity revealed a temporal
pattern, with a blunted response immediately after exercise, but near complete recovery after 20
minutes of recovery.
These findings are quiet important if we take in consideration that increased vascular
oxidative stress represents a major cause of reduced endothelial nitric oxide bioavailability, and
184

it compromises the pro-oxidant/anti-oxidant balance. Clearly, the present study provides an
excellent model to study the dynamic balance between pro-oxidant challenge and anti-oxidant
defense in the biological system.
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Chapter 6
Conclusion
Cardiovascular diseases remain the leading cause of death in the United States and most
western countries [11]. Indeed, cardiovascular disease is the underlying cause of death for 36.3%
of all deaths in 2004, or 1 of every 2.8 deaths in the United States. Among these cardiovascular
diseases, coronary heart disease caused 1 of every 5 deaths in the United States in 2004 [11]. An
estimated 79 million American adults (1 in 3) have 1 or more types of cardiovascular disease. Of
these, 37 million are estimated to be age 65 or older [11]. Finally, the economic burden of
cardiovascular disease is enormous [12], with the costs of cardiovascular disease totaling an
estimated $352 billion dollars in the United States, in 2004 [12].
Early identification of risk factors and subsequent risk factor modification represents an
important tool to fight back and try to decrease the incidence and prevalence of cardiovascular
diseases. Among the modifiable behaviors that increase risk of cardiovascular disease are
cigarette smoking, high blood pressure, obesity, and physical inactivity. Interestingly, exercise
training is an excellent and beneficial strategy to improve overall health. In fact, epidemiologic
studies have shown that physical activity reduces cardiovascular morbidity and mortality in the
general population [549-551], and in patients with coronary artery disease/myocardial infarction
[13,14]. The evidence clearly shows that regular exercise has a favorable effect on many
established risk factors for cardiovascular disease. For example, exercise training is associated
with beneficial changes in blood pressure, lipid metabolism, glucose metabolism, neurohormonal
factors, weight loss, etc. [552]. In addition, exercise training improves muscular function and
strength, the ability to utilize oxygen (“maximal oxygen consumption or aerobic capacity”),
muscle blood flow, and many other physiologic systems. Furthermore, although the effect of an
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exercise program on any single risk factor is generally small, the effects of continued, moderate
exercise training on overall cardiovascular risk, when combined with other lifestyle
modifications (e.g. proper nutrition, smoking cessation), can be dramatic [553].
Nevertheless, it is important to emphasize that despite the fact that exercise training is
beneficial; the mechanisms underlying the protective effect of physical activity on cardiovascular
disease are still not fully understood. It is, however, clear that there are distinct changes in the
vasculature, which could contribute to the protective effect of physical activity on cardiovascular
disease [554]. In that regard, the vascular benefits of long-term physical activity appear to be
mediated in part by improvements in endothelial structure and endothelial function in the
systemic, coronary, and pulmonary beds [528,555], as well as by increased bioavailability of
nitric oxide [556,557]. Indeed, several studies have shown that regular physical training
enhances endothelium-dependent vasodilation in the forearm and coronary circulation in patients
with hypertension and patients with coronary heart disease as well in healthy individuals
[13,194,558].
Thus one could argue that preserving healthy endothelial function may play a major role
in vascular tone, vascular smooth muscle proliferation and migration, inflammation, innate
immunity, and anticoagulation [557]. In fact, impaired endothelial function has been associated
with several risk factors for the development of atherosclerosis [554], and is associated with a
significantly higher incidence of cardiovascular events [559]. Given the changes in the
endothelium are associated with these events serial measures of markers of endothelial function
may prove to be important in monitoring individuals’ risk. In that regard, high-resolution
ultrasound has been used as a non-invasive technique to assess endothelial function in peripheral
arteries [560]. Indeed, non-invasive evaluation of brachial artery flow-mediated dilation has
187

emerged as a useful tool to study vascular function. This method assesses the ability of the
endothelium to dilate in response to shear-induced increase in nitric oxide. The dilatory response
associated with increased flow is thought to be endothelium dependent, and is subsequently used
as a marker of endothelial function. For example, it has been reported that brachial artery flow
mediated dilation is reduced in the presence of numerous cardiovascular risk factors [561-563]
and holds predictive value for cardiovascular events [564]. In addition, aging is associated with a
progressive decline in endothelial-dependent vasodilation [565]. Finally, there is also evidence of
a link between decreased vascular reactivity and physical function [292,376].
Clearly, the assessment of vascular function in clinical research has emerged as a
powerful tool on vascular biology. Indeed, its determination might provide significant insight
about vascular “health”. It is this underlying assumption that has led to the overall idea of this
dissertation. Indeed, this work was motivated with the idea to continue to explore the effects of
exercise on the vasculature. The outcomes within each of the projects within this dissertation in
some unique way have contributed to a slightly better understanding of the possible underlying
mechanisms and/or controllers that govern vascular function. Clearly, this information is not
only important from a research point of view, but also may help health professionals from
different background to improve their delivery as health providers. Ultimately, the main focus of
this work was to determine how the vasculature may be influenced or may influence physical
function.
The first step in the research process started with a follow-up study of previous work
from this laboratory. Indeed, those studies showed several associations between strength and
vascular measures [4] and improvements in vasoreactivity following isolated resistive types of
exercises [6]. Importantly, these adaptations occurred within four weeks of training. These
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studies were used as a foundation to keep exploring the effects of training on the vasculature,
specifically the effects of resistance training on blood flow responses. Resistance training not
only impacts strength and endurance, but also contributes to the maintenance of functional ability
[425]. Thus the initial study was aimed to investigate the influence of two volumes (high and
low) of whole-body circuit weight training on forearm vascular function in younger healthy
college individuals. The findings revealed significant and similar increases in strength for the
high and low volume groups. However, despite the increases in strength, vascular changes were
only seen in the subjects who had lower vascular function prior to training [566]. Thus the study
finding indicated that individuals with evidence of low vascular function may respond favorably
to whole-body circuit weight training.
So it is perhaps not a surprise that the second project in this dissertation focused on
individuals who may have lower vascular function due to some sort of pathologic condition. The
population selected for the second study was a group of individuals with peripheral neuropathy.
The major reason for that selection is the fact that irrespective of etiology, pathological changes
associated with the disease are in many cases consistent with ischemia, secondary to vascular
insufficiencies [8]. The main focus of the second study was to examine the link between vascular
and physical function. The importance of such a link is to recognize that a large component of
physical decline could be secondary to a loss of vascular function. If such a link can be found the
development of strategies aimed at preserving vascular function could eventually help
individuals remain physically able, even in the face of certain pathologic conditions. The
findings of the second study confirmed a relationship between measures of vascular and physical
function in peripheral neuropathy. Indeed, individuals with greater physical function scores
exhibited more favorable measures of arterial inflow and venous outflow. Specifically,
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individuals in the lowest tertile of the time up and go and those with a 6 minute walk distance
score <400m had significantly lower peak reactive hyperemia blood flow responses and peak
vascular conductance compared to the other groups. In addition, individuals in the top tertile of
knee extension and knee flexion exhibited faster venous outflow half-time than the other tertiles.
These findings fit “The Disablement Pathway” and suggest that lower physical function may, in
part, be a consequence of deterioration of peripheral vascular function in individuals with
peripheral neuropathy. Future longitudinal studies are needed to confirm the relationship
between vascular and physical function and to determine whether exercise interventions can
maintain and/or improve vascular function and contribute to the preservation of functional ability
in individuals with peripheral neuropathy.
Although the previous studies were able to provide important information on how the
vasculature may be influenced or may influence physical function, these findings also
demonstrated how complex the study of vascular function could be. In fact, the initial studies
could only speculate regarding the true “controllers” that could mediate vascular function. So the
last step in this process was to begin the exploration in some putative factors thought to control
vascular function. Within this last step the work by Deanfield et al., [9] was particularly
motivating and stimulating. Indeed, Deanfield et al., [9] have speculated the vascular function is
very much influenced by the balance of pro- and anti-oxidants. In fact, a negative balance, which
is termed oxidative stress, has been implicated in a number of human diseases as well as in
accelerated aging [544,567].
Interestingly, it appears that the balance is very much controlled by a molecule that is
released by the vascular endothelium under different conditions, which is nitric oxide. Thus the
third project was the initial development of the idea that the balance between pro- and anti190

oxidants would be very much influenced by the nitric oxide status of an individual. If the balance
is in favor of oxidative stress this might mean that the vasculature would be more vulnerable as
defined by less reactive.
Clearly this step was a significant extension from the previous studies, and because of
that it was thought that these investigations should first be conducted in healthy trained
individuals which hopefully would allow for the establishment of a data set to which other
populations could ultimately be compared. Thus the last project was intended to examine the
effects of an acute bout of exercise on nitric oxide bioavailability, oxidative stress and antioxidants markers, and brachial artery reactivity before, at peak exercise, and in recovery. The
two major unique outcomes of this final study indicated a significant increase in reactive oxygen
species and peroxynitrite, and a decrease in the anti-oxidant glutathione peroxidase at peak
exercise. In addition, brachial vasoreactivity revealed a temporal pattern, with a blunted response
immediately after exercise, and near complete recovery after 20 minutes of recovery. These
findings support the a-priori hypotheses, and suggest an acute bout of exercise contributes to a
significant rise in reactive oxygen stress on the brachial artery, which can in part be buffered by
anti-oxidants systems, but may cause temporary blunting of the reactivity of the brachial artery.
In summary the findings of this dissertation further add to the current understanding of
the role of the vasculature in physical function. It appears that physical function is very much
influenced by the vasculature even in individuals with significant disease. Moreover, the
vasculature can be acutely modified, and may improve over time in individuals involved in
physical training. The acute modification of exercise appears to be at least in part negative (i.e.
reduced vascular reactivity) due to oxidative stress. However, the ‘negative’ effects of acute
exercise on the vasculature are short-lived in highly trained athletes suggesting a significant
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buffering capacity. Obviously future studies will have to determine if these effects are in part a
component of the signaling pathways that may enhance vascular function as is evident within the
literature. The improvements in vascular function following training were again noted in this
dissertation, although those benefits were seen only in those who had evidence of low function
prior to training. Futures studies will continue this line of research in order to improve the
current understanding of vascular function. In the same manner, it is imperative to recognize that
the implementation of proper exercise programs is necessary to keep blood vessels healthy.
Clearly, these findings have set the stage for a series of additional experiments with endothelial
homeostasis as its focus.

192

References
1.

Booth FW, et al. Waging war on modern chronic diseases: primary prevention through
exercise biology. J Appl Physiol 88: 774-778, 2000.

2.

Vanhoutte PM. Endothelial control of vasomotor function: from health to coronary
disease. Circ J 67: 572-575, 2003.

3.

Raitakari OT, and Celermajer DS. Flow-mediated dilatation. British journal of clinical
pharmacology 50: 397-404, 2000.

4.

Alomari MA, et al. Measurements of vascular function using strain-gauge
plethysmography: technical considerations, standardization, and physiological findings.
American journal of physiology 286: H99-H107, 2004.

5.

Alomari MA, et al. Modification of forearm vascular function following short-term
handgrip exercise training. Int J Sports Med 22: 361-365, 2001.

6.

Allen JD, et al. Time course of improved flow-mediated dilation after short-term exercise
training. Medicine and science in sports and exercise 35: 847-853, 2003.

7.

CONGRESS US, and Session TCd. Senate Report 108-35: Departments of Labor, Health
and Human Srevices, and Education, and Related Agencies Appropriation Bill, 2005.
2004.

8.

Krishnan AV, et al. Nerve excitability properties in lower-limb motor axons: evidence for
a length-dependent gradient. Muscle & nerve 29: 645-655, 2004.

9.

Deanfield JE, et al. Endothelial function and dysfunction: testing and clinical relevance.
Circulation 115: 1285-1295, 2007.

10.

Minino AM, et al. Deaths: preliminary data for 2004. Natl Vital Stat Rep 54: 1-49, 2006.

193

11.

Rosamond W, et al. Heart disease and stroke statistics--2007 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation 115: e69-171, 2007.

12.

American, et al. Heart Disease and Stroke Statistics. 2004 Update Dallas.

13.

Hambrecht R, et al. Effect of exercise on coronary endothelial function in patients with
coronary artery disease. The New England journal of medicine 342: 454-460, 2000.

14.

Niebauer J, et al. Attenuated progression of coronary artery disease after 6 years of
multifactorial risk intervention: role of physical exercise. Circulation 96: 2534-2541,
1997.

15.

Linke A, et al. Exercise and the coronary circulation-alterations and adaptations in
coronary artery disease. Progress in cardiovascular diseases 48: 270-284, 2006.

16.

Services UDoHaH. Physical Activity and Health: A Report of the Surgeon General.
Atlanta, Ga. edited by US Department of Health and Human Services, Centers for
Disease Control and Prevention, Disease NCfC, and Prevention and Health
Promotion1996.

17.

Pate RR, et al. Physical activity and public health. A recommendation from the Centers
for Disease Control and Prevention and the American College of Sports Medicine. Jama
273: 402-407, 1995.

18.

Physical activity and cardiovascular health. NIH Consensus Development Panel on
Physical Activity and Cardiovascular Health. Jama 276: 241-246, 1996.

19.

Braunwald E. Pathophysiology of Heart Failure. In: Heart Disease; A Textbook of
Cardiovascular Medicine, edited by Braunwald E. Philadelphia, PA: W. B Sunders
Company, 1992, p. 393-418.

20.

Pina IL, et al. Exercise and heart failure: A statement from the American Heart
Association Committee on exercise, rehabilitation, and prevention. Circulation 107:
1210-1225, 2003.
194

21.

Dubach P, et al. Exercise training in chronic heart failure: why, when and how. Swiss
Med Wkly 131: 510-514, 2001.

22.

Kitzman DW. Exercise intolerance. Progress in cardiovascular diseases 47: 367-379,
2005.

23.

Association AH. Heart Disease and Stroke Statistics: 2005 Update. Dallas, Tex;
American Heart Association; 2005. 2005.

24.

O'Connell JB, and Bristow MR. Economic impact of heart failure in the United States:
time for a different approach. J Heart Lung Transplant 13: S107-112, 1994.

25.

Massie BM, and Shah NB. Evolving trends in the epidemiologic factors of heart failure:
rationale for preventive strategies and comprehensive disease management. American
heart journal 133: 703-712, 1997.

26.

Kannel WB, and Belanger AJ. Epidemiology of heart failure. American heart journal
121: 951-957, 1991.

27.

Roger VL, et al. Trends in heart failure incidence and survival in a community-based
population. Jama 292: 344-350, 2004.

28.

Lloyd-Jones DM, et al. Lifetime risk for developing congestive heart failure: the
Framingham Heart Study. Circulation 106: 3068-3072, 2002.

29.

Levy D, et al. The progression from hypertension to congestive heart failure. Jama 275:
1557-1562, 1996.

30.

Bibbins-Domingo K, et al. Predictors of heart failure among women with coronary
disease. Circulation 110: 1424-1430, 2004.

31.

National Heart L, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on
Cardiovascular and Lung Diseases. Bethesda, Md: 2006.

195

32.

Hunt SA, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of
Chronic Heart Failure in the Adult: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart
Failure): developed in collaboration with the American College of Chest Physicians and
the International Society for Heart and Lung Transplantation: endorsed by the Heart
Rhythm Society. Circulation 112: e154-235, 2005.

33.

Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and
diastolic heart failure in elderly patients. Heart Dis 5: 279-294, 2003.

34.

Zile MR, et al. Diastolic heart failure: definitions and terminology. Progress in
cardiovascular diseases 47: 307-313, 2005.

35.

Zile MR, and Simsic JM. Diastolic heart failure: diagnosis and treatment. Clinical
cornerstone 3: 13-24, 2000.

36.

Packer M. Pathophysiology of chronic heart failure. Lancet 340: 88-92, 1992.

37.

Bonow RO, and Udelson JE. Left ventricular diastolic dysfunction as a cause of
congestive heart failure. Mechanisms and management. Annals of internal medicine 117:
502-510, 1992.

38.

Grossman W. Diastolic dysfunction in congestive heart failure. The New England journal
of medicine 325: 1557-1564, 1991.

39.

Clark AL. Origin of symptoms in chronic heart failure. Heart (British Cardiac Society)
92: 12-16, 2006.

40.

Brozena SC. Examination of the Patient Suspected to Have Heart Failure. In: Heart
Failure A Clinician's Guide to Ambulatory Diagnosis and Treatment, edited by Jessup
ML, and Loh E. Totowa, New Jersey: Humana Press, 2003, p. 87-102.

41.

Perloff JK. The jugular venous pulse and third heart sound in patients with heart failure.
The New England journal of medicine 345: 612-614, 2001.
196

42.

Lorell BH, and Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and
prognosis. Circulation 102: 470-479, 2000.

43.

Vasan RS, et al. Congestive heart failure with normal left ventricular systolic function.
Clinical approaches to the diagnosis and treatment of diastolic heart failure. Archives of
internal medicine 156: 146-157, 1996.

44.

Myers J, and Froelicher VF. Hemodynamic determinants of exercise capacity in chronic
heart failure. Annals of internal medicine 115: 377-386, 1991.

45.

Corra U, et al. Cardiopulmonary exercise testing and prognosis in chronic heart failure: a
prognosticating algorithm for the individual patient. Chest 126: 942-950, 2004.

46.

Sparrow J, et al. Assessment of functional capacity in chronic heart failure: time-limited
exercise on a self-powered treadmill. British heart journal 71: 391-394, 1994.

47.

Piepoli MF, et al. Statement on cardiopulmonary exercise testing in chronic heart failure
due to left ventricular dysfunction: recommendations for performance and interpretation
Part II: How to perform cardiopulmonary exercise testing in chronic heart failure. Eur J
Cardiovasc Prev Rehabil 13: 300-311, 2006.

48.

Maldonado-Martin S, et al. The relationship of a 6-min walk to VO(2 peak) and VT in
older heart failure patients. Medicine and science in sports and exercise 38: 1047-1053,
2006.

49.

Borg GA. Perceived exertion: a note on "history" and methods. Medicine and science in
sports 5: 90-93, 1973.

50.

Drexler H, and Coats AJ. Explaining fatigue in congestive heart failure. Annu Rev Med
47: 241-256, 1996.

51.

Ingle L, et al. The reproducibility and sensitivity of the 6-min walk test in elderly patients
with chronic heart failure. European heart journal 26: 1742-1751, 2005.

197

52.

Beniaminovitz A, and Mancini DM. The role of exercise-based prognosticating
algorithms in the selection of patients for heart transplantation. Current opinion in
cardiology 14: 114-120, 1999.

53.

Statement on cardiopulmonary exercise testing in chronic heart failure due to left
ventricular dysfunction: recommendations for performance and interpretation Part III:
Interpretation of cardiopulmonary exercise testing in chronic heart failure and future
applications. Eur J Cardiovasc Prev Rehabil 13: 485-494, 2006.

54.

Piepoli MF. Exercise rehabilitation in heart disease: the real "polypill" for primary and
secondary prevention. Monaldi archives for chest disease = Archivio Monaldi per le
malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica
tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo 64:
88-93, 2005.

55.

Mancini D, et al. Peak VO(2): a simple yet enduring standard. Circulation 101: 10801082, 2000.

56.

Kemps HM, et al. Reproducibility of onset and recovery oxygen uptake kinetics in
moderately impaired patients with chronic heart failure. Eur J Appl Physiol 2007.

57.

Mancini DM, et al. Value of peak exercise oxygen consumption for optimal timing of
cardiac transplantation in ambulatory patients with heart failure. Circulation 83: 778-786,
1991.

58.

Costanzo MR, et al. Selection and treatment of candidates for heart transplantation. A
statement for health professionals from the Committee on Heart Failure and Cardiac
Transplantation of the Council on Clinical Cardiology, American Heart Association.
Circulation 92: 3593-3612, 1995.

59.

Opasich C, et al. Peak exercise oxygen consumption in chronic heart failure: toward
efficient use in the individual patient. J Am Coll Cardiol 31: 766-775, 1998.

60.

Stelken AM, et al. Prognostic value of cardiopulmonary exercise testing using percent
achieved of predicted peak oxygen uptake for patients with ischemic and dilated
cardiomyopathy. J Am Coll Cardiol 27: 345-352, 1996.
198

61.

Osman AF, et al. The incremental prognostic importance of body fat adjusted peak
oxygen consumption in chronic heart failure. J Am Coll Cardiol 36: 2126-2131, 2000.

62.

Arena R, and Humphrey R. Comparison of ventilatory expired gas parameters used to
predict hospitalization in patients with heart failure. American heart journal 143: 427432, 2002.

63.

Mejhert M, et al. Ventilatory variables are strong prognostic markers in elderly patients
with heart failure. Heart (British Cardiac Society) 88: 239-243, 2002.

64.

Opasich C, et al. Six-minute walking performance in patients with moderate-to-severe
heart failure; is it a useful indicator in clinical practice? European heart journal 22: 488496, 2001.

65.

Woo MA, et al. Six-minute walk test and heart rate variability: lack of association in
advanced stages of heart failure. Am J Crit Care 6: 348-354, 1997.

66.

Guyatt GH, et al. The 6-minute walk: a new measure of exercise capacity in patients with
chronic heart failure. Can Med Assoc J 132: 919-923, 1985.

67.

Dracup K, et al. Quality of life in patients with advanced heart failure. J Heart Lung
Transplant 11: 273-279, 1992.

68.

Califf RM, et al. A randomized controlled trial of epoprostenol therapy for severe
congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
American heart journal 134: 44-54, 1997.

69.

Olsen SL, et al. Carvedilol improves left ventricular function and symptoms in chronic
heart failure: a double-blind randomized study. J Am Coll Cardiol 25: 1225-1231, 1995.

70.

Meyer K, et al. Effects of exercise training and activity restriction on 6-minute walking
test performance in patients with chronic heart failure. American heart journal 133: 447453, 1997.

199

71.

Bittner V, et al. Prediction of mortality and morbidity with a 6-minute walk test in
patients with left ventricular dysfunction. SOLVD Investigators. Jama 270: 1702-1707,
1993.

72.

Cahalin LP, et al. The six-minute walk test predicts peak oxygen uptake and survival in
patients with advanced heart failure. Chest 110: 325-332, 1996.

73.

ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:
111-117, 2002.

74.

Schiller NB, et al. Recommendations for quantitation of the left ventricle by twodimensional echocardiography. American Society of Echocardiography Committee on
Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am
Soc Echocardiogr 2: 358-367, 1989.

75.

Zugck C, et al. Is the 6-minute walk test a reliable substitute for peak oxygen uptake in
patients with dilated cardiomyopathy? European heart journal 21: 540-549, 2000.

76.

Herling IM. Taking a History in a Patient with Heart Failure. In: Heart Failure A
Clinician's Guide to Ambulatory Diagnosis and Treatment, edited by Jessup ML, and
Loh E. Totowa, New Jersey: Humana Press, 2003, p. 17-24.

77.

Association TNYH. The Criteria Committe of the New York Heart Association.
Diseases of the Heart and Blodd Vessels: Nomenclature and Criteria for Diagnosis.
Boston, Mass: Little Brown; 1964: 1964.

78.

Hunt SA, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic
Heart Failure in the Adult: Executive Summary A Report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee
to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure):
Developed in Collaboration With the International Society for Heart and Lung
Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104:
2996-3007, 2001.

79.

Zelis R, and Sinoway L. Pathophysiology of congestive heart failure. In: Textbook of
Internal Medicine, edited by Kelly WN. Philadelphia: Lippincott, 1989.
200

80.

Sokolow M, and McIlroy MB. In: Clinical cardiology. Los Altos, CA: Lange Medical
Publications, 1986.

81.

Zelis R, et al. Time-constant adaptations in heart failure. European heart journal 12
Suppl C: 2-7, 1991.

82.

Popjes ED. Heart Failure and Fatigue. In: Heart Failure A Clinician's Guide to
Ambulatory Diagnosis and Treatment edited by Jessup M. Totowa, New Jersy: Humana
Press, 2003, p. 25-56.

83.

DiSalvo T. The Clinical Syndrome of Heart Failure. In: Heart Failure A comprehensive
guide to diagnosis and treatment, edited by Dec W. New Yprk, 2005: Marcel Dekker,
2005, p. 181-203.

84.

Opie LH. The neuroendocrinology of congestive heart failure. Cardiovasc J S Afr 13:
171-178, 2002.

85.

Adams KF, Jr. Pathophysiologic role of the renin-angiotensin-aldosterone and
sympathetic nervous systems in heart failure. Am J Health Syst Pharm 61 Suppl 2: S4-13,
2004.

86.

Katz SD, et al. Training improves endothelium-dependent vasodilation in resistance
vessels of patients with heart failure. J Appl Physiol 82: 1488-1492, 1997.

87.

Houser SR, and Margulies KB. Is depressed myocyte contractility centrally involved in
heart failure? Circulation research 92: 350-358, 2003.

88.

Udelson JE, et al. New concepts in post-infarction ventricular remodeling. Reviews in
cardiovascular medicine 4 Suppl 3: S3-12, 2003.

89.

Kjaer A, and Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic
and therapeutic perspectives. Clinical physiology (Oxford, England) 21: 661-672, 2001.

90.

Grossman W, et al. Wall stress and patterns of hypertrophy in the human left ventricle.
The Journal of clinical investigation 56: 56-64, 1975.
201

91.

Zile MR, et al. Changes in diastolic function during development and correction of
chronic LV volume overload produced by mitral regurgitation. Circulation 87: 13781388, 1993.

92.

Piepoli M, et al. A neural link to explain the "muscle hypothesis" of exercise intolerance
in chronic heart failure. American heart journal 137: 1050-1056, 1999.

93.

Piepoli MF. Exercise training in heart failure. Curr Cardiol Rep 7: 216-222, 2005.

94.

Forfar JC. Neuroendocrine activation in congestive heart failure. The American journal of
cardiology 67: 3C-5C, 1991.

95.

Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance.
Clinical cardiology 18: 440-445, 1995.

96.

Sigurdsson A, and Swedberg K. The role of neurohormonal activation in chronic heart
failure and postmyocardial infarction. American heart journal 132: 229-234, 1996.

97.

Guyton AC, and J.E. H. Cardiac Failure. In: Textbook of Medical Physiology.
Philadelphia: W.B. Saunders Company, 2000, p. 235-236.

98.

Osterziel KJ, et al. Haemodynamic changes caused by alteration of autonomic activity in
patients with heart failure. British heart journal 63: 221-224, 1990.

99.

Rea RF, and Berg WJ. Abnormal baroreflex mechanisms in congestive heart failure.
Recent insights. Circulation 81: 2026-2027, 1990.

100.

Thames MD, et al. Abnormalities of baroreflex control in heart failure. J Am Coll Cardiol
22: 56A-60A, 1993.

101.

Zelis R, and Flaim SF. Alterations in vasomotor tone in congestive heart failure. Progress
in cardiovascular diseases 24: 437-459, 1982.

202

102.

Cohn JN, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic
congestive heart failure. The New England journal of medicine 311: 819-823, 1984.

103.

Swedberg K, et al. Hormones regulating cardiovascular function in patients with severe
congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
Circulation 82: 1730-1736, 1990.

104.

Levine TB, et al. Activity of the sympathetic nervous system and renin-angiotensin
system assessed by plasma hormone levels and their relation to hemodynamic
abnormalities in congestive heart failure. The American journal of cardiology 49: 16591666, 1982.

105.

Ferguson DW, et al. Clinical and hemodynamic correlates of sympathetic nerve activity
in normal humans and patients with heart failure: evidence from direct
microneurographic recordings. J Am Coll Cardiol 16: 1125-1134, 1990.

106.

Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in
heart failure. J Am Coll Cardiol 22: 72A-84A, 1993.

107.

Drexler H. Reduced exercise tolerance in chronic heart failure and its relationship to
neurohumoral factors. European heart journal 12 Suppl C: 21-28, 1991.

108.

Hirsch AT, et al. Baroreceptor function in congestive heart failure: effect on
neurohumoral activation and regional vascular resistance. Circulation 75: IV36-48, 1987.

109.

Remme WJ. Therapeutic strategies and neurohormonal control in heart failure. European
heart journal 15 Suppl D: 129-138, 1994.

110.

Guyton AC, and Hall JE. Textbook of Medical Physiology. In: Textbook of Medical
Physiology. Philadelphia: W.B. Saunders Company, 2000, p. 195-209.

111.

Hackenthal E, et al. Morphology, physiology, and molecular biology of renin secretion.
Physiological reviews 70: 1067-1116, 1990.

203

112.

Dzau VJ, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in
congestive heart failure. Circulation 63: 645-651, 1981.

113.

Paul M, et al. Activation of the renin-angiotensin system in heart failure and hypertrophy-studies in human hearts and transgenic rats. European heart journal 15 Suppl D: 63-67,
1994.

114.

Schelling P, et al. Angiotensin and cell growth: a link to cardiovascular hypertrophy?
Journal of hypertension 9: 3-15, 1991.

115.

Benedict CR, et al. Comparative neurohormonal responses in patients with preserved and
impaired left ventricular ejection fraction: results of the Studies of Left Ventricular
Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 22:
146A-153A, 1993.

116.

Morali GA, et al. Muscle sympathetic nerve activity and renal responsiveness to atrial
natriuretic factor during the development of hepatic ascites. The American journal of
medicine 91: 383-392, 1991.

117.

Crawford DC, et al. Angiotensin II induces fibronectin expression associated with cardiac
fibrosis in the rat. Circulation research 74: 727-739, 1994.

118.

Sadoshima J, and Izumo S. Molecular characterization of angiotensin II--induced
hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of
the AT1 receptor subtype. Circulation research 73: 413-423, 1993.

119.

Woodiwiss AJ, et al. Reduction in myocardial collagen cross-linking parallels left
ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 103:
155-160, 2001.

120.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions
and congestive heart failure. The SOLVD Investigators. The New England journal of
medicine 325: 293-302, 1991.

204

121.

Effects of enalapril on mortality in severe congestive heart failure. Results of the
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The
CONSENSUS Trial Study Group. The New England journal of medicine 316: 14291435, 1987.

122.

Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for
treatment of coronary artery disease in patients with preserved left ventricular function. J
Am Coll Cardiol 27: 1048-1052, 1996.

123.

Goldsmith SR, et al. Arginine vasopressin and the renal response to water loading in
congestive heart failure. The American journal of cardiology 58: 295-299, 1986.

124.

Goldsmith SR. Baroreflex loading maneuvers do not suppress increased plasma arginine
vasopressin in patients with congestive heart failure. J Am Coll Cardiol 19: 1180-1184,
1992.

125.

Goldsmith SR, et al. Increased plasma arginine vasopressin levels in patients with
congestive heart failure. J Am Coll Cardiol 1: 1385-1390, 1983.

126.

Francis GS, et al. Comparison of neuroendocrine activation in patients with left
ventricular dysfunction with and without congestive heart failure. A substudy of the
Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724-1729, 1990.

127.

Lee WH, and Packer M. Prognostic importance of serum sodium concentration and its
modification by converting-enzyme inhibition in patients with severe chronic heart
failure. Circulation 73: 257-267, 1986.

128.

Goetz KL. Physiology and pathophysiology of atrial peptides. Am J Physiol 254: E1-15,
1988.

129.

Nakaoka H, et al. Plasma levels of atrial natriuretic factor in patients with congestive
heart failure. The New England journal of medicine 313: 892-893, 1985.

130.

Richards AM, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left
ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99:
786-792, 1999.
205

131.

Cody RJ, et al. Atrial natriuretic factor in normal subjects and heart failure patients.
Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. The
Journal of clinical investigation 78: 1362-1374, 1986.

132.

Cody RJ, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in
patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.

133.

McMurray JJ, et al. Plasma endothelin in chronic heart failure. Circulation 85: 13741379, 1992.

134.

Cacoub P, et al. Plasma endothelin and pulmonary pressures in patients with congestive
heart failure. American heart journal 126: 1484-1488, 1993.

135.

Ito H, et al. Endothelin-1 induces hypertrophy with enhanced expression of musclespecific genes in cultured neonatal rat cardiomyocytes. Circulation research 69: 209-215,
1991.

136.

Pousset F, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart
failure. European heart journal 18: 254-258, 1997.

137.

Bozkurt B, et al. Pathophysiologically relevant concentrations of tumor necrosis factoralpha promote progressive left ventricular dysfunction and remodeling in rats.
Circulation 97: 1382-1391, 1998.

138.

Levine B, et al. Elevated circulating levels of tumor necrosis factor in severe chronic
heart failure. The New England journal of medicine 323: 236-241, 1990.

139.

Testa M, et al. Circulating levels of cytokines and their endogenous modulators in
patients with mild to severe congestive heart failure due to coronary artery disease or
hypertension. J Am Coll Cardiol 28: 964-971, 1996.

140.

Clark AL, et al. Skeletal muscle and the control of ventilation on exercise: evidence for
metabolic receptors. European journal of clinical investigation 25: 299-305, 1995.

206

141.

Piepoli M, et al. Contribution of muscle afferents to the hemodynamic, autonomic, and
ventilatory responses to exercise in patients with chronic heart failure: effects of physical
training. Circulation 93: 940-952, 1996.

142.

Coats AJ. Heart failure: What causes the symptoms of heart failure? Heart (British
Cardiac Society) 86: 574-578, 2001.

143.

Sullivan MJ, et al. Relation between central and peripheral hemodynamics during
exercise in patients with chronic heart failure. Muscle blood flow is reduced with
maintenance of arterial perfusion pressure. Circulation 80: 769-781, 1989.

144.

Drexler H, et al. Alterations of skeletal muscle in chronic heart failure. Circulation 85:
1751-1759, 1992.

145.

Wilson JR, et al. Exertional fatigue due to skeletal muscle dysfunction in patients with
heart failure. Circulation 87: 470-475, 1993.

146.

Mancini DM, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR
skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation
80: 1338-1346, 1989.

147.

Massie B, et al. Skeletal muscle metabolism in patients with congestive heart failure:
relation to clinical severity and blood flow. Circulation 76: 1009-1019, 1987.

148.

Sullivan MJ, et al. Skeletal muscle biochemistry and histology in ambulatory patients
with long-term heart failure. Circulation 81: 518-527, 1990.

149.

Drexler H. Skeletal muscle failure in heart failure. Circulation 85: 1621-1623, 1992.

150.

Lipkin DP, and Poole-Wilson PA. Symptoms limiting exercise in chronic heart failure.
Br Med J (Clin Res Ed) 292: 1030-1031, 1986.

151.

You Fang Z, and Marwick TH. Mechanisms of exercise training in patients with heart
failure. American heart journal 145: 904-911, 2003.
207

152.

Piepoli MF, et al. Reduced peripheral skeletal muscle mass and abnormal reflex
physiology in chronic heart failure. Circulation 114: 126-134, 2006.

153.

Jondeau G, et al. Regional specificity of peak hyperemic response in patients with
congestive heart failure: correlation with peak aerobic capacity. J Am Coll Cardiol 22:
1399-1402, 1993.

154.

Minotti JR, et al. Impaired skeletal muscle function in patients with congestive heart
failure. Relationship to systemic exercise performance. The Journal of clinical
investigation 88: 2077-2082, 1991.

155.

Magnusson G, et al. Skeletal muscle strength and endurance in chronic congestive heart
failure secondary to idiopathic dilated cardiomyopathy. The American journal of
cardiology 73: 307-309, 1994.

156.

Mancini DM, et al. Contribution of skeletal muscle atrophy to exercise intolerance and
altered muscle metabolism in heart failure. Circulation 85: 1364-1373, 1992.

157.

Wilson JR, et al. Exercise intolerance in patients with chronic heart failure: role of
impaired nutritive flow to skeletal muscle. Circulation 69: 1079-1087, 1984.

158.

Zelis R, et al. Regional blood flow in congestive heart failure: concept of compensatory
mechanisms with short and long time constants. The American journal of cardiology 62:
2E-8E, 1988.

159.

Wiener DH, et al. Abnormal skeletal muscle bioenergetics during exercise in patients
with heart failure: role of reduced muscle blood flow. Circulation 73: 1127-1136, 1986.

160.

Lipkin DP, et al. Abnormalities of skeletal muscle in patients with chronic heart failure.
International journal of cardiology 18: 187-195, 1988.

161.

Minotti JR, et al. Skeletal muscle response to exercise training in congestive heart failure.
The Journal of clinical investigation 86: 751-758, 1990.

208

162.

Dubach P, and Froelicher VF. Cardiac rehabilitation for heart failure patients. Cardiology
76: 368-373, 1989.

163.

Sullivan MJ, et al. Exercise training in patients with chronic heart failure delays
ventilatory anaerobic threshold and improves submaximal exercise performance.
Circulation 79: 324-329, 1989.

164.

Hanson P. Exercise testing and training in patients with chronic heart failure. Medicine
and science in sports and exercise 26: 527-537, 1994.

165.

Astrand PO, et al. Cardiac Output During Submaximal and Maximal Work. J Appl
Physiol 19: 268-274, 1964.

166.

Higginbotham MB, et al. Regulation of stroke volume during submaximal and maximal
upright exercise in normal man. Circulation research 58: 281-291, 1986.

167.

Franciosa JA, et al. Lack of correlation between exercise capacity and indexes of resting
left ventricular performance in heart failure. The American journal of cardiology 47: 3339, 1981.

168.

Sullivan MJ, and Cobb FR. Central hemodynamic response to exercise in patients with
chronic heart failure. Chest 101: 340S-346S, 1992.

169.

Weber KT, et al. Oxygen utilization and ventilation during exercise in patients with
chronic cardiac failure. Circulation 65: 1213-1223, 1982.

170.

Cohn JN, and Rector TS. Prognosis of congestive heart failure and predictors of
mortality. The American journal of cardiology 62: 25A-30A, 1988.

171.

Sullivan MJ, and Hawthorne MH. Exercise intolerance in patients with chronic heart
failure. Progress in cardiovascular diseases 38: 1-22, 1995.

172.

Galbo H, et al. Glucagon and plasma catecholamine responses to graded and prolonged
exercise in man. J Appl Physiol 38: 70-76, 1975.
209

173.

Zelis R, et al. A comparison of regional blood flow and oxygen utilization during
dynamic forearm exercise in normal subjects and patients with congestive heart failure.
Circulation 50: 137-143, 1974.

174.

Leimbach WN, Jr., et al. Direct evidence from intraneural recordings for increased
central sympathetic outflow in patients with heart failure. Circulation 73: 913-919, 1986.

175.

Wilson JR, et al. Sympathetic vasoconstriction during exercise in ambulatory patients
with left ventricular failure. Circulation 79: 1021-1027, 1989.

176.

Drexler H, and Lu W. Endothelial dysfunction of hindquarter resistance vessels in
experimental heart failure. Am J Physiol 262: H1640-1645, 1992.

177.

Kubo SH, et al. Endothelium-dependent vasodilation is attenuated in patients with heart
failure. Circulation 84: 1589-1596, 1991.

178.

Buller NP, et al. Direct measurement of skeletal muscle fatigue in patients with chronic
heart failure. British heart journal 65: 20-24, 1991.

179.

Zelis R, et al. A comparison of the effects of vasodilator stimuli on peripheral resistance
vessels in normal subjects and in patients with congestive heart failure. The Journal of
clinical investigation 47: 960-970, 1968.

180.

LeJemtel TH, et al. Failure to augment maximal limb blood flow in response to one-leg
versus two-leg exercise in patients with severe heart failure. Circulation 74: 245-251,
1986.

181.

Fagard R, et al. Effects of angiotensin antagonism on hemodynamics, renin, and
catecholamines during exercise. J Appl Physiol 43: 440-444, 1977.

182.

Sullivan MJ, et al. Exercise training in patients with severe left ventricular dysfunction.
Hemodynamic and metabolic effects. Circulation 78: 506-515, 1988.

210

183.

Wilson JR, et al. Evaluation of energy metabolism in skeletal muscle of patients with
heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation 71: 5762, 1985.

184.

Massie BM, et al. Skeletal muscle metabolism during exercise under ischemic conditions
in congestive heart failure. Evidence for abnormalities unrelated to blood flow.
Circulation 78: 320-326, 1988.

185.

Cicoira M, et al. Prediction of mortality in chronic heart failure from peak oxygen
consumption adjusted for either body weight or lean tissue. J Card Fail 10: 421-426,
2004.

186.

Clark AL, et al. The role of right and left ventricular function in the ventilatory response
to exercise in chronic heart failure. Circulation 89: 2062-2069, 1994.

187.

Davies LC, et al. Enhanced prognostic value from cardiopulmonary exercise testing in
chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. European
heart journal 27: 684-690, 2006.

188.

Lee AP, et al. Long-term effects of physical training on coronary patients with impaired
ventricular function. Circulation 60: 1519-1526, 1979.

189.

Hambrecht R, et al. Effects of exercise training on left ventricular function and peripheral
resistance in patients with chronic heart failure: A randomized trial. Jama 283: 30953101, 2000.

190.

Piepoli MF, et al. Exercise training meta-analysis of trials in patients with chronic heart
failure (ExTraMATCH). BMJ (Clinical research ed 328: 189, 2004.

191.

Coats AJ, et al. Controlled trial of physical training in chronic heart failure. Exercise
performance, hemodynamics, ventilation, and autonomic function. Circulation 85: 21192131, 1992.

192.

Clausen JP. Circulatory adjustments to dynamic exercise and effect of physical training
in normal subjects and in patients with coronary artery disease. Progress in
cardiovascular diseases 18: 459-495, 1976.
211

193.

Holmgren A, et al. Effect of training on work capacity, total hemoglobin, blood volume,
heart volume and pulse rate in recumbent and upright positions. Acta physiologica
Scandinavica 50: 72-83, 1960.

194.

Hornig B, et al. Physical training improves endothelial function in patients with chronic
heart failure. Circulation 93: 210-214, 1996.

195.

Hambrecht R, et al. Regular physical exercise corrects endothelial dysfunction and
improves exercise capacity in patients with chronic heart failure. Circulation 98: 27092715, 1998.

196.

Linke A, et al. Endothelial dysfunction in patients with chronic heart failure: systemic
effects of lower-limb exercise training. J Am Coll Cardiol 37: 392-397, 2001.

197.

Bank AJ, et al. Effects of short-term forearm exercise training on resistance vessel
endothelial function in normal subjects and patients with heart failure. J Card Fail 4:
193-201, 1998.

198.

McCartney N. Role of resistance training in heart disease. Medicine and science in sports
and exercise 30: S396-402, 1998.

199.

Pollock ML, et al. AHA Science Advisory. Resistance exercise in individuals with and
without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory
from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical
Cardiology, American Heart Association; Position paper endorsed by the American
College of Sports Medicine. Circulation 101: 828-833, 2000.

200.

Magnusson G, et al. High intensity knee extensor training, in patients with chronic heart
failure. Major skeletal muscle improvement. European heart journal 17: 1048-1055,
1996.

201.

Hare DL, et al. Resistance exercise training increases muscle strength, endurance, and
blood flow in patients with chronic heart failure. The American journal of cardiology 83:
1674-1677, A1677, 1999.

212

202.

Pu CT, et al. Randomized trial of progressive resistance training to counteract the
myopathy of chronic heart failure. J Appl Physiol 90: 2341-2350, 2001.

203.

Maiorana A, et al. Combined aerobic and resistance exercise training improves functional
capacity and strength in CHF. J Appl Physiol 88: 1565-1570, 2000.

204.

Maiorana A, et al. Effect of aerobic and resistance exercise training on vascular function
in heart failure. American journal of physiology 279: H1999-2005, 2000.

205.

Oka RK, et al. Impact of a home-based walking and resistance training program on
quality of life in patients with heart failure. The American journal of cardiology 85: 365369, 2000.

206.

Ohtsubo M, et al. Metabolic abnormality of calf skeletal muscle is improved by localised
muscle training without changes in blood flow in chronic heart failure. Heart (British
Cardiac Society) 78: 437-443, 1997.

207.

Mancini DM, et al. Benefit of selective respiratory muscle training on exercise capacity
in patients with chronic congestive heart failure. Circulation 91: 320-329, 1995.

208.

Laughlin MH, and Ripperger J. Vascular transport capacity of hindlimb muscles of
exercise-trained rats. J Appl Physiol 62: 438-443, 1987.

209.

Sinoway LI, et al. Enhanced maximal metabolic vasodilatation in the dominant forearms
of tennis players. J Appl Physiol 61: 673-678, 1986.

210.

Drexler H, et al. Contrasting peripheral short-term and long-term effects of converting
enzyme inhibition in patients with congestive heart failure. A double-blind, placebocontrolled trial. Circulation 79: 491-502, 1989.

211.

Adamopoulos S, et al. New aspects for the role of physical training in the management of
patients with chronic heart failure. International journal of cardiology 90: 1-14, 2003.

212.

Minotti JR, et al. Training-induced skeletal muscle adaptations are independent of
systemic adaptations. J Appl Physiol 68: 289-294, 1990.
213

213.

Stratton JR, et al. Training partially reverses skeletal muscle metabolic abnormalities
during exercise in heart failure. J Appl Physiol 76: 1575-1582, 1994.

214.

Coats AJ. Exercise rehabilitation in chronic heart failure. J Am Coll Cardiol 22: 172A177A, 1993.

215.

Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial
disease. J Endovasc Ther 13 Suppl 2: II3-9, 2006.

216.

Mohler ER, 3rd. Peripheral arterial disease: identification and implications. Archives of
internal medicine 163: 2306-2314, 2003.

217.

Hirsch AT, et al. ACC/AHA 2005 Practice Guidelines for the management of patients
with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal
aortic): a collaborative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and
Interventions, Society for Vascular Medicine and Biology, Society of Interventional
Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to
Develop Guidelines for the Management of Patients With Peripheral Arterial Disease):
endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic
Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113: e463-654,
2006.

218.

Dormandy J, et al. The natural history of claudication: risk to life and limb. Seminars in
vascular surgery 12: 123-137, 1999.

219.

McDermott MM, et al. Functional decline in peripheral arterial disease: associations with
the ankle brachial index and leg symptoms. Jama 292: 453-461, 2004.

220.

McDermott MM, et al. The ankle brachial index is associated with leg function and
physical activity: the Walking and Leg Circulation Study. Annals of internal medicine
136: 873-883, 2002.

214

221.

Dormandy JA, and Rutherford RB. Management of peripheral arterial disease (PAD).
TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31:
S1-S296, 2000.

222.

Ouriel K. Detection of peripheral arterial disease in primary care. Jama 286: 1380-1381,
2001.

223.

Hirsch AT, et al. Peripheral arterial disease detection, awareness, and treatment in
primary care. Jama 286: 1317-1324, 2001.

224.

Regensteiner JG, and Hiatt WR. Current medical therapies for patients with peripheral
arterial disease: a critical review. The American journal of medicine 112: 49-57, 2002.

225.

Selvin E, and Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in
the United States: results from the National Health and Nutrition Examination Survey,
1999-2000. Circulation 110: 738-743, 2004.

226.

Olson KW, and Treat-Jacobson D. Symptoms of peripheral arterial disease: a critical
review. J Vasc Nurs 22: 72-77, 2004.

227.

Meijer WT, et al. Peripheral arterial disease in the elderly: The Rotterdam Study.
Arteriosclerosis, thrombosis, and vascular biology 18: 185-192, 1998.

228.

Newman AB, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular
Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group.
Circulation 88: 837-845, 1993.

229.

Newman AB, et al. Ankle-arm index as a predictor of cardiovascular disease and
mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group.
Arteriosclerosis, thrombosis, and vascular biology 19: 538-545, 1999.

230.

Becker GJ, et al. The importance of increasing public and physician awareness of
peripheral arterial disease. J Vasc Interv Radiol 13: 7-11, 2002.

215

231.

Criqui MH, et al. Peripheral arterial disease in large vessels is epidemiologically distinct
from small vessel disease. An analysis of risk factors. American journal of epidemiology
129: 1110-1119, 1989.

232.

Creager MA, and Dzau VJ. Vascular disease of the extremities. In: Harrison's Principles
of Internal Medicine, edited by Braunwald EMcGraw-Hill, 2001, p. 1434-1435.

233.

Barletta G, et al. Quality of life in patients with intermittent claudication: relationship
with laboratory exercise performance. Vascular medicine (London, England) 1: 3-7,
1996.

234.

Creager MA. Clinical assessment of the patient with claudication: the role of the vascular
laboratory. Vascular medicine (London, England) 2: 231-237, 1997.

235.

Beckman JA, et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and
management. Jama 287: 2570-2581, 2002.

236.

Vink A, et al. The contribution of plaque and arterial remodeling to de novo
atherosclerotic luminal narrowing in the femoral artery. J Vasc Surg 36: 1194-1198,
2002.

237.

Ross R. Atherosclerosis--an inflammatory disease. The New England journal of medicine
340: 115-126, 1999.

238.

Dieter RS, et al. The significance of lower extremity peripheral arterial disease. Clinical
cardiology 25: 3-10, 2002.

239.

Cerne A, and Kranjec I. Atherosclerotic burden in coronary and peripheral arteries in
patients with first clinical manifestation of coronary artery disease. Heart Vessels 16:
217-226, 2002.

240.

Worthley SG, et al. Atherosclerosis and the vulnerable plaque--pathogenesis: Part I.
Australian and New Zealand journal of medicine 30: 600-607, 2000.

216

241.

Libby P, and Theroux P. Pathophysiology of coronary artery disease. Circulation 111:
3481-3488, 2005.

242.

Donnelly R, et al. ABC of arterial and venous disease. Non-invasive methods of arterial
and venous assessment. BMJ (Clinical research ed 320: 698-701, 2000.

243.

Regensteiner JG, et al. Chronic changes in skeletal muscle histology and function in
peripheral arterial disease. Circulation 87: 413-421, 1993.

244.

Dormandy J, et al. Major amputations: clinical patterns and predictors. Seminars in
vascular surgery 12: 154-161, 1999.

245.

Da Silva A, et al. The Basle longitudinal study: report on the relation of initial glucose
level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality.
Journal of chronic diseases 32: 797-803, 1979.

246.

Gey DC, et al. Management of peripheral arterial disease. American family physician 69:
525-532, 2004.

247.

McDermott MM, et al. Leg symptoms in peripheral arterial disease: associated clinical
characteristics and functional impairment. Jama 286: 1599-1606, 2001.

248.

Martin WH, 3rd, et al. Effects of aging, gender, and physical training on peripheral
vascular function. Circulation 84: 654-664, 1991.

249.

Criqui MH, et al. The sensitivity, specificity, and predictive value of traditional clinical
evaluation of peripheral arterial disease: results from noninvasive testing in a defined
population. Circulation 71: 516-522, 1985.

250.

Criqui MH, and Denenberg JO. The generalized nature of atherosclerosis: how peripheral
arterial disease may predict adverse events from coronary artery disease. Vascular
medicine (London, England) 3: 241-245, 1998.

251.

Falcone RA, et al. Peripheral arterial disease rehabilitation: a review. Journal of
cardiopulmonary rehabilitation 23: 170-175, 2003.
217

252.

Hirsch AT, and L MR. Intermittent Claudication. Curr Treat Options Cardiovasc Med 3:
167-180, 2001.

253.

Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field
surveys. Bulletin of the World Health Organization 27: 645-658, 1962.

254.

Treat-Jacobson D, and Walsh ME. Treating patients with peripheral arterial disease and
claudication. J Vasc Nurs 21: 5-14; quiz 15-16, 2003.

255.

Halperin JL. Evaluation of patients with peripheral vascular disease. Thrombosis
research 106: V303-311, 2002.

256.

Dolan NC, et al. Peripheral artery disease, diabetes, and reduced lower extremity
functioning. Diabetes care 25: 113-120, 2002.

257.

Dormandy J, et al. The fate of patients with critical leg ischemia. Seminars in vascular
surgery 12: 142-147, 1999.

258.

Doyle J, and Creager MA. Pharmacotherapy and behavioral intervention for peripheral
arterial disease. Reviews in cardiovascular medicine 4: 18-24, 2003.

259.

Hiatt WR, and Jones DN. The role of hemodynamics and duplex ultrasound in the
diagnosis of peripheral arterial disease. Current opinion in cardiology 7: 805-810, 1992.

260.

Donnelly R, et al. ABC of arterial and venous disease: vascular complications of
diabetes. BMJ (Clinical research ed 320: 1062-1066, 2000.

261.

McDermott MM, et al. The ankle brachial index and change in lower extremity
functioning over time: the Women's Health and Aging Study. Journal of the American
Geriatrics Society 50: 238-246, 2002.

262.

Weitz JI, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower
extremities: a critical review. Circulation 94: 3026-3049, 1996.

218

263.

Ouriel K, et al. Critical evaluation of stress testing in the diagnosis of peripheral vascular
disease. Surgery 91: 686-693, 1982.

264.

Regensteiner JG. Exercise rehabilitation for the patient with intermittent claudication: a
highly effective yet underutilized treatment. Current drug targets 4: 233-239, 2004.

265.

Gardner AW, et al. Progressive vs single-stage treadmill tests for evaluation of
claudication. Medicine and science in sports and exercise 23: 402-408, 1991.

266.

Labs KH, et al. Reliability of treadmill testing in peripheral arterial disease: a comparison
of a constant load with a graded load treadmill protocol. Vascular medicine (London,
England) 4: 239-246, 1999.

267.

Carter SA. Clinical measurement of systolic pressures in limbs with arterial occlusive
disease. Jama 207: 1869-1874, 1969.

268.

Ogren M, et al. Ten year cerebrovascular morbidity and mortality in 68 year old men
with asymptomatic carotid stenosis. BMJ (Clinical research ed 310: 1294-1298, 1995.

269.

McDermott MM, et al. Asymptomatic peripheral arterial disease is independently
associated with impaired lower extremity functioning: the women's health and aging
study. Circulation 101: 1007-1012, 2000.

270.

Vogt MT, et al. Functional status and mobility among elderly women with lower
extremity arterial disease: the Study of Osteoporotic Fractures. Journal of the American
Geriatrics Society 42: 923-929, 1994.

271.

McDermott MM. Ankle brachial index as a predictor of outcomes in peripheral arterial
disease. The Journal of laboratory and clinical medicine 133: 33-40, 1999.

272.

McKenna M, et al. The ratio of ankle and arm arterial pressure as an independent
predictor of mortality. Atherosclerosis 87: 119-128, 1991.

273.

Criqui MH, et al. Mortality over a period of 10 years in patients with peripheral arterial
disease. The New England journal of medicine 326: 381-386, 1992.
219

274.

Newman AB, et al. Mortality over four years in SHEP participants with a low ankle-arm
index. Journal of the American Geriatrics Society 45: 1472-1478, 1997.

275.

Hiatt WR, et al. Clinical trials for claudication. Assessment of exercise performance,
functional status, and clinical end points. Vascular Clinical Trialists. Circulation 92: 614621, 1995.

276.

Fontaine R. Die chirurgische Behandlung der peripheren Durchblutungsstorungen. Helv
Chir Acta 5/6: 199-533, 1954.

277.

Rutherford RB, et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 26: 517-538, 1997.

278.

Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus
(TASC). Eur J Vasc Endovasc Surg 19 Suppl A: Si-xxviii, S1-250, 2000.

279.

D.E. Strandness Jd. Hemodynamics and the Vascular Laboratory. In: Peripheral Artery
Disease:Diagnosis and Treatment, edited by Jay D. Coffman M, and Robert T. Eberhardt
M. Totowa, New Jersey: Humana Press, 2003, p. 55-63.

280.

Glagov S, et al. Compensatory enlargement of human atherosclerotic coronary arteries.
The New England journal of medicine 316: 1371-1375, 1987.

281.

Clarkson TB, et al. Remodeling of coronary arteries in human and nonhuman primates.
Jama 271: 289-294, 1994.

282.

Dzau VJ, et al. Vascular biology and medicine in the 1990s: scope, concepts, potentials,
and perspectives. Circulation 87: 705-719, 1993.

283.

Frangos JA, et al. Flow effects on prostacyclin production by cultured human endothelial
cells. Science (New York, NY 227: 1477-1479, 1985.

284.

Cooke JP, et al. Flow stimulates endothelial cells to release a nitrovasodilator that is
potentiated by reduced thiol. Am J Physiol 259: H804-812, 1990.
220

285.

Kiechl S, and Willeit J. The natural course of atherosclerosis. Part I: incidence and
progression. Arteriosclerosis, thrombosis, and vascular biology 19: 1484-1490, 1999.

286.

Alexander RW, and Dzau VJ. Vascular biology: the past 50 years. Circulation 102:
IV112-116, 2000.

287.

Sumner DS, and Strandness DE, Jr. The relationship between calf blood flow and ankle
blood pressure in patients with intermittent claudication. Surgery 65: 763-771, 1969.

288.

Gyongyosi M, et al. Vascular remodeling in atherosclerotic femoral arteries: threedimensional US analysis. Radiology 233: 366-375, 2004.

289.

Longland CJ. The collateral circulation of the limb; Arris and Gale lecture delivered at
the Royal College of Surgeons of England on 4th February, 1953. Annals of the Royal
College of Surgeons of England 13: 161-176, 1953.

290.

Brevetti G, et al. Microcirculation and tissue metabolism in peripheral arterial disease.
Clin Hemorheol Microcirc 21: 245-254, 1999.

291.

Niebauer J, et al. Gene transfer of nitric oxide synthase: effects on endothelial biology. J
Am Coll Cardiol 34: 1201-1207, 1999.

292.

Yataco AR, et al. Endothelial reactivity and cardiac risk factors in older patients with
peripheral arterial disease. The American journal of cardiology 83: 754-758, 1999.

293.

Johnstone MT, et al. Impaired endothelium-dependent vasodilation in patients with
insulin-dependent diabetes mellitus. Circulation 88: 2510-2516, 1993.

294.

Clarkson P, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is
related to disease duration and low density lipoprotein cholesterol levels. J Am Coll
Cardiol 28: 573-579, 1996.

295.

Edwards AT, et al. Systemic responses in patients with intermittent claudication after
treadmill exercise. The British journal of surgery 81: 1738-1741, 1994.
221

296.

Thomson IA, et al. Effect of muscle ischaemia and iloprost during femorodistal
reconstruction on capillary endothelial swelling. International journal of
microcirculation, clinical and experimental / sponsored by the European Society for
Microcirculation 16: 284-290, 1996.

297.

Albelda SM, et al. Adhesion molecules and inflammatory injury. Faseb J 8: 504-512,
1994.

298.

Blann AD, and McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules
in atherosclerosis. Thrombosis and haemostasis 72: 151-154, 1994.

299.

Boger RH, et al. Biochemical evidence for impaired nitric oxide synthesis in patients
with peripheral arterial occlusive disease. Circulation 95: 2068-2074, 1997.

300.

Haltmayer M, et al. Erythrocyte mean corpuscular volume associated with severity of
peripheral arterial disease: an angiographic evaluation. Annals of vascular surgery 16:
474-479, 2002.

301.

Poredos P, and Zizek B. Plasma viscosity increase with progression of peripheral arterial
atherosclerotic disease. Angiology 47: 253-259, 1996.

302.

Neumann FJ, et al. Activation and decreased deformability of neutrophils after
intermittent claudication. Circulation 82: 922-929, 1990.

303.

Gresele P, et al. Platelet activation markers in patients with peripheral arterial disease--a
prospective comparison of different platelet function tests. Thrombosis and haemostasis
78: 1434-1437, 1997.

304.

Hickey NC, et al. Effect of surgery on the systemic inflammatory response to intermittent
claudication. The British journal of surgery 77: 1121-1124, 1990.

305.

Reid HL, et al. A simple method for measuring erythrocyte deformability. Journal of
clinical pathology 29: 855-858, 1976.

222

306.

Hedberg B, et al. Fibre loss and distribution in skeletal muscle from patients with severe
peripheral arterial insufficiency. European journal of vascular surgery 3: 315-322, 1989.

307.

Jansson E, et al. Calf muscle adaptation in intermittent claudication. Side-differences in
muscle metabolic characteristics in patients with unilateral arterial disease. Clinical
physiology (Oxford, England) 8: 17-29, 1988.

308.

England JD, et al. Muscle denervation in peripheral arterial disease. Neurology 42: 994999, 1992.

309.

Anker SD, et al. Wasting as independent risk factor for mortality in chronic heart failure.
Lancet 349: 1050-1053, 1997.

310.

Farinon AM, et al. Skeletal muscle and peripheral nerve changes caused by chronic
arterial insufficiency--significance and clinical correlations--histological, histochemical
and ultrastructural study. Clinical neuropathology 3: 240-252, 1984.

311.

Hiatt WR, et al. Effect of exercise training on skeletal muscle histology and metabolism
in peripheral arterial disease. J Appl Physiol 81: 780-788, 1996.

312.

Eames RA, and Lange LS. Clinical and pathological study of ischaemic neuropathy.
Journal of neurology, neurosurgery, and psychiatry 30: 215-226, 1967.

313.

Angquist KA, and Sjostrom M. Intermittent claudication and muscle fiber fine structure:
morphometric data on mitochondrial volumes. Ultrastructural pathology 1: 461-470,
1980.

314.

Hammarsten J, et al. Capillary supply and muscle fibre types in patients with intermittent
claudication: relationships between morphology and metabolism. European journal of
clinical investigation 10: 301-305, 1980.

315.

McGuigan MR, et al. Muscle fiber characteristics in patients with peripheral arterial
disease. Medicine and science in sports and exercise 33: 2016-2021, 2001.

223

316.

Steinacker JM, et al. Expression of myosin heavy chain isoforms in skeletal muscle of
patients with peripheral arterial occlusive disease. J Vasc Surg 31: 443-449, 2000.

317.

Henriksson J, et al. Enzyme activities, fibre types and capillarization in calf muscles of
patients with intermittent claudication. Scandinavian journal of clinical and laboratory
investigation 40: 361-369, 1980.

318.

Sjostrom M, et al. Intermittent claudication and muscle fiber fine structure: correlation
between clinical and morphological data. Ultrastructural pathology 1: 309-326, 1980.

319.

Pette D, and Staron RS. Mammalian skeletal muscle fiber type transitions. International
review of cytology 170: 143-223, 1997.

320.

Schiaffino S, and Reggiani C. Molecular diversity of myofibrillar proteins: gene
regulation and functional significance. Physiological reviews 76: 371-423, 1996.

321.

Jaschinski F, et al. Changes in myosin heavy chain mRNA and protein isoforms of rat
muscle during forced contractile activity. Am J Physiol 274: C365-370, 1998.

322.

Hudlicka O. Development and adaptability of microvasculature in skeletal muscle. The
Journal of experimental biology 115: 215-228, 1985.

323.

Brass EP, and Hiatt WR. Acquired skeletal muscle metabolic myopathy in atherosclerotic
peripheral arterial disease. Vascular medicine (London, England) 5: 55-59, 2000.

324.

Hiatt WR, et al. Effect of diagnostic criteria on the prevalence of peripheral arterial
disease. The San Luis Valley Diabetes Study. Circulation 91: 1472-1479, 1995.

325.

Lundgren F, et al. Muscle enzyme adaptation in patients with peripheral arterial
insufficiency: spontaneous adaptation, effect of different treatments and consequences on
walking performance. Clin Sci (Lond) 77: 485-493, 1989.

326.

Marbini A, et al. Abnormal muscle mitochondria in ischemic claudication. Acta
neurologica Belgica 86: 304-310, 1986.
224

327.

Kemp GJ, et al. Calf muscle mitochondrial and glycogenolytic ATP synthesis in patients
with claudication due to peripheral vascular disease analysed using 31P magnetic
resonance spectroscopy. Clin Sci (Lond) 89: 581-590, 1995.

328.

Hiatt WR, et al. Skeletal muscle carnitine metabolism in patients with unilateral
peripheral arterial disease. J Appl Physiol 73: 346-353, 1992.

329.

Pepine CJ, and Welsch MA. Therapeutic potential of carnitine supplementation in
patients with angina pectoris. In: The Carnitine System in the Heart: A New Therapeutic
Approach to Cardiovascular Diseases edited by Ferrari R, and de Jong JW. Dordrecht,
Neth,: Kluwer Acad. Publ., 1994, p. 185-220.

330.

Hands LJ, et al. Muscle metabolism in patients with peripheral vascular disease
investigated by 31P nuclear magnetic resonance spectroscopy. Clin Sci (Lond) 71: 283290, 1986.

331.

Pernow B, et al. Leg blood flow and muscle metabolism in occlusive arterial disease of
the leg before and after reconstructive surgery. Clinical science and molecular medicine
49: 265-275, 1975.

332.

Hiatt WR, et al. Carnitine metabolism during exercise in patients with peripheral vascular
disease. J Appl Physiol 62: 2383-2387, 1987.

333.

Brevetti G, et al. Carnitine-related alterations in patients with intermittent claudication:
indication for a focused carnitine therapy. Circulation 93: 1685-1689, 1996.

334.

Duling BR, and Berne RM. Longitudinal gradients in periarteriolar oxygen tension. A
possible mechanism for the participation of oxygen in local regulation of blood flow.
Circulation research 27: 669-678, 1970.

335.

Intaglietta M, et al. Microvascular and tissue oxygen distribution. Cardiovascular
research 32: 632-643, 1996.

336.

Curtis SE, et al. Role of the vascular endothelium in O2 extraction during progressive
ischemia in canine skeletal muscle. J Appl Physiol 79: 1351-1360, 1995.
225

337.

Bruttig SP, and Joyner WL. Metabolic characteristics of cells cultured from human
umbilical blood vessels: comparison with 3T3 fibroblasts. Journal of cellular physiology
116: 173-180, 1983.

338.

Boswell CA, et al. Acute endothelial cell contraction in vitro: a comparison with vascular
smooth muscle cells and fibroblasts. Microvasc Res 43: 178-191, 1992.

339.

Sorlie D, and Myhre K. Effects of physical training in intermittent claudication.
Scandinavian journal of clinical and laboratory investigation 38: 217-222, 1978.

340.

Bauer TA, et al. Oxygen uptake kinetics during exercise are slowed in patients with
peripheral arterial disease. J Appl Physiol 87: 809-816, 1999.

341.

Gardner AW, et al. Prediction of claudication pain from clinical measurements obtained
at rest. Medicine and science in sports and exercise 24: 163-170, 1992.

342.

Brass EP, et al. Decreased NADH dehydrogenase and ubiquinol-cytochrome c
oxidoreductase in peripheral arterial disease. American journal of physiology 280: H603609, 2001.

343.

Grassi B, et al. Faster adjustment of O2 delivery does not affect V(O2) on-kinetics in
isolated in situ canine muscle. J Appl Physiol 85: 1394-1403, 1998.

344.

Greenhaff PL, et al. Metabolic inertia in contracting skeletal muscle: a novel approach for
pharmacological intervention in peripheral vascular disease. British journal of clinical
pharmacology 57: 237-243, 2004.

345.

Schweiger H. Investigations on the biochemical characteristics of chronically
underperfused muscle. Angiology 42: 239-250, 1991.

346.

Adair TH, et al. Growth regulation of the vascular system: evidence for a metabolic
hypothesis. Am J Physiol 259: R393-404, 1990.

347.

Larsen OA, and Lassen NA. Effect of daily muscular exercise in patients with
intermittent claudication. Lancet 2: 1093-1096, 1966.
226

348.

Gardner AW, and Poehlman ET. Exercise rehabilitation programs for the treatment of
claudication pain. A meta-analysis. Jama 274: 975-980, 1995.

349.

Leng GC, et al. Exercise for intermittent claudication. Cochrane database of systematic
reviews (Online) CD000990, 2000.

350.

Hiatt WR, et al. Benefit of exercise conditioning for patients with peripheral arterial
disease. Circulation 81: 602-609, 1990.

351.

Hiatt WR, et al. Superiority of treadmill walking exercise versus strength training for
patients with peripheral arterial disease. Implications for the mechanism of the training
response. Circulation 90: 1866-1874, 1994.

352.

Clifford PC, et al. Intermittent claudication: is a supervised exercise class worth while?
British medical journal 280: 1503-1505, 1980.

353.

Regensteiner JG, et al. Exercise training improves functional status in patients with
peripheral arterial disease. J Vasc Surg 23: 104-115, 1996.

354.

Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of
functional impairment. Vascular medicine (London, England) 2: 238-242, 1997.

355.

Regensteiner JG, and Hiatt WR. Exercise rehabilitation for patients with peripheral
arterial disease. Exerc Sport Sci Rev 23: 1-24, 1995.

356.

Degischer S, et al. Physical training for intermittent claudication: a comparison of
structured rehabilitation versus home-based training. Vascular medicine (London,
England) 7: 109-115, 2002.

357.

Wullink M, et al. A primary care walking exercise program for patients with intermittent
claudication. Medicine and science in sports and exercise 33: 1629-1634, 2001.

358.

Association AM. Current Procedural Terminology (CPT) Chicago: 2001.

227

359.

Stewart AH, and Lamont PM. Exercise for intermittent claudication. Supervised
programmes should be universally available. BMJ (Clinical research ed 323: 703-704,
2001.

360.

Menard JR, et al. Long-term results of peripheral arterial disease rehabilitation. J Vasc
Surg 39: 1186-1192, 2004.

361.

Tan KH, et al. Exercise training and peripheral vascular disease. The British journal of
surgery 87: 553-562, 2000.

362.

Zetterquist S. The effect of active training on the nutritive blood flow in exercising
ischemic legs. Scandinavian journal of clinical and laboratory investigation 25: 101-111,
1970.

363.

Dahllof AG, et al. Metabolic activity of skeletal muscle in patients with peripheral
arterial insufficiency. European journal of clinical investigation 4: 9-15, 1974.

364.

Weiss T, et al. Effect of intensive walking exercise on skeletal muscle blood flow in
intermittent claudication. Angiology 43: 63-71, 1992.

365.

Ekroth R, et al. Physical training of patients with intermittent claudication: indications,
methods, and results. Surgery 84: 640-643, 1978.

366.

Johnson EC, et al. Effects of exercise training on common femoral artery blood flow in
patients with intermittent claudication. Circulation 80: III59-72, 1989.

367.

Tan KH, et al. Exercise training for claudicants: changes in blood flow, cardiorespiratory
status, metabolic functions, blood rheology and lipid profile. Eur J Vasc Endovasc Surg
20: 72-78, 2000.

368.

Terjung RL, et al. Peripheral adaptations to low blood flow in muscle during exercise.
The American journal of cardiology 62: 15E-19E, 1988.

369.

Yang HT, et al. Training increases collateral-dependent muscle blood flow in aged rats.
Am J Physiol 268: H1174-1180, 1995.
228

370.

Mathien GM, and Terjung RL. Muscle blood flow in trained rats with peripheral arterial
insufficiency. Am J Physiol 258: H759-765, 1990.

371.

Gustafsson T, and Kraus WE. Exercise-induced angiogenesis-related growth and
transcription factors in skeletal muscle, and their modification in muscle pathology. Front
Biosci 6: D75-89, 2001.

372.

Gustafsson T, et al. Exercise-induced expression of angiogenesis-related transcription
and growth factors in human skeletal muscle. Am J Physiol 276: H679-685, 1999.

373.

Gustafsson T, et al. Increased expression of VEGF following exercise training in patients
with heart failure. European journal of clinical investigation 31: 362-366, 2001.

374.

Deschenes MR, and Ogilvie RW. Exercise stimulates neovascularization in occluded
muscle without affecting bFGF content. Medicine and science in sports and exercise 31:
1599-1604, 1999.

375.

Gavin TP, and Wagner PD. Effect of short-term exercise training on angiogenic growth
factor gene responses in rats. J Appl Physiol 90: 1219-1226, 2001.

376.

Brendle DC, et al. Effects of exercise rehabilitation on endothelial reactivity in older
patients with peripheral arterial disease. The American journal of cardiology 87: 324-329,
2001.

377.

Kingwell BA. Nitric oxide as a metabolic regulator during exercise: effects of training in
health and disease. Clinical and experimental pharmacology & physiology 27: 239-250,
2000.

378.

Lloyd PG, et al. Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric
oxide. American journal of physiology 281: H2528-2538, 2001.

379.

Pararajasingam R, et al. The role of screening blood tests in patients with arterial disease
attending vascular outpatients. Eur J Vasc Endovasc Surg 16: 513-516, 1998.

229

380.

Ernst E. Influence of regular physical activity on blood rheology. European heart journal
8 Suppl G: 59-62, 1987.

381.

Fellmann N. Hormonal and plasma volume alterations following endurance exercise. A
brief review. Sports medicine (Auckland, NZ 13: 37-49, 1992.

382.

Ciuffetti G, et al. Effect of physical training on leukocyte rheology throughout induced
ischaemia. Int Angiol 9: 246-250, 1990.

383.

Hiatt WR, et al. Carnitine and acylcarnitine metabolism during exercise in humans.
Dependence on skeletal muscle metabolic state. The Journal of clinical investigation 84:
1167-1173, 1989.

384.

Kohler M. [Lactate and pyruvate behavior in femoral venous blood before and following
directed training in femoral artery occlusion]. Klinische Wochenschrift 49: 1210-1218,
1971.

385.

Ruell PA, et al. Intermittent claudication. The effect of physical training on walking
tolerance and venous lactate concentration. European journal of applied physiology and
occupational physiology 52: 420-425, 1984.

386.

Holloszy JO, and Coyle EF. Adaptations of skeletal muscle to endurance exercise and
their metabolic consequences. J Appl Physiol 56: 831-838, 1984.

387.

Booth FW, and Narahara KA. Vastus lateralis cytochrome oxidase activity and its
relationship to maximal oxygen consumption in man. Pflugers Arch 349: 319-324, 1974.

388.

Wibom R, et al. Adaptation of mitochondrial ATP production in human skeletal muscle
to endurance training and detraining. J Appl Physiol 73: 2004-2010, 1992.

389.

Bylund AC, et al. Enzyme activities in skeletal muscles from patients with peripheral
arterial insufficiency. European journal of clinical investigation 6: 425-429, 1976.

390.

Bauer TA, et al. Impaired muscle oxygen use at onset of exercise in peripheral arterial
disease. J Vasc Surg 40: 488-493, 2004.
230

391.

Criqui MH, et al. The prevalence of peripheral arterial disease in a defined population.
Circulation 71: 510-515, 1985.

392.

Hiatt WR, et al. Diagnostic methods for peripheral arterial disease in the San Luis Valley
Diabetes Study. Journal of clinical epidemiology 43: 597-606, 1990.

393.

Lundgren F, et al. Intermittent claudication--surgical reconstruction or physical training?
A prospective randomized trial of treatment efficiency. Annals of surgery 209: 346-355,
1989.

394.

Rybicki KJ, et al. Arterial pressure responses to increasing interstitial potassium in
hindlimb muscle of dogs. Am J Physiol 247: R717-721, 1984.

395.

Rotto DM, et al. Reflex cardiovascular and ventilatory responses to increasing H+
activity in cat hindlimb muscle. J Appl Physiol 67: 256-263, 1989.

396.

Stebbins CL, et al. Prostaglandins contribute to cardiovascular reflexes evoked by static
muscular contraction. Circulation research 59: 645-654, 1986.

397.

Haouzi P, et al. Vascular distension in muscles contributes to respiratory control in sheep.
Respiration physiology 99: 41-50, 1995.

398.

Boska MD, et al. 31P MRS studies of exercising human muscle at high temporal
resolution. Magn Reson Med 41: 1145-1151, 1999.

399.

Zatina MA, et al. 31P nuclear magnetic resonance spectroscopy: noninvasive biochemical
analysis of the ischemic extremity. J Vasc Surg 3: 411-420, 1986.

400.

Pipinos, II, et al. Abnormal mitochondrial respiration in skeletal muscle in patients with
peripheral arterial disease. J Vasc Surg 38: 827-832, 2003.

401.

Lesnefsky EJ, et al. Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion,
aging, and heart failure. Journal of molecular and cellular cardiology 33: 1065-1089,
2001.
231

402.

Coats AJ. The "muscle hypothesis" of chronic heart failure. Journal of molecular and
cellular cardiology 28: 2255-2262, 1996.

403.

Clark MG, et al. Microvascular regulation of muscle metabolism. Current opinion in
clinical nutrition and metabolic care 1: 205-210, 1998.

404.

Wilson JR, et al. Impaired skeletal muscle nutritive flow during exercise in patients with
congestive heart failure: role of cardiac pump dysfunction as determined by the effect of
dobutamine. The American journal of cardiology 53: 1308-1315, 1984.

405.

Ponikowski P, et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in
patients with chronic heart failure. Circulation 104: 544-549, 2001.

406.

Ponikowski PP, et al. Muscle ergoreceptor overactivity reflects deterioration in clinical
status and cardiorespiratory reflex control in chronic heart failure. Circulation 104: 23242330, 2001.

407.

Regensteiner JG, et al. Functional benefits of peripheral vascular bypass surgery for
patients with intermittent claudication. Angiology 44: 1-10, 1993.

408.

Pipinos, II, et al. Mitochondrial defects and oxidative damage in patients with peripheral
arterial disease. Free radical biology & medicine 41: 262-269, 2006.

409.

Kemp GJ, et al. Quantitative analysis by 31P magnetic resonance spectroscopy of
abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise.
NMR in biomedicine 6: 302-310, 1993.

410.

Pipinos, II, et al. Pentoxifylline reverses oxidative mitochondrial defect in claudicating
skeletal muscle. The Journal of surgical research 102: 126-132, 2002.

411.

Bhat HK, et al. Skeletal muscle mitochondrial DNA injury in patients with unilateral
peripheral arterial disease. Circulation 99: 807-812, 1999.

412.

Pipinos, II, et al. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a
mitochondrial defect in claudicating skeletal muscle. J Vasc Surg 31: 944-952, 2000.
232

413.

Argov Z, and Bank WJ. Phosphorus magnetic resonance spectroscopy (31P MRS) in
neuromuscular disorders. Annals of neurology 30: 90-97, 1991.

414.

Adams V, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is
associated with exercise intolerance. J Am Coll Cardiol 33: 959-965, 1999.

415.

Conn EH, et al. Exercise responses before and after physical conditioning in patients with
severely depressed left ventricular function. The American journal of cardiology 49: 296300, 1982.

416.

Belardinelli R, et al. Randomized, controlled trial of long-term moderate exercise training
in chronic heart failure: effects on functional capacity, quality of life, and clinical
outcome. Circulation 99: 1173-1182, 1999.

417.

Hulsmann M, et al. Muscle strength as a predictor of long-term survival in severe
congestive heart failure. Eur J Heart Fail 6: 101-107, 2004.

418.

Tyni-Lenne R, et al. Comprehensive local muscle training increases aerobic working
capacity and quality of life and decreases neurohormonal activation in patients with
chronic heart failure. Eur J Heart Fail 3: 47-52, 2001.

419.

Regensteiner J, and Hirsch A. Claudication: the primary symptom of peripheral artery
disease In: Peripheral artery disease handbook, edited by Hiatt WR, Hirsch AT, and
Regensteiner JG e. Boca Raton (FL): CRC: 2001, p. 95-117.

420.

Jones PP, et al. Functional improvements following StairMaster vs. treadmill exercise
training for patients with intermittent claudication. Journal of cardiopulmonary
rehabilitation 16: 47-55, 1996.

421.

Langbein WE, et al. Increasing exercise tolerance of persons limited by claudication pain
using polestriding. J Vasc Surg 35: 887-893, 2002.

422.

Cachovan M, and Rogatti W. Improvement of peripheral and cardiopulmonary
performance after a short-term exercise program with additive prostaglandin E1.
Angiology 52: 381-391, 2001.
233

423.

Mannarino E, et al. Effects of physical training on peripheral vascular disease: a
controlled study. Angiology 40: 5-10, 1989.

424.

Riebe D, et al. Comparison of two progressive treadmill tests in patients with peripheral
arterial disease. Vascular medicine (London, England) 6: 215-221, 2001.

425.

American College of Sports Medicine Position Stand. The recommended quantity and
quality of exercise for developing and maintaining cardiorespiratory and muscular
fitness, and flexibility in healthy adults. Medicine and science in sports and exercise 30:
975-991, 1998.

426.

Feigenbaum MS, and Pollock ML. Prescription of resistance training for health and
disease. Medicine and science in sports and exercise 31: 38-45, 1999.

427.

Hurley BF, and Roth SM. Strength training in the elderly: effects on risk factors for agerelated diseases. Sports medicine (Auckland, NZ 30: 249-268, 2000.

428.

Kingwell BA, et al. Four weeks of cycle training increases basal production of nitric
oxide from the forearm. Am J Physiol 272: H1070-1077, 1997.

429.

Sinoway LI, et al. A 30-day forearm work protocol increases maximal forearm blood
flow. J Appl Physiol 62: 1063-1067, 1987.

430.

Rakobowchuk M, et al. Endothelial function of young healthy males following whole
body resistance training. J Appl Physiol 98: 2185-2190, 2005.

431.

Maiorana A, et al. Exercise training, vascular function, and functional capacity in middleaged subjects. Medicine and science in sports and exercise 33: 2022-2028, 2001.

432.

Green DJ, et al. Comparison of resistance and conduit vessel nitric oxide-mediated
vascular function in vivo: effects of exercise training. J Appl Physiol 97: 749-755;
discussion 748, 2004.

433.

Maiorana A, et al. The effect of combined aerobic and resistance exercise training on
vascular function in type 2 diabetes. J Am Coll Cardiol 38: 860-866, 2001.
234

434.

Bond V, Jr., et al. Lower leg high-intensity resistance training and peripheral
hemodynamic adaptations. Can J Appl Physiol 21: 209-217, 1996.

435.

Joyner MJ, et al. From Belfast to Mayo and beyond: the use and future of
plethysmography to study blood flow in human limbs. J Appl Physiol 91: 2431-2441,
2001.

436.

Cramer M LY, Beach K, Martin D, Strandness DE, Jr. Standardization of venous flow
measurements by strain gauge plethysmography in normal subjects. Bruit VII: 33-39,
1983.

437.

Hokanson DE, et al. An electrically calibrated plethysmograph for direct measurement of
limb blood flow. IEEE Trans Biomed Eng 22: 25-29, 1975.

438.

McKenzie R. The lumbar spine. Mechanical diagnosis & therapy. Waikanae: Spinal
Publications New Zeland Ltd, 2003.

439.

Kraemer WJ, et al. American College of Sports Medicine position stand. Progression
models in resistance training for healthy adults. Medicine and science in sports and
exercise 34: 364-380, 2002.

440.

Leong B, et al. Maximal motor unit discharge rates in the quadriceps muscles of older
weight lifters. Medicine and science in sports and exercise 31: 1638-1644, 1999.

441.

Rutherford OM, and Jones DA. The role of learning and coordination in strength training.
European journal of applied physiology and occupational physiology 55: 100-105, 1986.

442.

McCall GE, et al. Muscle fiber hypertrophy, hyperplasia, and capillary density in college
men after resistance training. J Appl Physiol 81: 2004-2012, 1996.

443.

Green DJ, et al. Modification of forearm resistance vessels by exercise training in young
men. J Appl Physiol 77: 1829-1833, 1994.

444.

Thrall JH. Prevalence and costs of chronic disease in a health care system structured for
treatment of acute illness. Radiology 235: 9-12, 2005.
235

445.

Laghi Pasini F, et al. Peripheral neuropathy associated with ischemic vascular disease of
the lower limbs. Angiology 47: 569-577, 1996.

446.

Resnick HE, et al. Diabetes, peripheral neuropathy, and old age disability. Muscle &
nerve 25: 43-50, 2002.

447.

Guralnik JM, et al. Lower-extremity function in persons over the age of 70 years as a
predictor of subsequent disability. The New England journal of medicine 332: 556-561,
1995.

448.

Verbrugge LM, and Jette AM. The disablement process. Soc Sci Med 38: 1-14, 1994.

449.

DeMott TK, et al. Falls and gait characteristics among older persons with peripheral
neuropathy. American journal of physical medicine & rehabilitation / Association of
Academic Physiatrists 86: 125-132, 2007.

450.

Richardson JK, and Hurvitz EA. Peripheral neuropathy: a true risk factor for falls. The
journals of gerontology 50: M211-215, 1995.

451.

McDowell I, et al. Community screening for dementia: the Mini Mental State Exam
(MMSE) and Modified Mini-Mental State Exam (3MS) compared. Journal of clinical
epidemiology 50: 377-383, 1997.

452.

Kamei N, et al. Effectiveness of Semmes-Weinstein monofilament examination for
diabetic peripheral neuropathy screening. Journal of diabetes and its complications 19:
47-53, 2005.

453.

Hopman MT, et al. Increased vascular resistance in paralyzed legs after spinal cord injury
is reversible by training. J Appl Physiol 93: 1966-1972, 2002.

454.

Podsiadlo D, and Richardson S. The timed "Up & Go": a test of basic functional mobility
for frail elderly persons. Journal of the American Geriatrics Society 39: 142-148, 1991.

236

455.

Bischoff HA, et al. Identifying a cut-off point for normal mobility: a comparison of the
timed 'up and go' test in community-dwelling and institutionalised elderly women. Age
and ageing 32: 315-320, 2003.

456.

Ogren M, et al. Leg blood flow and long-term cardiovascular prognosis in men with
typical and atypical intermittent claudication. Eur J Vasc Endovasc Surg 26: 272-279,
2003.

457.

Proctor DN, et al. Age and regional specificity of peak limb vascular conductance in
men. J Appl Physiol 98: 193-202, 2005.

458.

Cheung JY, et al. Calcium and ischemic injury. The New England journal of medicine
314: 1670-1676, 1986.

459.

Nagamatsu M, et al. Ischemic reperfusion causes lipid peroxidation and fiber
degeneration. Muscle & nerve 19: 37-47, 1996.

460.

Fu Q, et al. Age-related influences of leg vein filling and emptying on blood volume
redistribution and sympathetic reflex during lower body negative pressure in humans. The
Japanese journal of physiology 52: 77-84, 2002.

461.

Welsch MA, et al. Influence of venous function on exercise tolerance in chronic heart
failure. Journal of cardiopulmonary rehabilitation 22: 321-326, 2002.

462.

Rolland YM, et al. Reliability of the 400-m usual-pace walk test as an assessment of
mobility limitation in older adults. Journal of the American Geriatrics Society 52: 972976, 2004.

463.

Steffen TM, et al. Age- and gender-related test performance in community-dwelling
elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up & Go Test, and
gait speeds. Physical therapy 82: 128-137, 2002.

464.

Katsiaras A, et al. Skeletal muscle fatigue, strength, and quality in the elderly: the Health
ABC Study. J Appl Physiol 99: 210-216, 2005.

237

465.

Ostchega Y, et al. Isokinetic leg muscle strength in older americans and its relationship to
a standardized walk test: data from the national health and nutrition examination survey
1999-2000. Journal of the American Geriatrics Society 52: 977-982, 2004.

466.

Paterson DH, et al. Longitudinal study of determinants of dependence in an elderly
population. Journal of the American Geriatrics Society 52: 1632-1638, 2004.

467.

Li H, and Forstermann U. Nitric oxide in the pathogenesis of vascular disease. The
Journal of pathology 190: 244-254, 2000.

468.

Behrendt D, and Ganz P. Endothelial function. From vascular biology to clinical
applications. The American journal of cardiology 90: 40L-48L, 2002.

469.

Celermajer DS, et al. Non-invasive detection of endothelial dysfunction in children and
adults at risk of atherosclerosis. Lancet 340: 1111-1115, 1992.

470.

Lauer T, et al. Indexes of NO bioavailability in human blood. News Physiol Sci 17: 251255, 2002.

471.

Palmer RM, et al. L-arginine is the physiological precursor for the formation of nitric
oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153: 12511256, 1988.

472.

Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta 1411: 273-289,
1999.

473.

Vincent AM, et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine
reviews 25: 612-628, 2004.

474.

Valko M, et al. Free radicals and antioxidants in normal physiological functions and
human disease. The international journal of biochemistry & cell biology 39: 44-84, 2007.

475.

Valko M, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer.
Chem Biol Interact 160: 1-40, 2006.
238

476.

Kovacic P, and Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and
electron transfer. Curr Med Chem 8: 773-796, 2001.

477.

Davies KJ, et al. Free radicals and tissue damage produced by exercise. Biochem Biophys
Res Commun 107: 1198-1205, 1982.

478.

Miyazaki H, et al. Strenuous endurance training in humans reduces oxidative stress
following exhausting exercise. Eur J Appl Physiol 84: 1-6, 2001.

479.

Di Massimo C, et al. Possible involvement of oxidative stress in exercise-mediated
platelet activation. Clin Hemorheol Microcirc 30: 313-316, 2004.

480.

Gladwin MT, et al. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in
the transport and metabolism of nitric oxide by hemoglobin in the human circulation.
Proceedings of the National Academy of Sciences of the United States of America 97:
9943-9948, 2000.

481.

Eston RG, and Williams JG. Reliability of ratings of perceived effort regulation of
exercise intensity. Br J Sports Med 22: 153-155, 1988.

482.

Gallez B, and Swartz HM. In vivo EPR: when, how and why? NMR in biomedicine 17:
223-225, 2004.

483.

Berliner LJ, and Fujii H. In vivo spin trapping of nitric oxide. Antioxid Redox Signal 6:
649-656, 2004.

484.

Swartz HM, et al. Use of electron paramagnetic resonance spectroscopy to evaluate the
redox state in vivo. Antioxid Redox Signal 9: 1757-1771, 2007.

485.

Kozlov AV, et al. Various intracellular compartments cooperate in the release of nitric
oxide from glycerol trinitrate in liver. Br J Pharmacol 139: 989-997, 2003.

486.

Fink B, et al. ESR techniques for the detection of nitric oxide in vivo as an index of
endothelial function. Pharmacol Rep 58 Suppl: 8-15, 2006.
239

487.

Corretti MC, et al. Guidelines for the ultrasound assessment of endothelial-dependent
flow-mediated vasodilation of the brachial artery: a report of the International Brachial
Artery Reactivity Task Force. J Am Coll Cardiol 39: 257-265, 2002.

488.

Welsch MA, et al. Stability and reproducibility of brachial artery flow-mediated dilation.
Medicine and science in sports and exercise 34: 960-965, 2002.

489.

Shing CM, et al. The effect of consecutive days of exercise on markers of oxidative
stress. Appl Physiol Nutr Metab 32: 677-685, 2007.

490.

Laursen PB, et al. A comparison of the cycling performance of cyclists and triathletes. J
Sports Sci 21: 411-418, 2003.

491.

Lounana J, et al. Relationship between %HRmax, %HR reserve, %VO2max, and %VO2
reserve in elite cyclists. Medicine and science in sports and exercise 39: 350-357, 2007.

492.

Lovlin R, et al. Are indices of free radical damage related to exercise intensity. European
journal of applied physiology and occupational physiology 56: 313-316, 1987.

493.

Michailidis Y, et al. Sampling time is crucial for measurement of aerobic exerciseinduced oxidative stress. Medicine and science in sports and exercise 39: 1107-1113,
2007.

494.

Alessio HM, et al. Exercise-induced oxidative stress before and after vitamin C
supplementation. Int J Sport Nutr 7: 1-9, 1997.

495.

Watson TA, et al. Antioxidant restriction and oxidative stress in short-duration
exhaustive exercise. Medicine and science in sports and exercise 37: 63-71, 2005.

496.

Steensberg A, et al. Prolonged exercise, lymphocyte apoptosis and F2-isoprostanes. Eur J
Appl Physiol 87: 38-42, 2002.

497.

Leeuwenburgh C, and Heinecke JW. Oxidative stress and antioxidants in exercise. Curr
Med Chem 8: 829-838, 2001.
240

498.

Vollaard NB, et al. Exercise-induced oxidative stress:myths, realities and physiological
relevance. Sports medicine (Auckland, NZ 35: 1045-1062, 2005.

499.

Morrow JD, et al. A series of prostaglandin F2-like compounds are produced in vivo in
humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the
National Academy of Sciences of the United States of America 87: 9383-9387, 1990.

500.

Ji LL. Antioxidants and oxidative stress in exercise. Proc Soc Exp Biol Med 222: 283292, 1999.

501.

Banerjee AK, et al. Oxidant, antioxidant and physical exercise. Mol Cell Biochem 253:
307-312, 2003.

502.

Davies KJ. An overview of oxidative stress. IUBMB Life 50: 241-244, 2000.

503.

Chance B, et al. Hydroperoxide metabolism in mammalian organs. Physiological reviews
59: 527-605, 1979.

504.

Andersen RE, et al. Effects of lifestyle activity vs structured aerobic exercise in obese
women: a randomized trial. Jama 281: 335-340, 1999.

505.

Barja G. Mitochondrial oxygen radical generation and leak: sites of production in states 4
and 3, organ specificity, and relation to aging and longevity. J Bioenerg Biomembr 31:
347-366, 1999.

506.

Antunes F, and Cadenas E. Estimation of H2O2 gradients across biomembranes. FEBS
Lett 475: 121-126, 2000.

507.

Kissner R, et al. Formation and properties of peroxynitrite as studied by laser flash
photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem Res Toxicol
10: 1285-1292, 1997.

508.

Vina J, et al. Free radicals in exhaustive physical exercise: mechanism of production, and
protection by antioxidants. IUBMB Life 50: 271-277, 2000.
241

509.

Downey JM. Free radicals and their involvement during long-term myocardial ischemia
and reperfusion. Annual review of physiology 52: 487-504, 1990.

510.

Duarte JA, et al. Endothelium-derived oxidative stress may contribute to exerciseinduced muscle damage. Int J Sports Med 14: 440-443, 1993.

511.

Vina J, et al. Mechanism of free radical production in exhaustive exercise in humans and
rats; role of xanthine oxidase and protection by allopurinol. IUBMB Life 49: 539-544,
2000.

512.

Chakraborti T, et al. Oxidant, mitochondria and calcium: an overview. Cellular
signalling 11: 77-85, 1999.

513.

Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to
inflammation and fibrosis. Alcohol 34: 9-19, 2004.

514.

Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy.
Subcell Biochem 38: 65-78, 2005.

515.

Kikuchi A, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's
disease and multiple system atrophy. Neurobiol Dis 9: 244-248, 2002.

516.

Clarkson PM, and Thompson HS. Antioxidants: what role do they play in physical
activity and health? The American journal of clinical nutrition 72: 637S-646S, 2000.

517.

Sen CK. Oxidants and antioxidants in exercise. J Appl Physiol 79: 675-686, 1995.

518.

Meister A, and Anderson ME. Glutathione. Annu Rev Biochem 52: 711-760, 1983.

519.

McArdle A, et al. Exercise and skeletal muscle ageing: cellular and molecular
mechanisms. Ageing Res Rev 1: 79-93, 2002.

520.

Davies KJ. Oxidative stress, antioxidant defenses, and damage removal, repair, and
replacement systems. IUBMB Life 50: 279-289, 2000.
242

521.

Jenkins RR. Free radical chemistry. Relationship to exercise. Sports medicine (Auckland,
NZ 5: 156-170, 1988.

522.

Inal M, et al. Effect of aerobic and anaerobic metabolism on free radical generation
swimmers. Medicine and science in sports and exercise 33: 564-567, 2001.

523.

Bloomer RJ, et al. Effects of acute aerobic and anaerobic exercise on blood markers of
oxidative stress. J Strength Cond Res 19: 276-285, 2005.

524.

Elosua R, et al. Response of oxidative stress biomarkers to a 16-week aerobic physical
activity program, and to acute physical activity, in healthy young men and women.
Atherosclerosis 167: 327-334, 2003.

525.

Chakraborti T, et al. Targets of oxidative stress in cardiovascular system. Mol Cell
Biochem 187: 1-10, 1998.

526.

Sen CK, et al. Skeletal muscle and liver glutathione homeostasis in response to training,
exercise, and immobilization. J Appl Physiol 73: 1265-1272, 1992.

527.

Ji LL. Exercise-induced modulation of antioxidant defense. Ann N Y Acad Sci 959: 82-92,
2002.

528.

Franzoni F, et al. Physical activity, plasma antioxidant capacity, and endotheliumdependent vasodilation in young and older men. Am J Hypertens 18: 510-516, 2005.

529.

Plotnick GD, et al. Effect of antioxidant vitamins on the transient impairment of
endothelium-dependent brachial artery vasoactivity following a single high-fat meal.
JAMA 278: 1682-1686, 1997.

530.

Ng CK, et al. Impairment of endothelial function--a possible mechanism for
atherosclerosis of a high-fat meal intake. Ann Acad Med Singapore 30: 499-502, 2001.

531.

Lekakis J, et al. Effects of acute cigarette smoking on endothelium-dependent arterial
dilatation in normal subjects. The American journal of cardiology 81: 1225-1228, 1998.
243

532.

Ghiadoni L, et al. Mental Stress Induces Transient Endothelial Dysfunction in Humans.
Circulation 102: 2473-2478, 2000.

533.

Silvestro A, et al. Vitamin C prevents endothelial dysfunction induced by acute exercise
in patients with intermittent claudication. Atherosclerosis 165: 277-283, 2002.

534.

Thompson PD, et al. The acute versus the chronic response to exercise. Medicine and
science in sports and exercise 33: S438-445; discussion S452-433, 2001.

535.

Dobrosielski DA, et al. Biphasic responses of the brachial artery diameter following
forearm occlusion: a blunted response in the elderly. Dyn Med 5: 4, 2006.

536.

Tanaka H, et al. Increases in blood flow and shear stress to nonworking limbs during
incremental exercise. Medicine and science in sports and exercise 38: 81-85, 2006.

537.

Thijssen DH, et al. Sympathetic nervous system contributes to the age-related impairment
of flow-mediated dilation of the superficial femoral artery. American journal of
physiology 291: H3122-3129, 2006.

538.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New
England journal of medicine 352: 1685-1695, 2005.

539.

Forstermann U, and Munzel T. Endothelial nitric oxide synthase in vascular disease: from
marvel to menace. Circulation 113: 1708-1714, 2006.

540.

Lee IM, and Paffenbarger RS, Jr. Associations of light, moderate, and vigorous intensity
physical activity with longevity. The Harvard Alumni Health Study. American journal of
epidemiology 151: 293-299, 2000.

541.

Sesso HD, et al. Physical activity and coronary heart disease in men: The Harvard
Alumni Health Study. Circulation 102: 975-980, 2000.

542.

Selye H. The general adaptation syndrome. In: The Stress of Life. New York: McGrawHill, 1978, p. pp. 160-161.
244

543.

Booth FW, et al. Molecular and cellular adaptation of muscle in response to physical
training. Acta physiologica Scandinavica 162: 343-350, 1998.

544.

Lum H, and Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol
Cell Physiol 280: C719-741, 2001.

545.

Szocs K. Endothelial dysfunction and reactive oxygen species production in
ischemia/reperfusion and nitrate tolerance. Gen Physiol Biophys 23: 265-295, 2004.

546.

O'Donnell VB, et al. Nitric oxide inhibition of lipid peroxidation: kinetics of reaction
with lipid peroxyl radicals and comparison with alpha-tocopherol. Biochemistry 36:
15216-15223, 1997.

547.

Mezzetti A, et al. Systemic oxidative stress and its relationship with age and illness.
Associazione Medica "Sabin". Journal of the American Geriatrics Society 44: 823-827,
1996.

548.

Taddei S, et al. Age-related reduction of NO availability and oxidative stress in humans.
Hypertension 38: 274-279, 2001.

549.

Paffenbarger RS, Jr., et al. The association of changes in physical-activity level and other
lifestyle characteristics with mortality among men. The New England journal of medicine
328: 538-545, 1993.

550.

Castelli WP. Epidemiology of coronary heart disease: the Framingham study. The
American journal of medicine 76: 4-12, 1984.

551.

Blair SN, et al. Changes in physical fitness and all-cause mortality. A prospective study
of healthy and unhealthy men. JAMA 273: 1093-1098, 1995.

552.

Thompson PD, et al. Exercise and physical activity in the prevention and treatment of
atherosclerotic cardiovascular disease: a statement from the Council on Clinical
Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council
on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).
Circulation 107: 3109-3116, 2003.
245

553.

Myers J. Cardiology patient pages. Exercise and cardiovascular health. Circulation 107:
e2-5, 2003.

554.

Wannamethee SG, and Shaper AG. Physical activity and cardiovascular disease. Semin
Vasc Med 2: 257-266, 2002.

555.

Miyachi M, and Yano H. Thinning of the capillary endothelium with physical activity
shortens the diffusion distance of the pulmonary air-blood barrier. Acta physiologica
Scandinavica 157: 513-514, 1996.

556.

Higashi Y, and Yoshizumi M. Exercise and endothelial function: role of endotheliumderived nitric oxide and oxidative stress in healthy subjects and hypertensive patients.
Pharmacol Ther 102: 87-96, 2004.

557.

Moyna NM, and Thompson PD. The effect of physical activity on endothelial function in
man. Acta physiologica Scandinavica 180: 113-123, 2004.

558.

Goto C, et al. Effect of different intensities of exercise on endothelium-dependent
vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress.
Circulation 108: 530-535, 2003.

559.

Schachinger V, et al. Prognostic impact of coronary vasodilator dysfunction on adverse
long-term outcome of coronary heart disease. Circulation 101: 1899-1906, 2000.

560.

Celermajer DS. Noninvasive detection of atherosclerosis. The New England journal of
medicine 339: 2014-2015, 1998.

561.

Celermajer DS, et al. Endothelium-dependent dilation in the systemic arteries of
asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll
Cardiol 24: 1468-1474, 1994.

562.

Laurent S, et al. Flow-dependent vasodilation of brachial artery in essential hypertension.
Am J Physiol 258: H1004-1011, 1990.

246

563.

Tawakol A, et al. Hyperhomocyst(e)inemia is associated with impaired endotheliumdependent vasodilation in humans. Circulation 95: 1119-1121, 1997.

564.

Quyyumi AA. Prognostic value of endothelial function. The American journal of
cardiology 91: 19H-24H, 2003.

565.

Eskurza I, et al. Effect of acute and chronic ascorbic acid on flow-mediated dilatation
with sedentary and physically active human ageing. The Journal of physiology 556: 315324, 2004.

566.

Green DJ, et al. Exercise-induced improvement in endothelial dysfunction is not
mediated by changes in CV risk factors: pooled analysis of diverse patient populations.
American journal of physiology 285: H2679-2687, 2003.

567.

Cai H, and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of
oxidant stress. Circulation research 87: 840-844, 2000.

247

Appendix: Consent Form
CONSENT TO PARTICIPATE IN A RESEARCH STUDY
1. Title of Study: Effects of an Acute Bout of Exercise on Nitric Oxide Bioavailability,
Oxidative Stress, and Antioxidant Defense Markers in Trained Individuals
2. Performance Sites:
LSU-Department of Kinesiology
Room 54 and 58, Exercise Laboratory and Vascular Laboratory
112 Huey P. Long Fieldhouse
Baton Rouge, LA 70803
3. Contacts:
The following investigators are available for questions at the telephone numbers listed
below:
Principal Investigator:

Michael A. Welsch, Ph.D.

Department:

Kinesiology

Telephone Number:

(225)578-9143

Co-Investigator

Arturo Arce, M.D.

Department:

Kinesiology

Telephone Number:

(225)578-20

4. Purpose of the Study:
The purpose of the present study is to examine the effects of an acute bout of exercise on
nitric oxide bioavailability, oxidative stress markers, and antioxidants markers, before,
immediately and 20 minutes after, in trained individuals.
5. Subjects:
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A. Inclusion Criteria You must be at least 18 years of age. Apparently healthy
highly trained cyclist.
B. Exclusion Criteria If you have unstable manifestations of cardiovascular,
metabolic, orthopedic, and/or neurological disease; active infection; risk for
adverse responses to exercise; taking any medication which may affect
cardiovascular function.
C. Maximum number of subjects: 20
6. Study Procedures:
If you are selected to participate in this study you will be involved for a total of 2 distinct
visits. They include a series of tests at the beginning, during and the end of the study.
On the first visit you will be asked to perform a bike time trial and we will take some
pictures of an artery in your arm.
The bike time trial will be performed on a stationary bike. You will begin pedaling at a
speed that would allow you to regulate your workload by pedaling cadence, just as you
would on a real cycle in a real competition. During the test we will measure the amount
of oxygen you consume and carbon dioxide you produce to allow us to more precisely
determine your fitness. We will measure oxygen and carbon dioxide using a metabolic
analyzer. You will breathe regular room air, but when you exhale, a machine will
measure how much air you are actually breathing out, and how much oxygen and carbon
dioxide is in your breath. We will also measure your heart rate and blood pressure at the
beginning, during and after the exercise.
In addition to the bike time trial, we will also take some pictures of an artery in your arm.
This will be done right before and immediately after the exercise test. To perform this test
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you will be asked to lie down on an examination bed. A laboratory technician will place 4
electrodes and 2 blood pressure cuffs on your chest and both arms, respectively. The
electrodes are used to examine your heartbeat. The cuffs are used to measure blood
pressure in the one arm and change blood flow to the hand in the other arm to allow us to
test how your arteries react. After all the equipment is in place an ultrasound technician
will be taking pictures of an artery in your arm before and after inflating a blood pressure
cuff on the forearm for 5-minutes. Throughout the procedure, heart rate, and blood
pressures will also be recorded. This test is called the brachial artery dilation test.
On the second visit you will again be asked to perform a bike time trial similar to the test
on the first visit. However, prior to the test a certified phlebotomist will place a HeparinLock in the antecubital vein of the left arm for the purpose of blood sampling prior to the
start of the exercise, at peak exercise, and 20 minutes after. The amount of blood drawn
at each time point will be about 10ml. The blood samples will be processed and prepared
for analyses. The purpose of the blood samples is to examine the influence of the exercise
test on factors that have an effect on the health of the blood vessels.
7. Benefits:
We cannot promise any benefits from being in the study. However, participation in this
study may assist the investigators in gathering information leading to better treatments for
cardiovascular disease. You will have the opportunity of having the required tests and
procedures performed during your participation in this study.
All clinic visits, physical examinations, study medication, laboratory tests,
electrocardiograms, and any other procedures associated with the conduct of this study
are free if you participate.
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8. Risks/Discomforts:
The possible risks and discomforts for this trial are detailed in this informed consent.
Blood sampling will be conducted by a certified and trained phlebotomist. The
discomforts and risks of a blood test are the pain of a needle going into the vein, possible
bruising and the remote risk of infection. However, if venipuncture is done properly,
there should be little pain and little risk for adverse reactions. The phlebotomist will
constantly monitor your condition during the course of the test. Inflation of the blood
pressure cuff on the forearm may cause some temporary discomfort in the forearm and
hand. If the discomfort is too severe you may terminate the procedure immediately by
asking the technician to stop the test. Temporary numbness and tingling in the hand
similar to the sensation of having your hand “fall asleep” may occur. There is no known
risk to the use of ultrasound to measure the size of the blood vessel. There is no
theoretical risk to blocking blood flow in the artery through inflation of the blood
pressure cuff. Not a single permanent adverse event has been associated with this
procedure in over 100,000 examinations reported in the medical literature. In addition to
the risks listed above, the procedures may have unknown, unforeseen or unanticipated
side effects. There is always the possibility that you will have a reaction that is currently
not known and not expected. The risks of the bike time trail test using the methods
described are minimal in this population but include: muscle soreness, stiffness or
tightness, or in some rare cases muscle injuries or more severe complications.
9. Measures taken to reduce risk
The risk in this study will be minimized as a result of proper evaluation, education, and
appropriate assessment of exercise responses and the presence of well trained personnel
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capable of monitoring exercise equipment.
10. Right to Refuse:
Your participation is voluntary. If you decide not to participate in this study you will not
suffer a penalty or loss of benefits to which you are otherwise entitled. If you decide to
participate in this study you may discontinue your participation at any time, without
penalty or loss of benefits.
11. Privacy:
Every effort will be made to keep the information we learn about you private.
Records of your participation in this study will be kept confidential except as required by
law. Any publication of the data will not identify you.
12. Financial Information:
You will have no financial obligations.
13. Withdrawal:
If you decide to participate in this study you may discontinue your participation at any
time, without penalty or loss of benefits and it will have no effect on the quality of your
medical care, academic standing, job status, etc.
14. Removal:
You will have completed the study after finishing the two visits. The length of each visit
will be approximately one hour.
The study has been discussed with me and all my questions have been answered. I may
direct additional questions regarding study specifics to the investigators. If I have
questions about subjects' rights or other concerns, I can contact Robert C. Mathews,
Chairman, LSU Institutional Review Board, (225)578-8692. I agree to participate in the
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study described above and acknowledge the researchers’ obligation to
provide me with a copy of this consent form if signed by me.
Subject Signature: ________________________________ Date: ___________
The study subject has indicated to me that he/she is unable to read. I certify that I have read this
consent form to the subject and explained that by completing the signature line above, the subject
has agreed to participate.
Signature of Reader: _______________________________ Date: ___________
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